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ABSTRACT
Most large acute stroke trials have shown no treatment effect. Functional
outcome is routinely used as the primary outcome in stroke trials. This is
usually analysed using a binary analysis, e.g. death or dependency versus
independence. This project assessed which statistical approaches are most
efficient in analysing functional outcome data from stroke trials.
Fifty five data sets from 47 (54,173 patients) completed randomised trials were
assessed. Re-analysing this data with a variety of statistical approaches showed
that methods which retained the ordinal nature of functional outcome data
were statistically more efficient than those which collapsed the data into two or
more groups. Ordinal logistic regression, t-test, robust rank test, bootstrapping
the difference in mean rank, or the Wilcoxon test are recommended. When
assessing sample size, using ordinal logistic regression to analyse data instead
of a binary outcome can reduce the sample size needed for a given power by
28%. Ordinal methods may not be appropriate for trials of treatments which
not only increase the proportion of patients having a good outcome but also
have an increase in hazard, such as thrombolytics.
Adjusting the analysis performed for prognostic factors can have an additional
effect on sample size. Re-analysing data from 23 stroke trials (25,674
patients), where covariate data was supplied, showed that ordinal logistic
regression adjusted for age, sex and baseline stroke severity reduced the
sample size needed for a given statistical power by around 37%. Alternatively
trialists could increase the statistical power to find an effect for a given sample
xii
size, as it is argued that stroke trials have been too small and therefore
underpowered.
Stroke prevention trials also routinely collect binary data, e.g. stroke/no stroke.
Converting this data into ordinal outcomes, e.g. fatal stroke/non-fatal stroke/no
stroke and analysing these with a method which takes into account the ordered
nature of the data also increases the statistical power to find a treatment
effect. This method also provides additional information on the effect of
treatment on the severity of events.
Using ordinal methods of analysis may improve the design and statistical
analysis of both acute and stroke prevention trials. Smaller trials would help
stroke developments by reducing time to completion, study complexity, and
financial expense.
xiii
ACKNOWLEDGEMENTS
The work in this thesis was carried out under the supervision of Professor Philip
Bath, Division of Stroke Medicine, University of Nottingham; he was the
architect of both the acute and prevention OASTprojects. I would like to thank
him for his unending optimism in the OASTproject and for his encouragement
throughout.
I would also like to thank Timothy Collier, Professor Stuart Pocock and Dr
James Carpenter, all from the Medical Statistics Unit, london School of Hygiene
and Tropical Medicine, for their statistical and programming guidance with this
project. I acknowledge Dr Chamila Geeganage, Division of Stroke Medicine,
University of Nottingham, for collating the data used in the OAST prevention
analysis, and her for her help with this part of the project; and Dr Gillian Sare
Division of Stroke Medicine, University of Nottingham, for her medical input and
help in updating the HRTexample used in Chapter 7. I would like to thank all of
the OAST collaborators for sharing the data with this project and reviewing
draft manuscripts.
Iwould also like to show appreciation to all my friends, past and present, at the
Division of Stroke Medicine for their support and encouragement over the
years. Margaret Adrian, Dr Claire Allen, Alison Columbine, Fiona Hammonds, Dr
Gillian Sare, Sally Utton and Graham Watson for taking the time to proof read
my thesis. Wim Clarke, Sharon Ellender (for tea making), Dr Timothy England,
Tanya Payne, Hazel Sayers, Beverly Whysall and Dr Mark Willmot for their
advice, encouragement and friendship. And last but not least my research side-
kick Dr Nikola Sprigg for many years of friendship both inside and outside of
work and for always being on the other end of the phone!
xlv
I would also like to thank Dr Kelly Handley for her statistical ear and pedantic
nature and Katie Pike for reading and commenting on my thesis.
A big thank you to all my family and friends ....too many to mention, you know
who you are.
xv
LIST OF COLLABORATORS
The following collaborators provided individual patient data from their trial, and
commented on draft manuscripts:
Abciximab: H Adams (USA), K Dougherty (USA); W Hacke (Germany),
ASK: G Donnan (Australia)
ASSIST 07 & 10: S Davis (Australia)
ATLANTIS A & B: G Albers, S Hamilton (USA)
BEST Pilot & Main: D Barer (UK)
Citicoline 1, 7, 10, 18: A Davalos (Spain)
Corr: S Corr (UK)
Dover Stroke Unit: P Langhorne (UK)
DCLHb: P Koudstaal, R Saxena (Netherlands)
DESTINY: E Juettler, W Hacke (Germany)
Ebselen: T Yamaguchi (Japan)
ECASS II: W Hacke, E Bluhmki (Germany)
Factor VII: S Mayer (USA), K Begtrup (Denmark)
FISS: R Kay (Hong Kong)
FOOD 3: M Dennis (UK)
Gilbertson: L Gilbertson (UK)
INWEST: N-G Wahlgren, N Ahmed (Sweden)
1ST: P Sandercock (UK)
Kuopio Stroke Unit: J Sivenius (Finland)
Logan: P Logan (UK)
MAST-I: L Candelise (Italy), J Wardlaw (UK)
Minocycline: Y Lampl, M Boaz (Israel)
Newcastle Stroke Unit: H Rodgers (UK)
NINDS: J Marler (USA)
xvi
Nottingham Stroke Unit: N Lincoln, P Berman (UK)
Parker: C Parker (UK)
RANNTAS I & II, STIPAS, TESS I & II: P Bath (UK), B Musch (USA)
Statin withdrawal: J Castillo (Spain)
Walker 1 & 2: M Walker (UK)
Young: J Young, A Forster (UK)
We thank the patients who took part in these studies, and the tria lists who
shared their data.
xvii
ADL
AF
ANOVA
BI
CEA
CHD
Cl
Cl
LIST OF ABBREVIATIONS
Activities of daily living
Atrial fibrillation
Analysis of variance
Barthel Index
Carotid endarterectomy
Coronary heart disease
Confidence interval
Chief Investigator
CONSORT Consolidated Standards of Reporting Trials
CT Computer tomography
CVD
DCLHb
EADL
FAST
GEE
GO
GOS
HRT
ICF
ICIDH
IMPACT
IPD
IQR
LACI
MI
Cerebrovascular disease
Diaspirin cross-linked haemoglobin
Extended activities of daily living
Face-Arm-Speech Test
Generalised estimating equations
Global outcome
Glasgow Outcome Scale
Hormone replacement therapy
International Classification of Functioning, Disability and Health
International Classification of Impairments, Disabilities and
Handicaps
International Mission for Prognosis and Clinical Trial
Individual patient data
Interquartile range
Lacunar infarction
Myocardial infarction
xviii
MRI
mRS
NIHSS
OAST
OHS
OR
OT
PACI
PE
PEG
PI
POCI
PT
SU
TACI
TIA
UA
VISTA
VTE
WHO
3Q
Magnetic resonance imaging
Modified Rankin Scale
National Institute of Health Stroke Scale
Optimising Analysis of Stroke Trials
Oxford Handicap Scale
Odds ratio
Occupational therapy
Partial anterior circulation infarction
Pulmonary embolism
Percutaneous endoscopic gastrostomy
Principal Investigator
Posterior circulation infarction
Physiotherapy
Stroke unit
Total anterior circulation infarction
Transient ischaemic attack
Unstable angina
Virtual Stroke Trials Archive
Venous thromboembolism
World Health Organisation
Three Questions Outcome
xix
To Mum, Dad, Theresa, Nicola and Dicky Mint
"1put my heart and my soul into my work, and have lost my mind in the
process"
Vincent Van Gogh
xx
CHAPTER 1
INTRODUCTION
1
PUBLICATIONS/PRESENTATIONS CONTRIBUTING TO THIS CHAPTER
Gray L.l, Sprigg N, Bath P.M.W, Boysen G, De Deyn P, Leys D, O'Neill D,
Ringelstein EB, for the TAIST Investigators (2007) Sex differences in quality of life
in stroke survivors: data from the 'Tinzaparin in Acute Ischaemic Stroke Trial'
(TAIST). Stroke. 38 (11):2960-4.
Gray L.l, Sprigg N, Bath P.M.W, serensen P, undenstrern E, Boysen G, De Deyn
P.P, Friis P, Leys D, Marttila R, Olsson J-E, O'Neill D, Ringelstein B, MD; van der
Sande J-J, Turpie A.G.G, for the TAIST Investigators (2006) Significant variation in
mortality and functional outcome after acute ischaemic stroke between western
countries: data from the 'Tinzaparin in Acute Ischaemic Stroke Trial' (TAIST).
Journal of Neurology, Neurosurgery and Psychiatry 77: 327-333.
Sprigg N, Gray L.l, Bath P.M.W, undenstrern E, Boysen G, De Deyn P.P, Friis P,
Leys D, Marttila R, Olsson J-E, O'Neill D, Ringelstein B, van der Sande J-J, Turpie
A.G.G, for the TAIST Investigators (2007) Stroke severity, early recovery and
outcome are each related with clinical classification of stroke: data from the
Tinzaparin in Acute Ischaemic Stroke Trial' (TAIST) Journal of Neurological
sciences. 254(1-2):54-9.
Sprigg N, Gray L.l, Bath P.M.W, undenstrern E, Boysen G, De Deyn P.P, Friis P,
Leys D, Marttila R, Olsson J-E, O'Neill D, Ringelstein B, van der Sande J-J, Turpie
A.G.G, for the TAIST Investigators (2006) Relationship between outcome and
baseline blood pressure, pulse pressure, heart rate and rate-pressure product in
acute ischaemic stroke: data from the 'Tinzaparin in Acute Ischaemic Stroke Trial'
(TAIST). Journal of Hypertension 24(7), 1413-1417.
2
Bath P.M.W, Gray L.l (2005) Hormone replacement therapy and subsequent
stroke: a meta analysis. British Medical Journal, 330, 342
Abstract republished in Nature Clinical Practice Cardiovascular Medicine (2005) 2,
119. Abstract republished in Journal of Neurology, Neurosurgery and Psychiatry
(2005) 76, 838
Halkes P.H.A, Gray L.l, Bath P.M.W, Bousser M-G, Diener H-C, Guiraud-Chaumeil
B, Yatsu F, Algra A, on behalf of the Dipyridamole in Stroke Collaboration (DISC)
(2007) Dipyridamole plus aspirin in the secondary prevention after TIA or stroke of
arterial origin: a meta analysis by risk using individual patient data from
randomised trials. Journal of Neurology, Psychiatry and Neurosurgery
DOI:l0.1136/jnnp.2008.143875.
Bath P.M.W, Gray L.l (2007) Should Data Monitoring Committees assess efficacy
when considering safety in trials in acute stroke? International Journal of Clinical
Practice. 61 (10): 1749-1755.
3
1.1 INTRODUCTION
This chapter will briefly introduce the key themes of this thesis: stroke,
measuring outcome, and clinical trials in stroke. Section 1.4 will review in detail
the research carried into the statistical analysis of functional outcome scales so
far. The final section will outline the main aims of this project.
1.2 STROKE
The World Health Organisation (WHO) define stroke as "rapidly developed
clinical signs of focal or global disturbance of cerebral function, lasting more
than 24 hours or until death, with no apparent cause other than of vascular
origin" (WHO MONICAProject Principal Investigators, 1988). In lay terms, a
stroke can be thought of as a brain attack, which comes on very suddenly.
During a stroke the blood supply to part of the brain may be cut off, this loss
can cause brain cells to be damaged. These damaged brain cells can affect
bodily functions. For example, if damage occurs in the part of the brain which
controls limb function, movement of the limb could be affected (The Stroke
Association, 2008). The severity of a stroke can vary dramatically from
recovery in a day to severe disability or death (Warlow, 1998). Stroke is a
collective term for several types of brain injury, of which there are two main
types, ischaemic (inadequate blood flow) and haemorrhagic (a bleed) (see
Figure 1.1).
Ischaemic strokes are the most common type of stroke, accounting for around
85% of the total number (NHSdirect, 2001). Ischaemic stroke occurs when an
artery supplying blood to the brain becomes blocked, and therefore interrupts
the blood supply to the brain. Brain tissue starved of blood will die (cerebral
infarction).
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There are four causes of an ischaemic stroke:
• Embolism, where a blood clot formed in another part of the body
(usually the heart) travels through the bloodstream to the brain (20%).
• Thrombosis, where a blood clot forms in a main artery leading to the
brain or within the brain (50%).
• Lacunar stroke, which occurs when small vessels deep within the brain
become blocked (25%).
• Other causes, such as arterial dissection, arteritis, and infective
endocarditis, account for the remaining 5% of ischaemic strokes.
A haemorrhagic stroke occurs when a blood vessel in or around the brain
bursts, accounting for 15% of all strokes (Bamford et al., 1990).
FIGURE 1.1
Diagrams of an ischaemic and haemorrhagic stroke, taken from
http://www.strokerehabunit.ielen/AboutStroke/DifferentTypesofStrokel
'SCHAB~K; STROKE
~
HAEMOAAHAGtC STROKE
A transient ischaemic attack (TIA) is a related condition which does not fall
within the definition of a stroke. It is sometimes called a 'mini-stroke' as it
starts like a stroke but lasts for less than 24 hours and leaves no lasting
symptoms (Warlow et al., 1996).
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1.2.1 Epidemiology
Stroke is the third most common cause of death in the United Kingdom (UK),
preceded by cancer and myocardial infarction (heart attack), with one in four
men and one in five women expected to have a stroke by the age of 85 (Wolfe,
2000). Incidence measures the number of new cases in one year divided by the
number at risk (Bland, 2000). The incidence of stroke rises exponentially with
increasing age. Once aged over SS years the incidence of stroke doubles with
each successive decade (Wolfe, 2000), with an incidence of three per 10,000
when aged 30-40 increasing 100 fold to 300 per 10,000 when aged 80-90
(Bonita et al., 1984). Figure 1.2 shows age specific rates for cerebrovascular
events taken from the "Oxford Vascular Study". This was an observational
study looking at acute vascular events occurring in Oxfordshire between 2002
and 2005. This shows that the incidence of all events, apart from subarachnoid
haemorrhage, increase with age for both males and females (Rothwell et al.,
2005).
Males have a higher incidence of stroke compared to females, with an age-
standardised incidence ratio varying from 1.2 to 2.4 (Thorvaldsen et al., 1995).
Interestingly, although males have a greater incidence of stroke, females tend
to have a worse outcome after stroke. For example, females report worse
quality of life post stroke compared to males (Gray et al., 2007). There are
many possible reasons for this difference, including higher levels of atrial
fibrillation (irregular heart beat) and hypertension (high blood pressure) in
females prior to their stroke (Oi Carlo et al., 2003), and differences in their in-
hospital care. For example, males are more likely to receive thrombolytic
therapy, which is a highly efficacious clot busting treatment for ischaemic
stroke (Warner Gargano et al., 2008).
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FIGURE 1.2
All event!;
Age-specific rates for cerebrovascular events by sex.
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Differences in incidence rates are also apparent across ethnic groups. For
example, African and African-Caribbean males and females have approximately
double the risk of stroke compared to Caucasian males and females (Kakar et
al., 2006). It is thought that this could be attributable to higher levels of
hypertension and diabetes in African and African-Caribbean patients (Sacco et
al., 2001).
Stroke accounts for 10-12% of all deaths in industrialised countries, with 88%
of these in people aged 65 years or older (Bonita, 1992). The case fatality
(those people who die within a specific period after an event) at one month for
stroke patients depends heavily on age and health status. In 1984 a study
showed one month case fatality varying between 17% and 34% with an
average of 24%; with the one year case fatality being around 42% (Bonita et
al., 1984). It has been reported that case fatality is decreasing over time
(Feigin et al., 2003). For example, The Framingham Study found that between
the 54 year period 1950-2004, 30 day case fatality fell from 23% to 14% in
males, the same reduction was not seen for females (Carandang et al., 2006).
Although some suggest that case fatality has remained constant over time, with
a more recent study showing a one month case fatality of 25.7%, rising to
36.7% at six months (Wolfe et al., 2002).
Stroke is the leading cause of adult disability in the UK. In 2005 there were
over 900,000 people who have had a stroke living in England, with 300,000 of
these living with moderate to severe disability (National Audit Office, 2005). A
study comparing outcome after ischaemic stroke across eleven countries, found
that in the UK, at six months, post stroke 21% of patients had died, 63% were
still dependent on others and 37% were living in an institution (Gray et al.,
2006). Those in the UK also reported greater levels of dependency and poorer
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quality of life after stroke than other western countries, even after adjustment
for case mix and service quality markers (Gray et al., 2006, Gray et al., 2008).
1.2.2 Symptoms
Strokes affect different people in different ways depending on the type of
stroke, the area of the brain affected and the severity. The most common
symptoms are: numbness or weakness of the face, arm and/or leg weakness
(normally on one side of the body), confusion, difficulty speaking, difficulty with
vision, dizziness and sudden severe headaches. In the late 1990's the Face-
Arm-Speech Test (FAST) was developed to help rapidly identify those suffering
from a stroke. This involves checking individuals for facial weakness, arm
weakness and speech problems. The use of this test has been shown to
increase diagnosis of stroke by paramedics (Harbison et al., 2003). The FAST
test has since been advertised to the public by the Stroke Association to
encourage people to ring 999 on seeing these symptoms to allow prompt care.
Less common symptoms include: nausea, fever, vomiting, loss of
consciousness, fainting or convulsions (Warlow et al., 1996).
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1.2.3 Diagnosis
Diagnosis of stroke has three main elements; history, clinical examination and
imaging. After initial stabilisation it is imperative that a history is obtained from
either the patient or a relative. This is to establish the time of onset (important
for treatment options), possible causes, presence of risk factors and history of
any cardiac disorders (Vuadens and Bogousslavsky, 1998). The clinical
examination is usually directed at confirming cardiovascular disease. The doctor
will carry out a general examination (blood pressure etc) and then a full
detailed neurological examination. The neurological examination will assess
cranial nerves, meningeal signs, motor system, posture and gait, reflexes,
coordination, sensation and cognitive function. Once the clinical examination
has taken place a clinical diagnosis should have been made (de Freitas and
Bogousslavsky, 1997).
Investigations are then carried out to confirm the type and cause of stroke.
Imaging (either by cranial computed tomography (CT) scan or magnetic
resonance imaging (MRI), see Figure 1.3 for an example of the two scan types)
is the most accurate method for distinguishing between ischaemic and
haemorrhagic stroke. This is important to determine as haemorrhagic strokes
are treated differently (Jager, 2000). The new National Stroke Strategy for the
UK states that patients with potential strokes should be imaged within 24 hours
of onset (Department of Health, 2007). Scanning patients very early allows
doctors to treat ischaemic strokes with a thrombolytic agent, a powerful clot
busting drug which is only licensed to be given within the first three hours of
stroke onset.
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FIGURE 1.3
A comparison of CT and MR scan of a mild lacunar stroke.
CT Scan MRI Scan
Reprinted from The Lancet, 362. 9391, Warlow C et al. Stroke, 1211-1224., Copyright
(2003), with permission from Elsevier.
1.2.4 Prognostic factors
A prognostic factor is a situation, condition, or a characteristic of a patient, that
can be used to estimate the chance of recovery from a disease, or the chance
of the disease recurring (i.e. the patients' prognosis). Prognostic factors which
are used to assess prognosis in stroke patients include; type of stroke, stroke
subtype, level of consciousness, severity of the stroke and age.
As previously discussed, stroke patients can be grouped as ischaemic or
haemorrhagic. Patients with haemorrhagic strokes have a five times higher
case fatality compared to those with an ischaemic stroke (Bamford et al.,
1990). Once a CT scan has confirmed diagnosis, those with ischaemic stroke
can then be further sub classified. In 1991 a classification for sub groups of
ischaemic stroke was developed, this is often referred to as the Bamford
Classification (Bamford et al., 1991).
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Four sub groups of ischaemic stroke were established:
• Total anterior circulation infarction (TAc!) tv 20% of patients
• Partial anterior circulation infarction (PACI) tv 30% of patients
• Posterior circulation infarction (POCI) tv 25% of patients
• Lacunar infarction (LAC!) tv 25% of patients
The prognosis of patients who fall into these categories is very different, and
therefore this classification can be used as a prognostic factor.
FIGURE 1.4
Proportion of patients who are dead, dependent, or independent a year after
first stroke by type of stroke and by clinical subtype of ischaemic stroke.
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Reprinted from The Lancet, 362. 9391, Warlow C et al. Stroke, 1211-1224., Copyright
(2003), with permission from Elsevier.
Patients with a TAC! have suffered a large infarct with both cortical and sub
cortical involvement, with slow recovery (Sprigg et al., 2007). These patients
have the worse prognosis with high mortality (see Figure 1.4). Patients with a
PACI are more likely to have recurrent strokes, while patients with POCI are at
the greatest risk of a recurrent stroke later in the first year after initial onset.
Patients with POCI have the best chance of a good functional outcome post
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stroke. Patients with LACI have suffered from small infarcts, but can still
remain substantially disabled. Table 1.1 shows the percentage of deaths in
each sub group at one month and one year (Bamford et al., 1991, Ebrahim and
Harwood, 2003).
There is a very small minority of patients (around 1%) with ischaemic stroke
who do not fall into either category.
TABLE 1.1
Clinical stroke subtype and mortality (Bamford et al., 1991, Ebrahim and
Harwood, 2003).
One month One year
% deaths % deaths
TACI 39 60
PACI 4 16
LACI 2 11
POCI 7 19
Haemorrhagic stroke 52 62
Level of consciousness is also an important prognostic factor. Consciousness is
routinely measured with the Glasgow Coma Scale, patients are scored between
three (deep unconsciousness) and 15 (normal state) (Teasdale and Jennett,
1974). The Glasgow Coma Scale is highly related to both mortality at two
weeks and outcome at three months (Weir et al., 2003). Severity is related to
level of consciousness, with patients with more severe stroke tending to have a
lower level of consciousness. The National Institute of Health Stroke Scale
(NIHSS) (Brott et al., 1989) is a well validated measure of stroke severity and
has been shown to be strongly related to outcome at both seven days and
three months. A higher score on the NIHSS reflects greater severity and it has
been shown that for every unit increase on the NIHSS, the likelihood of a good
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outcome at seven days is decreased by 24%, and by 17% at three months
(Adams et al., 1999).
The increasing risk of stroke with increasing age is well documented, but age is
also an important prognostic factor. A study looking at producing models for
predicting prognosis found that the chance of surviving a stroke decreases by
3% with every year increase in age at stroke onset. It was also found that the
odds of becoming independent after a stroke also decrease with increasing age
(Odds Ratio (OR) 0.95, 95% Confidence Interval (Cl) 0.93-0.97) (Counsell et
al., 2002).
Other factors which can be used to predict early mortality are high blood
pressure (Sprigg et al., 2006), raised blood glucose, raised haematocrit, atrial
fibrillation, pupil changes, gaze paresis, abnormal breathing, abnormal body
temperature and meningeal irritation (Ebrahim and Harwood, 2003).
1.2.S Treatment
Currently there are four interventions which have been shown in randomised
controlled trials to improve outcome in acute stroke: admission to a stroke
unit; treatment with aspirin; treatment with thrombolytic therapy and most
recently, decompressive surgery for those with cerebral oedema. Admission to
a stroke unit can be used to treat patients with both ischaemic and
haemorrhagic stroke, whereas aspirin, thrombolytic therapy and decompressive
surgery may only be used in ischaemic cases. Unfortunately, there have been
no definitive clinical trials which have demonstrated beneficial medication for
patients with haemorrhagic stroke. If the bleed is life threatening, then surgical
evacuation of the clot can be considered (Warlow et al., 1996).
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Stroke units combine acute stroke care with rehabilitation. In 1997 a
systematic review was carried out on studies which looked at stroke unit care.
The review found that stroke units gave a reduction in death (OR0.83, 95% Cl
0.69 to 0.98), poor outcome (death or dependency) (OR 0.69, 95% Cl 0.59 to
0.82) and death or institutionalisation (OR 0.75, 95% Cl 0.65 to 0.87) (Stroke
unit trialists' collaboration, 1997).
Treatment with aspirin has been shown to have a limited effect, but has wide
utility. A data pooling project found that acute treatment with aspirin showed a
reduction in the combined outcome of death or non-fatal recurrent stroke of
one per 1000 patients treated (Chen et al., 2000).
In contrast, treatment with thrombolytics has been shown to be highly effective
but with limited availability. Thrombolytic treatment aims to break down the
clot and restore blood flow to the damaged part of the brain, and in doing this
reduce the area of brain damage and therefore improve outcome (Warlow et
al., 1996). The National Institute of Neurological Disorders and Stroke (NINDS)
trial showed that treatment within three hours of onset improved outcome at
three months, with an 11-13% absolute increase in the chance of minimum or
no disability (The National Institute Of Neurological Disorders And Stroke rt-Pa
Stroke Study Group, 1995).
Decompressive surgery involves removing a skull flap to alleviate intra-cranial
pressure and remove the risk of death from pressure building up in the brain. A
meta analysis of three trials (one of these is still ongoing) showed that patients
in the surgery group had a better outcome and improved survival (Vahedi et
al., 2007).
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1.2.6 Prevention
Most strokes are thought to be preventable; there are four reasons for this.
Firstly, variations in time and place, both within and between countries suggest
that stroke risk is changeable. Secondly, observational studies have shown that
migrants adopt the risk of their host environment. Thirdly, personal
characteristics are associated with the gradient of stroke risk (i.e. the lower the
level of the risk factor the lower the occurrence of stroke). Lastly, experimental
evidence from randomised controlled trials demonstrates that stroke incidence
is reduced following the reduction of stroke risk factors (Ebrahim and Harwood,
2003, Marmot and Poulter, 1992). A risk factor is defined as something that
predisposes a person to a morbid event (Millikan et al., 1987). Risk factors for
stroke can be split into two groups, those that can be modified, and those that
are non-modifiable. Modifiable risk factors include: high blood pressure,
cigarette smoking (Shinton and Beevers, 1989), heart disease, diabetes,
hormone replacement therapy use (Bath and Gray, 2005), and alcohol
consumption (Wolf, 1998). Non modifiable risk factors include: age, sex, family
history, and ethnicity (Wolf, 1998).
High blood pressure is a major modifiable risk factor. Blood pressure is
calculated using two measurements, one when the heart beats (systolic) and
one when the heart relaxes (diastolic). Both systolic and diastolic blood
pressure have been shown to be positively and independently associated with
the primary incidence of stroke. Reducing systolic blood pressure by 5.8 mmHg
has been shown to lead to a 42% reduction in the incidence of stroke (Collins et
al., 1990). Similarly, for diastolic blood pressure between the range of 70-110
mmHg, the risk of stroke doubles with each increase of 7.5 mmHg (MacMahon
et al., 1990). Blood pressure may be reduced by losing weight, eating a healthy
diet of low saturated fat, cholesterol and salt, being more physically active and
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lowering alcohol intake. Although modification of these factors can have an
effect on blood pressure, this effect is generally modest. For example, a 10 kg
drop in body weight may reduce systolic blood pressure by 6-16 mmHg, and 30
minutes of daily exercise leads to a reduction of around 3.3 mmHg (Bhatt et
al., 2007), therefore many patients will require blood pressure lowering
therapy.
1.2.7 Secondary prevention
The term secondary prevention refers to preventing further strokes in patients
who have already suffered a stroke. Those who have suffered from a stroke or
a TIA are at a higher risk of having a recurrent stroke than those who have not.
A population based study found that after TIA or minor stroke the risk of
recurrence was around 8-12% at seven days, 12-15% at one month and 17-
19% at three months, with the higher rates being seen in those with minor
stroke compared to TIA (Coull et al., 2004). The "Early use of Existing
Preventive Strategies for Stroke" (EXPRESS)study showed that early treatment
after TIA or minor stroke could reduce the risk of early recurrence by 80%
(Rothwell et al., 2007).
There are different treatment options available for the prevention of secondary
strokes depending on the cause of the initial event. If patients have suffered
from an ischaemic stroke there are medications available that may block the
formation of further blood clots and therefore reduce the risk of further strokes.
The most widely used treatment of this type is aspirin, which can reduce the
risk of stroke by around 13-22% (Antithrombotic Trialists' Collaboration, 2002).
There are other alternative therapies that work in a similar manner, including
clopidogrel and dipyridamole, and recently it has been shown that being treated
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with both dipyridamole and aspirin gives a greater risk reduction than aspirin
alone (Halkes et al., 2008).
Anticoagulants, such as warfarin, are recommended for those having suffered
an ischaemic stroke caused by a blood clot from the heart. The majority of
these patients will have atrial fibrillation (AF), which is an abnormal heart
rhythm. These patients are at a much higher risk of recurrent stroke than those
without AF. The "Birmingham Atrial Fibrillation Treatment of the Aged Study"
(BAFTA) showed that treatment with warfarin compared to aspirin significantly
reduced the risk of recurrent events (1.8% per year compared to 3.8% per
year, p=0.003) in patients aged over 75 (Mant et al., 2007).
Carotid surgery (endarterectomy) can be used for those whose stroke was
caused by a blocked blood vessel on the side of the neck, in order to clear the
blockage. The "North American Symptomatic Carotid Endarterectomy Trial"
(NASCET)showed that carotid surgery reduced two year absolute risk of stroke
by 17% (North American Symptomatic Carotid Endarterectomy Trial
Collaborators, 1991).
1.3 OUTCOME
Outcome is defined as "a change in a patient's current and future health status
that can be attributed to antecedent care" (Donabedian, 1980). Outcome after
stroke is important for clinical research as it can be used to measure an
individual's progress or to compare groups of patients. For example, in a clinical
trial, outcome (Le. number of recurrent strokes or level of disability) can be
used to compare a new treatment to the standard treatment after a predefined
length of time. There are many outcomes which can be used, from objective
measures such as mortality to more complex subjective measures such as
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quality of life. Functional outcome is regularly used as the primary outcome in
clinical trials on stroke.
1.3.1 Functional outcome
After suffering a stroke approximately a third of patients will die, a third will
return to full independence (although residual disability may be present) and a
third will have some sort of lasting disability and therefore dependency on
others.
In 1980 the WHO published the International Classification of Impairments,
Disabilities and Handicaps(ICIDH) (World Health Organization, 1980). This was
produced to give a framework against which information could be organised to
clarify the consequencesof disease (Kearney and Pryor, 2004). Impairment
was defined as any loss or abnormality of psychological, physiological or
anatomical structure or function, so for example, in stroke leg or arm
weakness. Disability was classified as any restriction or lack of ability to
perform an activity in a manner which is normal for a human being, i.e. the
functional results of impairment. Whereas, handicap is a disadvantage for a
given individual, normally resulting from a disability or impairment that limits
or prevents the person fulfilling their normal role. This model states that both
impairment and disability are pre-requisites of handicap, and therefore suitably
implying that impairment and disability cause handicap. In this model
impairment is the least important measure to the patient, with handicap being
the most important (Roberts and Counsell, 1998).
The ICIDH has been updated and revised and in 2001 the WHOpublished the
International Classification of Functioning, Disability and Health (IeF).
Importantly this revision included the opinions of disabled people, which were
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not represented in the ICIDH. This model is much more complex than the
original and aims to give a unified language and framework for the description
of health and health-related states. It is made up of two parts; the first part
considers physiological impairments, limits to activities and involvement in life
situations. The second part considers contextual factors such as the
environment and personal characteristics (World Health Organisation, 2001).
The term "disability" is no longer included as a component within the ICF, but
rather as an umbrella term for any impairment of body structure or function,
limitation of activities or restriction in participation (Bowling, 1997). The ICF as
a whole describes a person's level of functioning, with functioning now being a
continuum rather than only focusing on the extreme points.
Although the more recent ICF is now the accepted way of defining disability,
the scales used throughout this project were based on the previous definitions
and therefore use the terms impairment, disability and handicap.
1.3.2 Outcome scales
An outcome scale normally takes the form of a number of predefined levels on
an ordinal scale, normally ranging from the worst possible state to the best
possible state. Scales can either have a set of questions which, when answered,
give the patient a score, that relates to their place on the scale. Or conversely,
each level on the scale has a clear definition and the person assessing the
patient decides which level describes the patient best.
In stroke research the type of outcome used depends on whether the
researcher wants to measure impairment, disability or handicap. Impairment is
normally assessed using a scale for neurological deficit and handicap is gauged
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by using a scale which assesseschange in the patient's social role. Disability is
routinely determined using a scale which assesses Activities of Daily Living
(ADL). ADL scales generally include items on excretion (bowels, bladder,
toileting), mobility (transfers, wheelchair/walking, stairs), hygiene (grooming,
bathing), feeding and dressing. ADL scales can also be extended (EADL, also
called instrumental ADL) to take into account housework, shopping and leisure
activities (Barer and Nouri, 1989).
1.3.3 Choosing a scale
When choosing an outcome scale there are issues which need to be
investigated, namely: reliability, validity, sensitivity and simplicity (Wade,
1992). Reliability simply assessesthat the scale is measuring something that is
reproducible. For example, do different assessors give the same patient the
same score (inter-rater reliability) or do different methods of administration
produce comparable results (inter-method reliability). Reliability also measures
the extent to which the items within the scale are measuring the same
characteristic (internal consistency) (Streiner and Norman, 1995, Hantson and
De Keyser, 1994). Test-retest reliability is determined by administering the test
on the same population on two occasions and comparing the results, usually
with correlation (Bowling, 1997).
Validity assesseswhat the scale is actually measuring, and whether or not the
scale is measuring what it claims to be. There are three aspects to validity:
construct, criterion and content. Construct validity establishes whether the
results obtained from the scale concur with the results predicted from the
underlying theoretical model. Testing the scale against the gold standard
measures criterion validity. Content validity is measured by the extent to which
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the scale contains all relevant dimensions of what is being measured (Hantson
and De Keyser, 1994, Wade, 1992).
The scale chosen needs to be able to detect clinically important changes in the
patient's condition; this is referred to as the scale's sensitivity. The simplicity of
the scale is also important; using a simple measure will improve compliance
and reliability. Unfortunately, for a scale to be sensitive a complex measure is
normally required and therefore this decreases the reliability and simplicity,
leading to a trade off between the three (Wade, 1992).
Alongside these statistical factors, an outcome also needs to be able to detect
clinically relevant differences in the effectiveness of various therapies for a
given disease, with the smallest number of patients possible (Broderick et al.,
2000).
1.3.4 Frequentlv used outcome scales
There are many outcome scales available for measuring disability, impairment,
and handicap. In stroke research three scales are predominantly used in large
multi centre randomised controlled clinical trials; these are the Barthel Index,
modified Rankin Scale, and the Three Questions outcome, each is discussed in
detail below.
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Barthel Index (BI)
The Barthel Index (BI) was first published in 1965 as a simple and effective
way of measuring a patient's level of independence (Mahoney and Barthel,
1965). It consists of ten weighted items which measure feeding, bathing,
grooming, dressing, bowel control, bladder control, toileting, chair transfer, and
stair climbing. A score of zero is given when the patient cannot meet any of the
criteria, and 100 is the maximum score. Many have used the BI with a score
out of 20 rather than 100, as it is thought that larger score gives a false
impression of the scale's accuracy (Collin et al., 1988). Although not defined in
the scale, patients who die are usually given the arbitrary score of minus five to
distinguish them from those with the lowest level of dependence.
An example of the BI is given in Table 1.5 at the end of this chapter.
The reliability and validity of the BI are well established (Collin et al., 1988,
Granger et al., 1979, Wade and Langton Hewer, 1987). In 1996 a study which
re-evaluated the reliability and validity of stroke scales found that the BI was
the most reliable disability scale (D'Olhaberriague et al., 1996). The BI has
been shown not only to have high reliability and validity when used as an
ordinal scale, but also when dichotomised at 90 to compare those who are
independent (~90) against those who are dependent. The BI can be
administered reliably in a variety of ways, including face to face interview,
telephone interview and by using a postal questionnaire (Yeo et al., 1995). This
makes the BI especially useful in studies with a long follow up period or where
a large population of highly dependent patients is being assessed. The BI can
be used to predict outcome and has been shown to forecast survival, length of
hospital stay and progress in stroke patients (Wilkin et al., 1993). The main
disadvantages of the BI are the presence of profound floor and ceiling effects.
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Floor and ceiling effects occur when many participants are scored at the highest
or lowest point of the scale, although this is true for most measures of ADL.
The BI is also insensitive to small changes in functional ability. Some
modifications to the BI have been proposed to overcome some of these
problems (Granger et al., 1979), but none have sufficiently improved the
original in terms of reliability and validity to replace it (Wade, 1992). The BI is
the most commonly used ADL scale (Wade, 1992, Roberts and Counsell, 1998).
Modified Rankin Scale (mRS)
The Rankin Scale was developed as a five level scale in 1957 from research on
the prognosis of stroke (Rankin, 1957). The scale is a simple and relatively
crude measure of handicap and is the stroke equivalent of the Glasgow
Outcome Scale (GOS) for brain injury (Jennett and Bond, 1975). In 1991 the
Rankin Scale was modified for use in the UK-TIA study to accommodate
language disorders and cognitive defects (now referred to as the modified
Rankin Scale, mRS) (Farrell et al., 1991).
An example of the mRS is given in Table 1.6.
The mRS is used regularly throughout stroke research. This is probably due to
the ease of administration and time efficiency of the scale. When analysing the
mRS, the scale has historically been dichotomised, comparing patients with a
good outcome to those with a poor outcome. A review by Suiter of stroke
research found that most studies defined a good outcome as either having a
mRS of si or a mRS of S2 (Suiter et al., 1999). This raises concern, since de
Hann found that a valid dichotomy was at mRS S3 (de Haan et at., 1995).
The scale is predominantly used to measure handicap, although many agree
that the scale actually measures disability rather than handicap (Bloch, 1988).
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A study by de Hann in 1995 found that results from the mRS were strongly
associated with mobility, disability in daily and instrumental activities, and
living arrangements. It found a low association with cognitive and social
functioning. ADL were found to be the most important explanatory factor of
mRS scores. This study concluded that the mRS should therefore be used as a
measure of functional health and physical disability rather than a measure of
handicap (de Haan et al., 1995).
The reliability of the mRS is well documented. A study looking at the inter rater
agreement found that out of 100 pairs of raters, 65 agreed with the level of
handicap (van Swieten et al., 1988). Giving raters a structured interview to
follow has been shown to improve reliability further (Wilson et al., 2002). Little
is known about the validity of the mRS (Bowling, 1995). The mRS has low
sensitivity; this is probably due to the simplicity of the measure. Improvements
have been suggested for the mRS, including reducing the number of grades
and removing the assessment of walking, but these have not been
implemented as this reduction would lead to an even more decreased level of
sensitivity (van Swieten et al., 1988).
Three Questions outcome (3Q)
The International Stroke Trial (1ST) was a large randomised controlled trial
comparing treatment with aspirin, heparin or both in 19,435 patients with acute
ischaemic stroke (International Stroke Trial Collaborative Group, 1997). The
trialists wanted a simple method of assessing dependency, as the large sample
size meant that standard methods such as the BI would be too costly in terms
of both time and money.
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In 1994 a pilot study was carried out to identify a few simple questions which
could establish functional status in a valid and reliable way (Lindley et al.,
1994). The questions chosen also needed to be reliable when administered in a
variety of ways, including face to face interview, over the telephone or as a
postal questionnaire. The questions selected were:
1. Is the patient alive? (Vital status question)
2. In the last two weeks did you require help from another person for
everyday activities? (Dependency question)
3. Do you feel you have made a complete recovery from your stroke?
(Recovery question)
By comparing the 3Q outcome with the BI and the Oxford Handicap Scale
(OHS) (Bamford et al., 1989) (a variant of the mRS), the study found that
asking these three simple questions was a valid way of distinguishing between
patients who had good and bad functional outcomes after stroke. They found
that even though the scale was crude, as the intention of the study was to look
at overall functional outcome for a large group of people it was sufficient to do
this. The study ascertained that there was no significant difference in the
accuracy of the scale when administered by either a postal questionnaire or a
telephone interview. When looking at the raters, it was found that patients
were better at rating themselves than carers when they had a good functional
outcome and, interestingly, that carers were better at rating the patients when
the patient had a bad outcome.
When comparing the BI and the OHS, it was found that the second question
could accurately identify a poor outcome, defined as BI<100, 75% of the time.
Similarly, the third question could identify an OHS score of zero (equivalent to
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mRS of zero) 90% of the time (Lindley et al., 1994). A study using data from
the Italian centres in the 1ST trial found comparable results (Celani et al.,
2002).
1.3.5 Issues with data from functional outcome scales
Data gained from outcome scales have particular properties which need to be
appreciated when choosing the type of analysis to carry out. There are four
main types of data that can be measured: nominal, ordinal, interval and ratio.
Nominal data is considered the lowest level of data, where the data are
categorical and no ordering can be applied. Examples of nominal data are
gender, blood group, and marital status. This type of data is usually analysed
using contingency tables and comparing frequencies using a chi square test
(Jakobsson, 2004, Wade, 1992).
Outcome scales are usually ordinal in nature. The central feature of ordinal data
is that it expresses increasing or decreasing order to the extent of some
observable phenomenon. For example, education is ordinal when measured as
"primary", "secondary", "college", "undergraduate" and "postgraduate" (Moses
et al., 1984). A secondary feature is that although there is clear ordering to the
categories the absolute distance between them is unknown (Agresti, 1984).
Using the BI as an example, a patient who scores 20 on the BI is more disabled
than someone scoring 40, but the patient scoring 40 does not necessarily have
half the disability of the patient who scored 20. Data from scales such as the SI
and mRS which produce numbered ordered categories are often mistaken for
continuous data, but the values are just indicating the order and not actual
numeric values. Historically across many disciplines, not only stroke, ordinal
data is analysed incorrectly. In 1984, Moses carried out a review of articles
from the New England Journal of Medicine over a six month period; this found
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that 18/168 studies collected ordinal data. Of these he found that 30%
dichotomised the data and 33% analysed the data in a contingency table that
ignored the ordering (Moses et al., 1984). A study looking at ordinal data
analysis in a rheumatology journal found similar results with only 39% of the
articles surveyed having appropriate data presentation and 63% having
appropriate analysis (Lavalley and Felson, 2002). A further study looking at
nursing research found that out of 166 articles, 51 had used ordinal methods,
with only 49% of these displaying this data appropriately and 57% using
appropriate data analysis (Jakobsson, 2004).
Another feature of data from outcome scales is its distribution. Data from the
BI, for example, has profound floor and ceiling effects. This is becausearound a
third of the patients will have died (scoring -5), around another third of the
patients will have recovered completely (scoring 100). The remaining patients
spread across the rest of the scale (See Figure 1.5).
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FIGURE 1.5
Distribution of SI at three months, data from the NINDS trial (The National
Institute of Neurological disorders stroke rt_PA stroke study group, 1995).
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This unusual distribution means that standard parametric methods such as
comparing means may not be valid and a non-parametric approach should be
taken.
Interval scale data is similar to ordinal data but the differences between the
scores are identical. Therefore the unit difference between ten and lion a
scale is the same as a difference between 50 and 51. An interesting point about
interval scales is that there is no natural zero, which means that ratios of the
data do not make sense. For example, like ordinal scales, a score of ten on an
interval scale is not twice as good as a score of five. A good example of an
interval scale is the Fahrenheit scale for temperature. Equal differences on this
scale represent equal differences in temperature, but a temperature of 30
degrees is not twice as warm as one of 15 degrees. Interval scale data can be
analysed using parametric methods (Wade, 1992).
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The final type of scale data is ratio. Ratio data are continuous data where both
the differences between units and ratios are interpretable. Unlike interval data,
ratio data have a natural zero. Height and weight are examples of ratio data,
two meters is twice as tall as one metre and the difference between 1.2 and 1.3
meters is the same as the difference between 5.6 and 5.7 meters (Bland,
2000). Parametric methods can be applied to ratio data.
1.4 CLINICAL TRIALS IN STROKE
Randomised controlled trials have greatly improved the care and outcome of
patients with acute stroke, although the number of trials carried out and
patients included is not reflected in the number of beneficial treatments. By the
end of 1999, around 74,000 patients with acute ischaemic stroke had been
included in 178 trials (Kidwell et al., 2001). A review of trials up to March 2006
gave much higher estimates with 9,409 completed stroke trials, 2,240 of these
being in the acute setting (Bath et al., 2007). The majority of these trials have
shown no treatment effect, with aspirin and thrombolysis with alteplase, the
only agents now being used in acute stroke. There are many possible reasons
for the failure of these trials, including the relevance of laboratory findings to
clinical stroke, inadequate sample size, the choice of primary outcome and its
statistical analysis.
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1.4.1 Relevance of laboratory findings
Many potential stroke treatments have shown efficacy in animal models but
there has been a difficulty in translating these results into humans. For
example, NXY-Os9, a neuroprotection agent, significantly reduces infarct
volume in mice, rats and marmosets, but when tested in a large clinical trial
showed neutral results (Lees et al., 2006, Bath et al., 2008). Many reasons
have been put forward for this failure including the quality of animal studies,
the design of animal studies (randomisation to treatment, blinding of outcome
measures, sample size calculation) and the applicability of animal studies to
humans (Sena et al., 2007). The "Collaborative Approach to Meta Analysis and
Review of Animal Data from Experimental Stroke" (CAMARADES) is a
multidisciplinary collaboration addressing these problems (Macleod and
Sandercock, 2005).
1.4.2 Inadequate sample size
In 2004 a review of sample size calculation in acute stroke trials was carried
out (Weaver et al., 2004). This review included 189 fully reported randomised
controlled trials and found that only 57 gave detail on their sample size
calculation (30%). Most of these 57 were published after 1996 with the
introduction of the "Consolidated Standards of Reporting Trials" (CONSORT)
statement, which required trials to include their sample size calculation in the
trial manuscript in order to be published in prestigious peer reviewed journals
(The CONSORT Statement, 1996). Of these 57 the majority were
underpowered, using unrealistic event rates and intervention effects or using
inappropriate outcomes, such as death (Weaver et al., 2004). For example, 24
trials had a primary outcome of death or dependency, and had a median
intended reduction of 12% (inter quartile range 10%-15%). Whereas on
completion, the actual median reduction found was 1.9% (inter quartile range -
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0.5%-5.4%), which shows a major overestimation of the desired clinically
important difference used in these trials.
It is important therefore to consider how sample size is to be calculated when
recommending any particular method of analysis to trialists.
1.4.3 Choice of primary outcome and its statistical analysis
In 1998, a study reviewed the outcomes used in stroke research and the
appropriateness of these outcomes and the statistical analysis applied to them.
All published acute stroke trials reported in English from 1955 to 1995 were
included in the review. They found that the most common measures of
disability were the BI (21%), trial specific outcomes (11%) and the mRS (9%).
This is a concern as more trials were using an unvalidated measure, as opposed
to the mRSwhich has been shown to be a reliable way of measuring disability.
Several of the trials assessed had measured disability using more than one
scale.
The review found that most trials had used a less than optimal method of
analysis. They found that many trials had analysed the outcome scale data as if
it were continuous, using parametric methods. Twelve trials using the BI
analysed it as a dichotomous variable, but with no standardisation in the cut-off
point used to define a good outcome. Five trials used a cut-off of ~60, four used
~70, one used ~90 and another trial used a cut-off of ~95 (Roberts and
Counsell, 1998).
This review highlights a plethora of problems in the choice of outcome and
analysis; these problems are assessed in the subsequent sections.
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Dichotomisation
Dichotomisation involves collapsing data into two groups; dichotomous data is
a type of nominal data. Dichotomous outcomes are perceived as clinically
meaningful, as clinical definitions can be placed on the groups and therefore
easily interpreted. For example, thrombolysis with alteplase reduced death or
dependency (defined by a score of greater than one on the mRS) by 13% in the
NINDS part two trial (The National Institute of Neurological Disorders and
Stroke rt-PA Stroke Study Group, 1995). Whereas an analysis based on the
actual ungrouped data would be presented as average improvements, e.g.
alteplase improved the mRS by one of seven points and BI by 22.5 (of 100)
points, which may be harder to explain to patients. However, using a
dichotomous outcome inherently means that clinical meaning is only attributed
to transitions in outcome that occur over the pre-specified cut-off point for a
favourable outcome. This is demonstrated in Figure 1.6, which shows an
artificial example of a trial which has chosen a cut-off for a good outcome of :S2
on the mRS. Much data is lost, for example, very severe patients who improve
a point on the mRS do not add anything as both their pre and post scores are
higher than the threshold for a "good outcome".
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FIGURE 1.6
The pitfalls of using a dichotomised outcome.
Included in the analysis
1o
Not contributing to analysis
Only those who cross
the cut-off
2
------Severe patients
who die
Severe patients
who improve/deteriorate
Mild patients
who improve/deteriorate
A review of the use of the BI and mRS in stroke trials found that a favourable
outcome was defined variably on the BI as ~50, ~60, ~75, ~85 and ~95, and
on the mRS as ::51,and ::52.Other trials had compared median scores and three
trials had used a combined BI/mRS scale. The review highlighted that most of
these end points were arbitrarily chosen and there was no evidence of
validation. The review concluded that it might be beneficial to use poor
outcome as an end point and to define this if any of the following occur; death,
institutionalisation, mRS>3, or BI<60 (Suiter et al., 1999).
In contrast, another study found that changing the outcome from mRS~2 to
mRS~3 did not change the result of a meta analysis looking at the efficacy of
thrombolytic therapy. The study concluded that if a treatment is beneficial it
probably doesn't matter where the data is dichotomised (Wardlaw et al., 2000).
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A post hoc study of the NINDS stroke trial data used classification and
regression tree analysis to find the most powerful binary outcome. The results
showed that end points which used the mRS cut at ~1 were the most powerful
(Broderick et al., 2000).
Berge and Barer (2002) recommended that if dichotomous outcomes were to
be used then the cut point should be set near the middle of the distribution of
the expected outcomes; this choice is thought to be more efficient than picking
an extreme value (Berge and Barer, 2002). Although it may be hard to judge at
the protocol development stage of a trial where the median will lie, this is
equivalent to the median test (Siegel and Castellan, 1988).
When picking a cut point for defining a favourable outcome, it is important to
take into account the population of patients to be recruited into the trial. A
recent trend in stroke trials has been to copy the outcomes used in a previous
trial which showed a statistically significant treatment effect, but this may lead
to trials picking an unsuitable cut. For example, the "Surgery for the Treatment
of Malignant Infarction of the Middle Cerebral Artery" (DESTINY)trial (Juttler et
al., 2007) of decompressive surgery, recruited patients who were suffering
from life-threatening brain swelling as a consequence of a massive ischaemic
stroke. These patients have very severe strokes and therefore a cut between
three and four on the mRS was chosen for the primary outcome. See Figure
1.7. In contrast, Figure 1.8 shows the distribution of the mRS from the NINDS
trial which included much milder patients and therefore used a cut between one
and two on the mRS. An advantage of dichotomy is that it negates the need to
assign arbitrary values to dead patients, where no value for death automatically
exists in the scale (Tilley et al., 1996).
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FIGURE 1.7
Distribution of outcomes in the DESTINY Trial (Juttler et al., 2007).
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FIGURE 1.8
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Distribution of outcomes in the NINDS Trial (The National Institute of
Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995).
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Overall, there appears to be little consensus as to where trialists should
dichotomise data. The main disadvantages of using outcomes which have been
dichotomised are the loss of information, as only those patients who move
across the chosen cut point will be included in the comparison and the difficulty
in choosing a place to cut the data. Hence, using a method which does not
require trialists to dichotomise will avoid these pitfalls. Choosing a method
which retains the original raw data may also allow tria lists to widen their
inclusion criteria into the trial. For example, the ongoing 'Efficacy of Nitric Oxide
in Stroke' (ENOS) trial (The ENOSTrial Investigators, 2006) restricts inclusion
to those who have a pre-stroke mRS of S2; this is because the primary
outcome is dichotomised at two and therefore those who were disabled prior to
their stroke will not realistically cross this point post stroke and therefore would
not add any information to the primary end point (The ENOS Trial
Investigators, 2006).
Patient specific outcomes
Berge and Barer (2002) suggested that trials should be using "patient specific
outcomes", i.e. a 'good' outcome has a separate definition for separate
prognostic groups (Berge and Barer, 2002). They contended though that for
this type of end point to work there needs to be an agreed standard method of
classifying patients into prognostic groups. They proposed the definitions given
in the Table 1.2.
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TABLE 1.2
Proposed outcome by Berge and Barer (2002).
Prognostic group Outcome group
Good Intermediate Bad
(mRS score) (mRS score) (mRS score)
Severe 0-3 4 S/dead
Moderate/bad 0-2 3 4-S/dead
Moderate/good 0-1 2-3 4-S/dead
Good 0-1 2 3-S/dead
The patient specific outcome was assessed alongside those which dichotomised,
in a study which aimed to find the most powerful end point for use in acute
stroke trials (Young et al., 2003). This study used simulation to explore the
patterns and magnitudes of treatment effects and the statistical power for a
range of end points based on the BI and mRS. The study found that generally
mRS end points were more powerful than those using the BI. It was also found
that the most powerful end points were patient specific, those which were
dichotomised towards the favourable extreme and those which combined the BI
and mRS.
A more recent paper has also focused on the patient specific outcome, and
aimed to find definitions of a good outcome on the mRS for various levels of
baseline severity, measured by the NIHSS scale (Adams et al., 2004). The
definitions used in this study are given in Table 1.3.
An example of the NIHSS is given in Table 1.7.
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TABLE 1.3
Definitions of a good outcome on the mRS for levels of baseline severity on the
NIHSS scale (Adams et al., 2004).
Baseline NIHSS score Outcome group
mRS
<8
8-14
>14
o
0-1
0-2
This paper takes the earlier work of Berge and Barer (2002) one step further by
giving actual levels of severity instead of just the subjective headings of mild,
moderate and severe. The study carried out its proposed analysis on three
completed and reported clinical trials. They found that although the patient
specific analysis did not change the overall result of any of the trials it gave the
opportunity to look at the effect of the treatment across the levels of baseline
severity (see Figure 1.9) (Adams et al., 2004).
FIGURE 1.9
Diagram of patient-specific outcome.
If NIHSS<8
o
o 1
If NIHSS 8-14
o 1
If NIHSS>14
2
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The phase two trial "Emergency administration of abciximab for treatment of
patients with acute ischemic stroke" (AbESTT)was one of the first stroke trials
to include a patient specific outcome as a secondary end point. This end point
along with the primary end point showed a beneficial effect of abciximab
compared to placebo (Abciximab Emergent Stroke Treatment Trial (AbESTT)
Investigators, 2005). A phase three trial was then initiated using the patient
specific outcome as the primary end point (AbESTTII). Unfortunately this trial
was terminated prematurely due to an excess of bleeding events in the
abciximab group. The patient specific outcome also did not show efficacy of
abciximab (Adams et al., 2008).
This type of outcome is perhaps more appealing than simple dichotomisation,
but it is still based on a group of dichotomised end points.
Global outcomes
Some have argued that restricting an end point to one scale may be limiting, as
no scale describes all dimensions of recovery from stroke. Global outcomes can
be used to combine data from two or more scales. The NINDS trial was the first
stroke trial to use a global end point, and utilised generalised estimating
equations to pool the data into one overall result using the Wald test (Tilley et
al., 1996). They combined data from four dichotomised scales, as shown in
Table 1.4.
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TABLE 1.4
NINDS global outcome definitions of a favourable outcome (Tilley et al., 1996).
Scale Dichotomy used
mRS
BI
NIHSS
GlasgowOutcome Scale (GaS)
<1
>95
<1
1
The NINDS trial showed a beneficial treatment effect for thrombolysis with
alteplase using both the global outcome and additionally testing each scale
separately. It does require data to be collected on four scales at the follow up
point which could increase the length and costs of follow ups and, as with the
patient specific outcome, is still based on dichotomised data and therefore has
all the disadvantages of these. The European Medicines Evaluation Authority is
also reluctant to consider global end paints as they may combine very diverse
data (Committee for Proprietary Medicinal Products (CPMP), 2001). Although a
study comparing a global outcome to those based on a single scale found that
combining the mRS and BI gave a more statistically powerful outcome than
analysing either scale on its own. They also found the global outcome to be
more powerful than a patient specific outcome (Young et al., 2003).
Type of analysis
Little work has been done looking at outcomes which maintain the raw data
from the outcome scales. By dichotomising ordinal scales information is lost
and it might be expected that types of statistical analysis that preserve and
utilise the data in this ordinal form may be more powerful.
A study carried out in 2006 reviewed 100 trials where the BI had been used as
the outcome (Song et al., 2006). They recommended that tria lists reported
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mean BI scores to facilitate meta analyses and that the Wilcoxon test appeared
to have the greatest power to detect differences between treatment groups
compared to dichotomised end points and using ordinal logistic regression
analysis. However, this is a confusing message as the paper advocates a non-
parametric method of analysis but also suggests giving parametric summary
statistics.
Summary
This literature review has shown the general lack of agreement on a standard
effective end point in stroke research. Most of the research in this area has
focused on reviewing the methods which have been used previously in
published clinical trials. Only the Young and NINDS studies (Young et al., 2003,
Broderick et al., 2000) tested to see which end points were the most powerful
and therefore should be recommended for use. Although the NINDS study only
considered binary end points and the Young study did not consider methods for
non parametric ordinal data, such as the Wilcoxon test. All of the studies
discussed above are based in the acute setting and although outcome scales
are frequently used in rehabilitation studies as well, no studies have focused on
this area.
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1.4.4 Published alternative statistical analysis of clinical trials
There have been several clinical trials where an alternative statistical analysis
has been performed and the results have been published. These give weight to
the argument that sub optimal end points and statistical analyses are being
used in clinical trials in stroke.
The first "European Cooperative Acute Stroke Study" (ECASS I) tested the
efficacy and safety of alteplase given within six hours of ischaemic stroke onset
(Hacke et al., 1995). The primary end paints were the median BI and mRS at
90 days post randomisation. The study was powered to detect a 15%
improvement of the median of each primary end point. The results showed no
statistically significant benefit for alteplase. The NINDS trial also tested
alteplase but with different time windows, 90 and 180 minutes. The NINDS trial
used a global end paint analysis as their primary outcome (Tilley et al., 1996)
and showed a beneficial result and the Food and Drug Administration therefore
licensed thrombolysis with alteplase for use in acute ischaemic stroke.
The ECASSI investigators undertook a post hoc analysis of the trial data to see
whether using a different statistical design would have given them a statistically
significant result. Global end point analysis was carried out on the ECASSI data
using three outcomes, :S1on the mRS, 2:95 on the BI and :S1on the NIHSS.
The global outcome analysis showed a statistically significant increase of
favourable outcome in the alteplase group (p=0.008, OR=1.5, 95% Cl 1.1 to
2.0). It was concluded that this post hoc analysis may indicate that the time
window for alteplase may be as long as six hours, and that the initial choice of
end point was sub optimal. However, as this was a retrospective analysis this
result could only be used to support data from the NINDS trial and not to show
efficacy in using alteplase in a six hour time window (Hacke et al., 1998).
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The second "European Cooperative Acute Stroke Study" (ECASSII) was similar
in design to ECASSI but used a lower dose of alteplase. Akin to ECASSI, no
significant benefit of alteplase was found. Again the researchers felt that had a
different outcome been used a statistically significant result may have been
found. The primary outcome used was the mRSdichotomised between one and
two. (See Figure 1.10). It was decided to re-analyse the data using
bootstrapping. Bootstrapping is a computer intensive method that involves
choosing random samples with replacement from a data set and analysing each
sample the same way, and then using these samples to make inferences
(bootstrapping will be described in further detail in Chapter 3) (Efron and
Tibshirani, 1993). Bootstrapping was chosen as its does not require the
researcher to make any assumptions about the distribution of the data. For
example, changing the cut on the mRS could be perceived as data driven, i.e.
picking a cut point which gives the lowest p value. The post hoc bootstrap
analysis showed a statistically significant beneficial treatment effect. The
ECASSII investigators concluded that further clinical trials would need to be
carried out to confirm this result (Stingele et al., 2001).
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FIGURE 1.10
Re-analysis of the ECASS II data.
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Figure 1.10 shows the arbitrary nature of dichotomous end points and the
effect the choice of cut can have on the result found. The cut point chosen in
the original trial shows no difference between the two groups (p=OA). If the
trialists had chosen the next cut up when setting up the trial, a statistically
significant result would have been found in the favour of alteplase (p=0.04).
More recently, both the NINDS and ECASS II trials have been re-analysed using
the Cochran Mantel-Haenszel test. This test compares two groups adjusting for
one or more variables (Savitz et al., 2007). Parallel to the previous paper,
when re-analysed a statistically significant result was found for the ECASS II
trial.
These examples have demonstrated how important the choice of primary
outcome and the subsequent analysis is. If dichotomising an outcome scale, the
choice of cut seems to be particularly important.
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1.5 OTHER AREAS USING ORDINAL SCALES
Stroke trials have come to a crisis polnt. Although a plethora of research has
been carried out using thousands of patients, only two treatments (aspirin and
thrombolysis with alteplase) have been proven to work and are being routinely
used. It is possible that lessons can be learnt from other therapeutic areas.
Many areas use ordinal scales as an outcome measure in clinical trials. Two
areas where work has been done to improve the statistical analysis of these are
traumatic brain injury and quality of life.
1.5.1 Traumatic brain injury
Traumatic brain injury trials also use an ordinal scale for their primary
outcome, the Glasgow Outcome Scale (GOS) (an example of the GaS is given
in Table 1.8), is a five level scale ranging from one (dead) to five (fully
recovered) (Jennett and Bond, 1975). The "International Mission for Prognosis
and Clinical Trial" (IMPACT)study is looking at ways to improve the design and
analysis of traumatic brain injury studies; they are interested in both clinical
trials and epidemiological studies (Marmarou et al., 2007). Part of this project
has looked at improving the analysis of data from the Gas. Historically the
majority of traumatic brain injury trials have, akin to stroke trials, dichotomised
outcome scales into favourable and unfavourable groups. The IMPACT study
has condemned this type of analysis as those with severe injury do not
contribute to the final outcome as their improvement will be limited and almost
certainly will not cross the pre-specified cut-off for a favourable outcome
(Murray et al., 2005).
IMPACTproposed the use of a patient specific outcome based on the work of
Berge and Barer (previously discussed in section 1.4.3) (Berge and Barer,
2002), although they termed this type of outcome as a "sliding dichotomy",
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They assessed this by comparing it with ordinal logistic regression analysis
using data from two completed clinical trials. Ordinal logistic regression
compares data across the whole scale and is similar to logistic regression but
does not require dichotomisation. Ordinal logistic regression makes the
assumption that odds ratio for the treatment covariate is the same for each
transition of the scale (termed 'proportional odds assumption') (see Figure
1.11).
FIGURE 1.11
Diagram of proportional odds assumption.
Control 0
Treatment 0
Control 0
Treatment 0
Proportional odds
Proportional odds
not met
They extended the previous work by using a prognostic model based on age,
baseline motor score, and baseline CT to divide patients into tertiles of risk,
with each risk group being given a different definition of a favourable outcome.
They found that the sliding dichotomy analysis was more sensitive than the
ordinal logistic regression. This type of analysis has since been used in two
trials of traumatic brain injury (Maas et al., 2006, Mendelow et al., 2005).
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The next part of the IMPACT project dealing with the analysis of ordinal
outcomes looked at taking into account covariates. They found that by
adjusting logistic regression analysis for seven important prognostic factors
sample size could be reduced by 25% (Hernandez et al., 2006).
This area of research is helpful for stroke trials, although the IMPACTstudy is
looking at a wide range of questions and therefore the focus is not just on
improving the statistical analysis of trials. The initial part of the project
advocates using a method of analysis that allows for shifts in outcome across
the whole scale, either by using ordinal logistic regression or a dichotomous
analysis with differing cuts for differing levels of risk, although the second part
looking at adjustment for covariates goes back to a limited logistic regression
analysis on dichotomised data.
1.5.2 Quality of life
Clinical trials in patients with cancer routinely use survival or time to
recurrence, as their primary outcome. More frequently, trials are including a
quality of life assessment as an outcome since this is perceived to be more
important to the patient and therefore an important factor in assessing the
efficacy of a new intervention.
Quality of life scales are similar to functional outcome scales as they are both
ordinal in nature. Therefore studies which have looked at the analysis of data
from quality of life scales maybe useful in improving the analysis of data from
functional outcome scales. The studies discussed here all use the Short-Form
36 health survey to measure quality of life, this measure contains 36 questions
on eight domains of quality of life resulting in a score of zero to lOO, where 100
is indicative of "good health" (Ware et al., 1993).
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The majority of work carried out in this area has looked at comparing the given
sample sizes needed if different methods of analysis are applied to trial data.
This type of analysis is analogous to looking at the power of that test; more
powerful tests will require smaller samples to find the same result as a lower
powered test. A study by Julious et al showed that methods of analysis which
rely on the assumptions of normality may not be suitable for quality of life data
and can lead to either over or under estimated sample sizes. Therefore
methods which do not make assumptions about distribution should be
employed (Julious et al., 2000). In contrast, others have suggested that where
scales have seven or more categories, methods such as the t-test which
assume normality may be reliably used, with the analysis of scales with fewer
categories using ordinal logistic regression (Waiters et al., 2001, Waiters,
2004).
Parallel to the ECASSII trial, bootstrapping (Efron and Tibshirani, 1993) has
also been assessedas an option for the analysis of quality of life data. Here it
was found that bootstrapping was no more powerful than other standard
methods and therefore given its complexity to carry out should not be
promoted for analysing quality of life data (Walters and Campbell, 2005).
The work of Walters and Campbell is interesting as quality of life data suffer the
same problems as functional outcome scale data (floor and ceiling effects,
nonlinearity), but this work is only based on Short-Form 36 health survey and
therefore may not be generalisable to other scales.
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1.6 AIM
The main aim of this project is to identify the most statistically efficient
techniques for analysing functional outcome data from stroke clinical trials. This
project intends to improve and extend on the research which has already been
carried out in five ways:
1. Using real trial data; functional outcome data follows an unusual
distribution which can be difficult to model with artificial data.
2. Using data from three stroke settings; all previous work has been
based on acute stroke trials, this project will include data from acute
stroke, rehabilitation, and stroke unit trials.
3. Assessing all methods of analysis; this project will not only assess
traditional nominal methods of analysis but also methods for ordinal
data, bootstrapping and modelling. The project will also look at other
outcomes which have been used in stroke trials, such as patient specific
outcomes and global outcomes which combine data from two or more
scales.
4. Adjustment for covariates; so far research has only considered
univariate methods. In some cases it may be beneficial to adjust for
imbalances in baseline characteristics or take into account prognostic
variables. After the assessment of univariate methods this project will
also assessmodels available for ordinal outcome scales.
5. To consider the analysis of stroke prevention trials.
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TABLE 1.5
Barthel Index (BI) (Mahoney and Barthel, 1965).
Scored out of 100 with those who have died coded as -5
Domain
Bowels
Item Points
Incontinent (or needs to 0
be given enemata)
Occasional accident 5
(once a week)
Continent 10
Incontinent, or 0
catheterised and unable
to manage alone
Occasional accident 5
(maximum once per 24
hours)
Continent 10
Dependent 0
Needs some help, but 5
can do something alone
Independent 10
Needs help with personal 0
care
Independent 5
face/hair/teeth/shaving
(implements provided)
Unable 0
Needs help cutting, 5
spreading butter, etc.
Independent 10
Bladder
Toilet use
Grooming
Feeding
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Transfer (from bed to Unable, no sitting 0
chair and back) balance
Major help (one or two 5
people, physical), can sit
Minor help (verbal or 10
physical)
independent 15
Mobility Immobile 0
Wheelchair independent, 5
including corners
Walks with help of one 10
person (verbal or
physical)
Independent (but may 15
use any aid; for
example, stick)
Dressing Dependent 0
Needs help but can do 5
about half unaided
Independent (including 10
buttons, zips, laces, etc.)
Stairs Unable 0
Needs help (verbal, 5
physical, carrying aid)
Independent 10
Bathing Dependent 0
Independent (or in 5
shower)
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TABLE 1.6
Modified Rankin Scale (mRS) (Rankin, 1957).
Level Description
o No symptoms
1 No significant disability, despite symptoms; able to perform all
usual duties and activities
2 Slight disability; unable to perform all previous activities but able to
look after own affairs without assistance
3 Moderate disability; requires some help, but able to walk without
assistance
4 Moderately severe disability; unable to walk without assistance and
unable to attend to own bodily needs without assistance
5 Severe disability; bedridden, incontinent and requires constant
nursing care and attention
6 Dead
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TABLE 1.7
National Institute of Health Stroke Scale (NIHSS) (Brott et al., 1989).
Domain
Level of Consciousness
Item Points
Alert, keenly responsive 0
Obeys, answers or 1
responds to minor
stimulation
Responds only to 2
repeated stimulation or
painful stimulation
(excludes reflex
response
Responds only with 3
reflex motor or totally
unresponsive
Answers both correctly 0
Answers one correctly or 1
patient unable to speak
due to any reason other
than aphasia or coma
Answers neither 2
correctly, or too
stuporous or aphasic
Performs both tasks 0
correctly
Performs 1 task correctly 1
Performs neither task 2
correctly
Normal 0
Partial gaze paise 1
Forced deviation or total 2
gaze paresis not
overcome by
oculocephalic maneuver
LOC questions (month
and age)
LOC commands (open
and close eyes and then
grip and release non-
paretic hand)
Best gaze
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Visual fields No visual loss 0
Partial hemianopia 1
Complete hemianopia 2
Bilateral hemianopia 3
(blind from any cause
including cortical
blindness)
Facial palsy Normal symmetrical 0
movement
Minor paralysis 1
(flattened nasolabial
fold, asymmetry on
smiling)
Partial paralysis (total or 2
near total lower face
paralysis)
Complete paralysis 3
(absence of facial
movement upper/lower
face)
Arm Motor (score both No drift - holds for full 0
right and left arm) 10 seconds
Drifts down before ten 1
seconds but does not hit
bed/support
Some effort against 2
gravity, but cannot get
up to 90 (or 45 if supine)
degrees
No effort against gravity, 3
limb falls
No movement 4
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Leg motor (score right No drift - holds for full 0
and left leg) five seconds
Drifts down before five 1
seconds but does not hit
bed/support
Some effort against 2
gravity
No effort against gravity, 3
limb falls
No movement 4
Limb ataxia Absent 0
Present in one limb 1
Present in two limbs 2
Best language No aphasia 0
Some loss of fluency or 1
comprehension
Severe aphasia - 2
fragmentary
communication, listener
carries burden of
communication
Mute, global aphasia. NO 3
usable speech OR
auditory comprehension
Dysarthria Normal 0
Slurs some words 1
So slurred as to be 2
unintelligible, or mute
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Extinction/Inattention No abnormality o
Inattention to any 1
sensory modality or
extinction to bilateral
simultaneous stimulation
in one sensory modality
Profound hemi- 2
inattention or hemi-
inattention to more than
one modality. Does not
recognize own hand
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TABLE 1.8
GlasgowOutcome Scale (GOS) (Jennett and Bond, 1975).
Level Description
1 Dead
2 Vegetative state: Unable to interact with environment;
unresponsive
3 Severe disability: Able to follow commands; unable to live
independently
4 Moderate disability: Able to live independently; unable to return to
work or school
5 Good recovery: Able to return to work or school
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CHAPTER 2
GENERAL METHODS
S9
PUBLICATIONS/PRESENTATIONS CONTRIBUTING TO THIS CHAPTER
Gray L.l, Bath P.M.W, OAST Collaborators (2005) Statistical analysis of ordered
outcome data. A review of methods used in the trials included in 'Optimising the
Analysis of Stroke Trials' project. (OAST) Poster presentation at the Research
Students Conference, Cambridge, April 2005.
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2.1 INTRODUCTION
This chapter details the general methods which apply to subsequent chapters.
In particular this chapter will discuss in detail the setting up of the trial
database which was used throughout this project. Chapter specific methods will
be discussed in the relevant chapter.
2.2 OPTIMISING ANALYSIS OF STROKE TRIALS DATA
This section will discuss the setting up of the 'Optimising Analysis of Stroke
Trials' (OAST) database.
2.2.1 Identification of trials
Individual patient data from randomised controlled trials assessing functional
outcome after stroke were sought from four groups of studies:
1. Trials showing significant benefit on their primary outcome
2. Trials showing significant harm on their primary outcome
3. Trials showing no significant effect but within a meta analysis showing
significant benefit
4. Trials showing no significant effect but within a meta analysis showing
significant harm
Trials relating to ineffective interventions as determined from published meta
analyses were excluded. Trials were identified using a number of search
strategies. Firstly, meta analyses of beneficial or harmful treatments were
identified from the Cochrane Library. Secondly, electronic searches of Medline,
Embase and PubMedwere carried out using the terms "Stroke" and "Trial", if
any trials of interventions not identified during the search of the Cochrane
Library were found, another search of the Cochrane Library was carried out
looking for reviews of that intervention. Thirdly, hand searches of the journals
Stroke and Cerebrovascular Diseases were carried out and all trials listed on
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the online directory of stroke clinical trials were assessed (see:
http://www.strokecenter.org /trials/). Finally, new trials of beneficial or harmful
interventions were sought from the announcement of the trial's results at
international conferences.
The Chief Investigator (Cl) of each trial identified was contacted and asked if
they would share their data with the 'Optimising Analysis of Stroke Trials'
(OAST) Collaboration. All contacted investigators were informed that all data
shared with the collaboration would be kept confidential and would not be used
for any other purposes. CIs were asked to share the following data (where
available):
• Randomisedtreatment (compulsory)
• Functional outcome data (compulsory)
• Age
• Sex
• Baselineseverity
Individual patient data from several studies had already been gathered in four
data pooling projects ('Blood pressure in Acute Stroke Collaboration' (BASC)
(Blood pressure in Acute Stroke Collaboration (BASC), 2001), community
occupational therapy (Walker et al., 2004), low molecular weight heparin,
tirilazad (The Tirilazad International Steering Committee, 2002» and was used
where relevant following agreement with the Cl.
Table 2.1 summarises the trials which were selected for inclusion and where
permission was granted and data were supplied. For some trials permission to
use data was not given, but it was possible to extract the data from the original
publication (MAST-E (Multicentre Acute Stroke Trial-Italy (MAST-I) Group,
1995), EAST (Enlimomab acute stroke trial investigators, 2001), Edaravone
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(The Edaravone Acute Brain Infarction Study Group (Chair: Eiichi Otomo MD),
2003), Helsinki (Kaste et al., 1995), PROACTII (Furlan et al., 1999), Orpington
2000 (Kalra et al., 2000), Streptokinase pilot (Morris et al., 1995), and FISS
TRIS (Wong et al., 2005».
2.2.2 Setting up the database
SASstatistical software version 8 (SAS Institute, Cary NC) was used for all data
manipulation. Initially each data set was reformatted into a SAS data set and
saved into a library. All data was reformatted so that variable names, labels
and formats were consistent across all data sets. The variables needed for this
project were then copied from the original data set and saved. These new data
sets were then merged together to create the final database to be used in this
project.
Trials where two or more effective or detrimental active treatments had been
compared to a control were treated as two or more separate trials; therefore
the control patients were duplicated in the database. From here on, these will
be treated as separate trials. For example, the INWEST (Wahlgren et al., 1994)
trial is included twice: low dose nimodipine versus control; and high dose
nimodipine versus control. This is because both high and low dose nimodipine
showed a detrimental treatment effect when compared to control. Whereas, the
1STtrial compared, in a factorial manner, aspirin and heparin with no treatment
(International Stroke Trial Collaborative Group, 1997). Here only aspirin versus
no aspirin is included as there was no effect seen for heparin versus no heparin.
From here on, the actual trials included in the OAST project will be named
'trials' whereas the total number of treatment comparisons will be referred to
as 'data sets'. Table 2.2 lists the trials where multiple data sets have been
included.
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2.2.3 Data checking
All data were checked against the original trial publication to ensure
consistency. Where discrepancies were found the authors were contacted and
changes were made based on their recommendations. In some cases,
especially in older trials, it was not possible to reflect the findings exactly as
they were reported in the original trial publication.
2.2.4 Data manipulation
To ensure consistency across the OAST database many decisions about the
format of the data had to be made. This section details the changes and
judgments made while compiling the OASTdatabase.
2.2.5 Primary functional outcome scale
Many of the trials included collected data on more than one functional outcome
scale. For example, the NINDS trial (The National Institute Of Neurological
Disorders And Stroke rt-Pa Stroke Study Group, 1995) used a global outcome
which merged data from four scales (mRS, BI, NIHSS, GOS) for its main
outcome. In cases such as this, a decision had to be made about which scale to
use in the functional outcome analysis. Since the mRS is used in modern trials,
the mRS has been taken as the main outcome in the OAST project. In older
clinical trials, the BI was routinely used so it was hoped that this would give
large equal numbers of trials to be analysed using the BI and mRS. No trials
were included with multiple scales which did not include the mRS.
For consistency within and across functional outcome scales decisions had to be
made about the coding of each scale. It was decided that patients who were
dead at the time of follow up should be coded as a unit lower/higher, depending
on the direction of the scale, than the worse level on each scale. For example
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the worse level of the BI is zero and the scale increases in units of five, so
those patients who had died were recoded as minus five. It was decided to
recode those who had died and not simply assign them to the worse level, as
some of the scales being assessed have been designed to have a level for
death, for example mRSand the 3Q scale, and it was felt that it would be more
consistent to therefore have a separate level for all scales. A unit below the
most severe category was chosen as this was straightforward to put into
practice for any scale and the actual value chosen does not affect most of the
statistical methods which are being compared. For example, those methods
which are based on ranks such as the Wilcoxon test, and those which collapse
the data, such as the chi square test are not affected by the actual value
assigned to dead patients. There is also evidence that assigning a lower score
on the BI to those who have died increases statistical power (Song et al.,
2006). Table 2.3 describes the scales included and the levels ascribed to those
patients who had died.
Only four of the trials included did not use the BI, mRS or 3Q scale to measure
functional outcome. Two related trials used the Nottingham ADL scale (Barer et
al., 1988), another trial used the Rivermead scale (Walker et al., 1996) and the
remaining trial used a thirty pojnt ADL scale (Sivenius et al., 1985) (See Table
2.3 for details of other scales).
Where no data on death at the time of follow up was given a number of
strategies were set in place to recode those patients who had died. If the mRS
had been assessedas well as the primary outcome scale then this was used to
recode the primary outcome scale, as the value six is routinely used to denote
death. In a similar manner to the mRS, the GOS or NIHSS scale were also
used. If the dates of death and randomisation were given then the time of
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death was calculated and where this fell before or at the time of follow up the
patients were recoded as dead.
2.2.6 Length of follow up
Some trials also had two follow up assessment times reported, for example,
ATLANTIS A (Clark et al., 2000), EAST (Enlimomab Acute Stroke Trial
Investigators, 2001), Ebselen (Yamaguchi et al., 1998) and Corr (Corr and
Bayer, 1995). If one of these times was reported as the primary outcome, data
from this time point was used, i.e. in the EASTtrial (Enlimomab Acute Stroke
Trial Investigators, 2001) the mRS was measured at day five, 30 and 90, but
day 90 was quoted as the primary outcome time. If equal emphasis was given
to two time polnts then the time point closest to three months was used, i.e. in
the Ebselentrial (Yamaguchi et al., 1998) no primary outcome time was listed,
instead both day 30 and day 90 were given as major end points; therefore the
data from day 90 was used here as the primary outcome.
2.3 STATISTICAL METHODS
All main analyses were carried out in SAS (version 8) or STATA(version 7 or
version 8). All P values quoted are two sided, with statistical significance
relating to a p value of less than or equal to 0.05.
The specific statistical methods relating to each results chapter are discussed
within that chapter. Throughout this project there are two broad approaches
used to compare the various methods of analyses; firstly re-analysing data
from completed clinical trials and secondly using simulation to create data sets
with known treatment effects. Re-analysing data from completed trials is the
preferred method of comparison in this project. Stroke trial data has
complicated covariate structures which are difficult to replicate using
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simulation. Different interventions also have differing types of treatment effect,
i.e. some treatments may work well in all patients whereas others may have
the greatest effect in those with mild impairments, and again this type of
intricacy is difficult to reproduce artificially. Simulation is used when the OAST
data set does not have sufficient data to answer a particular question, but
importantly where simulation is used it is based on actual trial data and
therefore the covariate structures are retained and only the treatment effect is
altered. The two approaches also look at two slightly different questions, re-
analysing completed trial data is based on the treatment effect found in that
trial, whereas simulation looks at the efficiency to detect specific known effect
sizes. Simulation methods are also difficult to explain to clinicians and trialists.
Both approaches have been used to compare statistical methods in the previous
literature, but to variable extents. Where actual completed trial data has been
used, usually only one or two trials have been included and only comparing a
limited number of statistical methods. For example, the two papers which re-
analyse data from the two ECASStrials only re-analysed one data set and with
only one additional method compared to the original endpoint (Hacke et al.,
1998, Stingele et al., 2001). Two types of simulation have been used
previously, simulating data from one completed clinical trial (Young et al.,
2003) and simulating hypothetical data with known distributions (Song et al.,
2006). None of the literature has simulated data from a vast variety of trial
types, as used in this project.
When evaluating various methods of statistical analysis there are three
comparators which can be used - the level of statistical significance (p value),
the sample size needed for a given power, or the level of statistical power for a
given sample size. Here I have used the level of statistical significance and the
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reduction in sample size gained from using specific methods. These are the two
comparators which are most frequently used in the previous literature. The
level of significance is important to trialists as a statistically significant result
showing benefit can be used to gain approval for new products, a comparison of
p values was used in the re-analysis of the ECASSand NINDS trials (Hacke et
al., 1998, Stingele et al., 2001, Savitz et al., 2007). The reduction in sample
size is meaningful to tria lists and can be directly translated into savings in
terms of the cost and duration of clinical trials. Reductions in sample size have
been used as the comparator in work comparing methods of analysis in trials of
brain injury (Murray et al., 2005, Hernandezet al., 2006).
Throughout this project the term "statistical efficiency" refers to the level of
statistical significance found, i.e. the most statistically efficient test will report
the smallest p value in comparison to the other tests being compared.
2.4 DESCRIPTION OF OAST DATA SET
A total of 55 data sets (54,173 patients) were included, these comprised
individual patient data from 38 trials and summary data extracted from the
publications of a further nine studies; six trials had two active treatment
groups, and one had three active groups so a further eight data sets were
available. This section will further describe the data included in the OASTdata
set.
2.4.1 Baseline data
Table 2.4 shows the baseline characteristics of the trials included. The data
related to 34 acute stroke trials, seven trials of rehabilitation (1,164 patients)
and six trials of stroke units (1,399 patients).
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Trial characteristics
There was great variation in the size of the trials included, ranging from 20 to
20,655 (mean 1153, median 302). The majority of the trials had recruited less
than 1,000 patients (96%), with only the mega trials, 1ST and the Chinese
Acute Stroke Trial (CAST), including approximately 20,000 each.
The included trials covered a wide range of interventions:
• Abciximab (AbESTT)
Inhibits clot formation by preventing fibrinogen binding between platelets. The
AbESTT phase II trial included here (400 patients) showed a non significant
improvement in functional outcome at three months. A subsequent phase three
trial was stopped prematurely due to increased bleeding events in the treated
group (Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators,
2005).
• Alteplase (ATLANTISA& B, ECASSII, NINDS)
Is a powerful thrombolytic agent (clot busting), which is now licensed for use in
acute ischaemic stroke within three hours of onset. Four trials included (2,179
patients) (Clark et al., 2000, Clark et al., 1999, Hacke et al., 1998, The
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study
Group, 1995).
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• Aspirin (CAST, 1ST)
Is an antiplatelet, i.e. it stops platelets sticking together. It reduces death or
dependency at six months and this reduction is probably caused by preventing
early recurrent strokes. Two trials included (40,090 patients) (CAST (Chinese
Acute Stroke Trial) Collaborative Group, 1997, International Stroke Trial
Collaborative Group, 1997).
• Atenolol - propranolol (BEST)
Belong to a class of drugs called beta-blockers. A data pooling project showed
that this class of drug increased death and dependency after stroke. Four trials
included (367 patients) (Blood pressure in Acute Stroke Collaboration (BASC),
2001, Barer et al., 1988). Figure 2.1 shows the data from the BEST main trial.
This shows the distribution of the Nottingham ADL scale and demonstrates,
akin to the BI, a 'U' shaped distribution is found.
FIGURE 2.1
Distribution of functional outcome by treatment group for the BEST main trial of
atenolol versus control (Barer et al., 1988).
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• Citicoline (Citicoline 1, 7, 10 and 18)
Is thought to have neuroprotective benefits and appears to improve outcome
after stroke. Four trials included (1,652 patients) (Clark et al., 2001, Clark et
al., 1997, Clark et al., 1999, Warach et al., 2000).
• DCLHb
Diaspirin cross-linked haemoglobin (DCLHb) induces hypertension and had
shown promise in animal models of stroke. A trial of DCLHb showed it
significantly worsened outcome after stroke (85 patients) (Saxena et al.,
1999).
• Ebselen
Is being investigated as a possible neuroprotectant in acute stroke. One small
trial (298 patients) to date has shown that ebselen given with 24 hours of
stroke onset improves outcome at one month (Yamaguchi et al., 1998).
• Edaravone
Is a novel free radical scavenger and has been shown to be neuroprotective
after stroke in one trial (250 patients) (The Edaravone Acute Brain Infarction
Study Group (Chair: Eiichi Otomo MD), 2003).
• Enlimomab (EAST)
Is a mouse monoclonal antibody which has been shown in laboratory studies to
stop white blood cells sticking to the internal lining of blood vessels. However,
when tested in ischaemic stroke, it was shown to worsen outcome (one trial,
623 patients) (Enlimomab Acute Stroke Trial Investigators, 2001).
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• Factor VIla
Treatment with factor VIla within four hours after the onset of intracerebral
haemorrhage has been shown to limit the growth of the hematoma, reduce
mortality, and improves functional outcomes at three month post stroke (399
patients) (Mayer et al., 2005). However, the follow up phase three trial showed
no effect of factor VIla on functional outcome (Mayer et al., 2007).
• Feeding (FOOD3)
The FOOD 3 trial compared feeding with a nasogastric tube versus
percutaneous endoscopic gastrostomy (PEG) tube. Fatality and poor outcome
was significantly higher for patients who were fed via PEGtube (321 patients)
(The FOODTrial Collaboration, 2005).
• Lowmolecular heparin - Nadroparin/ fraxiparine (FISS, FISS-TRIS)
Works by thinning the blood and has been shown to improve outcome at six
months in acute ischaemic stroke in these two trials. Two trials included (907
patients) (Kay et al., 1995, Wong et al., 2005).
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• Nimodipine (INWEST)
Is a calcium channel blocker and was originally used to treat hypertension. A
trial of nimodipine in acute ischemic stroke (295 patients) was stopped early
due to a poor outcome in the treated patients (Wahlgren et al., 1994). Figure
2.2 gives the distribution of the BI in the high dose group compared to control,
it shows an excess of deaths (-5) in the treated group and a greater percentage
of good outcomes in the control group. This plot also again demonstrates the
'U' shaped data distribution associated with the BI in acute stroke trials.
FIGURE 2.2
Distribution of functional outcome by treatment group for the INWEST trial of
high dose nimodipine versus control (Wahlgren et al., 1994).
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• Occupational therapy (Corr, Gilbertson, Logan, TOTAL, Walker I and
Walker II)
Is the assessment and treatment of physical and psychiatric conditions using
activities to prevent disability and promote independent function in all aspects
of daily life. A data pooling project showed that occupational therapy improves
outcome after stroke. Six trials included (1,040 patients) (Walker et al., 2004,
Corr and Bayer, 1995, Gilbertson et al., 2000, Logan et al., 1997, Parker et al.,
2001, Walker et al., 1999, Walker et al., 1996). Figure 2.3 shows the results
from a trial of occupational therapy in stroke patients not admitted to hospital.
This shows a non-typical distribution of the BI with patients bunched at the top
end of the scale, this is because the patients enrolled had suffered from mild
strokes and therefore had not scored badly on the BI at follow up.
FIGURE 2.3
Distribution of functional outcome by treatment group for the Walker II trial of
occupational therapy versus control in stroke patients not admitted to hospital
(Walker et al., 1999).
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• Physiotherapy (Young)
Is concerned with maximising function and movement and is beneficial after
stroke. One trial included (24 patients) (Young and Forster, 1992).
• Pro-urokinase (PROACTII)
Is another type of thrombolytic therapy and been shown to improve outcome
after stroke in one trial (180 patients), although it increasesearly haemorrhage
(Furlan et al., 1999).
• Selfotel (ASSIST)
Is an N-methyl-D-aspartate antagonist which blocks a receptor that can lead to
neuronal damage. However, selfotel increased mortality in two trials (570
patients) in patients with acute ischaemic stroke (Davis et al., 2000).
• Streptokinase (ASK, MAST-E,MAST-I)
Is a thrombolytic therapy which has efficacy in breaking down clots in heart
attack patients, but was shown to increase death and poor outcome in acute
ischaemic stroke. Three trials included (1,272 patients) (Donnan et al., 1996,
Multicentre Acute Stroke Trial-Italy (MAST-I) Group, 1995, The Multicenter
Acute Stroke Trial - EuropeStudy Group, 1996).
• Stroke units (Dover, Helsinki, Kuopio, Nottingham, Orpington,
Newcastle)
Involve a multidisciplinary team of doctors and therapists who specialise in
post-stroke care. Being treated on a stroke unit is highly beneficial after any
type of stroke. Six trials included (1,399 patients) (Stevens and Ambler, 1982,
Kaste et al., 1995, Sivenius et al., 1985, Juby et al., 1996, Kalra et al., 2000,
Aitken et al., 1993).
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• Tirilazad (RANTTAS I & II, STIPAS, TESS I & II)
Is a nonglucocorticoid, 21-aminosteroid which had been shown to work well in
animal models of stroke but was shown to worsen outcome in humans (five
trials, 1,702 patients) (The RANTTAS Investigators, 1996, Haley, 1998, The
STIPAS Investigators, 1994, Peters et al., 1996, Orgogozo, 1995).
Data from such a wide range of interventions means the results from this
project will be generalisable to many different types of trial. The different types
of intervention are also reflected in the timing of the treatments, this ranging
from stroke onset to three hours post stroke for the alteplase trials and up to
one month for the occupational therapy trials.
The majority of trials followed patients up at three months (66%), with other
follow ups occurring at six months (23%), one year (9%) and one month (2%).
Patient characteristics
A total of 54,173 patients are included in this project. Where possible, data on
age, sex and severity were also collated on these patients.
Similarly aged patients were recruited into the majority of trials (mean average
age 71 (range 66 to 78)), reflecting the average age group of those suffering
from a stroke. Almost all of the included trials recruited slightly more males
than females (mean percentage males 53%).
Only 14 (all acute) of the included trials measured baseline severity using the
NIHSS. The average NIHSS scores varied from eight up to 14, with a mean of
12. This reflects a moderate stroke severity.
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2.4.2 Primary outcome
Table 2.5 shows details on the types of analysis used in each trial. The BI was
used to measure functional outcome in 22 trials (47%), 18 used the mRS
(38%), three used the 3Q scale (6%), one used the Rivermead scale (2%), two
related trials used the Nottingham ADL scale (4%), and one trial used its own
ordinal measure of ADL (2%).
The method of analysing functional outcome used in the original trial
publications varied considerably. Twenty three (48.9%) trials assessed the
treatment effect using a method which required the data to be collapsed into
groups, e.g. chi-square test; 17 (36.2%) used a test based on comparing
medians and four (8.5%) used a test which compared means; the remaining
trials were unpublished so the method of analysis is not known.
Where data had been collapsed into two or more groups the cut points chosen
varied significantly. Cuts points used on the BI were: <100, <95 and <60. For
the mRS >1, >2 and >3 were used, with >2 being used in the most trials
(five).
Thirty (65%) of the included trials were individually neutral, therefore they
were part of a meta analysis showing a treatment effect. Fourteen trials (30%)
showed a beneficial treatment effect and only two (5%) showed a harmful
treatment effect.
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TABLE 2.1
Trials selected for inclusion into the OASTproject.
,f data supplied by PI, * no data supplied but able to extract summary data
from manuscript, le data not supplied.
Trial Year Intervention Individual
data
supplied
AbESTT(Abciximab Emergent Stroke 2005 Abcixmab ,f
Treatment Trial (AbESTT)
Investigators, 2005)
APTIGANEL(Albers et al., 2001) 2001 Aptiganel le
Hydrochloride
ASK (Donnan et al., 1996) 1996 Streptokinase ,f
ASSIST 07 (Davis et al., 2000) 2000 Selfotel ,f
ASSIST 10 (Davis et al., 2000) 2000 Selfotel ,f
ATLANTISA (Clark et al., 2000) 2000 Alteplase ,f
ATLANTIS B (Clark et al., 1999) 1999 Alteplase ,f
BEST(Barer et al., 1988) 1988 Low dose ~ ,f
blockade
BESTpilot (Barer et al., 1988) 1988 Low dose ~
blockade
Young (Young and Forster, 1992) 1992 Community
physiothera py
CAST (CAST (Chinese Acute Stroke 1997 Aspirin *
Trial) Collaborative Group, 1997)
Citicoline 1 (Clark et al., 1997) 1997 Citicoline ,f
Citicoline 7 (Clark et al., 1999) 1999 Citicoline ,f
Citicoline 10 (Warach et al., 2000) 2000 Citicoline ,f
Citicoline 18 (Clark et al., 2001) 2001 Citicoline ,f
Corr (Corr and Bayer, 1995) 1995 Occupational ,f
therapy
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Day hospital trial (Hui et al., 1995) 1995 Day hospital le
DCLHb (Saxena et al., 1999) 1999 DCLHb ,/
DIAS (Hacke et al., 2005) 2005 Desmoteplase le
Dover stroke unit trial (Stevens and 1982 Stroke Unit ,/
Ambler, 1982)
EAST (Enlimomab Acute Stroke Trial 2001 Enlimomab *
Investigators, 2001)
EBSELEN(Yamaguchi et al., 1998) 1998 Ebselen ,/
ECASS I (Hacke et al., 1995) 1995 Alteplase le
ECASS II (Hacke et al., 1998) 1998 Alteplase ,/
EDARAVONE(The Edaravone Acute 2003 Edaravone *
Brain Infarction Study Group, 2003)
Factor VII (Mayer et al., 2005) 2005 Recominant ,/
activated factor
VII
FISS (Kay et al., 1995) 1995 Low-molecular
weight heparin
FISS TRIS (Wong et al., 2005) 2005 Low-molecular *
weight heparin
FOOD 3 (Dennis, 2004) 2004 Percutaneous
endoscopic
gastrostomy
Gilbertson (Gilbertson et al., 2000) 2000 Occupational
therapy
GLYCINE (Gusev et al., 2000) 2000 Glycine le
Goteberg stroke study (Fagerberg et 2000 Stroke unit le
al., 2000)
Helsinki stroke unit trial (Kaste et al., 1995 Neurology ward *
1995)
Hyperbaric oxygen (Rusyniak et al., 2003 Hyperbaric
2003) oxygen
INWEST (Wahlgren et al., 1994) 1994 Nimodipine ,/
1ST (International Stroke Trial 1997 Aspirin ,/
Collaborative Group, 1997)
Indredavik (Indredavik et al., 1991) 1991 Stroke unit
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Kuopio stroke unit trial (Sivenius et al., 1985 Intensive
1985) treatment
Lincoln (Juby et al., 1996) 1996 Rehabilitation
unit
Logan (Logan et al., 1997) 1997 Occupationa I
therapy
Lubeluzole (Grotta and The USand 1997 Lubeluzole le
Canadian Lubeluzole Ischemic Stroke
Study Group, 1997)
MAST-I (Candelise et al., 1995) 1995 Streptokinase /
aspirin
MAST-E(Multicenter Acute Stroke Trial 1996 Streptokinase *
- Europe Study Group, 1996)
NINDS (The National Institute Of 1995 Alteplase
Neurological Disorders And Stroke rt-
PaStroke Study Group, 1995)
Orpington stroke unit trial (Kalra et al., 1993 Stroke unit
1993)
Orpington stroke unit trial (Kalra and 1995 Stroke unit
Eade, 1995)
Orpington stroke unit trial (Kalra et al., 2000 Stroke unit / *
2000) Stroke team
Parker (Parker et al., 2001) 2001 Occupational
therapy
PROACTI (del Zoppo et al., 1998) 1998 Recombinant le
Pro-Urokinase
PROACTII (Furlan et al., 1999) 1999 Recombinant *
Pro-Urokinase
RANTTAS(The RANTTASInvestigators, 1996 Tirilazad
1996)
RANTTASII (Haley, 1998) 1998 Tirilazad ,/
Rodgers (Aitken et al., 1993) 1993 Geriatric unit ,/
STIPAS(The STIPASInvestigators, 1993 Tirilazad ,/
1993)
Ronning stroke unit trial (Ronning and 1998 Stroke unit
Guldvog, 1998)
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STAT (Sherman et al., 2000) 2000 Ancrod le
Streptokinase pilot (Morris et al., 1995 Streptokinase *
1995)
Suiter stroke unit trial 2003 Stroke unit le
TESS (Peters et al., 1996) 1996 Tirilazad ./
TESS II (Orgogozo, 1995) 1995 Tirilazad ./
WALKERi (Walker et al., 1996) 1996 Dressing practice ./
WALKER2(Walker et al., 1999) 1999 Occupational ./
therapy
ZK200775 (Elting et al., 2002) 2002 AMPAAntagonist le
ZK200775
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TABLE 2.2
Trials included in the OAST project with multiple treatment comparisons.
Trial Comparison
BEST pilot (Barer et al.,
1988)
BEST (Barer et al., 1988)
FISS (Kay et al., 1995)
INWEST (Wahlgren et al.,
1994)
MAST-I (Candelise et al.,
1995)
Parker rehabilitation trial
(Parker et al., 2001)
Orpington stroke unit trial
(Kalra et al., 2000)
Atenolol vs. placebo
Propranolol vs. placebo
Atenolol vs. placebo
Propranolol vs. placebo
High dose Nadroparin vs. placebo
Low dose Nadroparin vs. placebo
High dose nimodipine vs. placebo
Low dose nimodipine vs. placebo
Aspirin vs. control
Streptokinase vs. control
Aspirin & Streptokinase vs. control
Leisure therapy vs. control
Activities of daily living therapy vs. control
Stroke team vs. domiciliary care
Stroke unit vs. domiciliary care
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TABLE 2.3
Description of scales used as the primary measure of functional outcome in the
OASTproject.
Scale Range Interval Coding For
Dependent- Independent Size Death
Barthel Index (Mahoney o - 100 5 -5
and Barthel, 1965)
Rankin Scale (Rankin, 5-0 1 6
1957)
Q3 Scale (Lindley et al., 2-4 1 1
1994)
Nottingham ADL 0-10 1 -1
(Ebrahim et al., 1985)
Rivermead ADL (Lincoln 0-16 1 -1
and Edmans, 1990)
ADL Scale (Sivenius et 0-30 1 -1
al., 1985)
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3.1 INTRODUCTION
As discussed previously, there is little agreement as to the 'best' way of
analysing data from functional outcome scales. Many trialists advocate
dichotomising scales into two groups and comparing those with a 'good' to
those with a 'bad' outcome, as this is thought to be clinically meaningful and
easier to interpret. However, there is little consensuson where scales should be
cut to create these groups or whether this actually matters (Wardlaw et al.,
2000).
Song et al have encouraged the use of parametric methods, such as the t-test
(Song et al., 2006), while others have categorised these as inappropriate for
ordinal data (Roberts et al., 1998). To date no research has considered
standard non-parametric methods, such as the Wilcoxon test, although
bootstrapping has been considered as a viable option (Stingele et al., 2001).
This chapter aims to identify which statistical methods might optimise the
analysis of data from functional outcome scales in stroke trials. This work
focuses on univariate methods which do not take account of potentially
confounding covariates. Methods such as the 'patient specific analysis' or those
which adjust for covariates will be addressed in subsequent chapters.
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3.2 METHODS
3.2.1 Trial data
All 55 data sets in the OASTproject were included in this analysis as only data
on functional outcome and treatment assignment were required. See Chapter 2
for details on the OASTdata set.
3.2.2 Statistical tests
Sixteen different statistical tests for assessing treatment effect were compared.
Some of these required the data to be collapsed into groups (such as the 2x2
chi square test) while others used the original ordinal data (such as Wilcoxon
test and t-test), Statistical tests which dichotomised data were assessed with
data collapsed at different places, e.g. mRS 0,1 versus 2-6, 0-2 versus 3-6 and
0-5 versus 6; see Table 3.1 for a complete listing of all dichotomisations for all
the tests compared. The tests compared are discussed in the subsequent
sections with technical detail being given for the less well known tests.
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• Chi-square test
The chi-square test is currently the most common method of analysis used in
stroke trials. Here the chi square test is used under five different conditions.
(i) 2x2 test - dead or poor outcome versus good outcome
(ii) 2x2 test - dead or poor outcome versus excellent outcome
(iii) 2x2 test - dead versus alive
(iv) 2x3 test (unordered data) - dead versus poor outcome versus
good outcome
(v) 2x4 test (unordered data) - dead versus poor outcome versus
good outcome versus excellent outcome
Not all of these comparisons could be carried out for all trials. For example, in
some of the rehabilitation trials no patients died and therefore these trials are
not included in the conditions where vital status is assessed. The same will
apply to the other statistical tests being compared where vital status is
assessed. Chi-square tests were performed without continuity correction
(Hollander and Wolfe, 1999) since most trials enrolled more than 100 patients.
Figures 3.1 and 3.2 show pictorially the cuts used on the mRSand BI and Table
3.1 defines the cuts used.
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FIGURE 3.1
A diagram of the various cut paints used on the modified Rankin Scale.
(i)
(ii)
(iii)
(iv)
(v)
FIGURE 3.2
o
o
A diagram of the various cut paints used on the Barthel Index.
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• Cochran-Armitage trend test
This test is similar to the chi square test but takes into account the ordering
across categories (Agresti, 2002). The 2xl table below shows a summary of the
data gained from a trial assessing two treatments using an ordinal scale. Here
the Cochran-Armitage trend test tests whether there is a linear trend in
binomial proportions across the levels of functional outcome.
Treatment Functional outcome (mRS)
o 1 i I total
Active (1) nlO nll nli nll nl+
Control (0) nOO nOl nOI nOI no+
The test statistic for the Cochran-Armitage trend test is given below, where s
denotes the functional outcome score:
Where
observed sample proportion of the response 1.
This test is used under two conditions:
(i) ordered data with three levels - dead versus poor outcome versus
good outcome
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(ii) ordered data with four levels - dead versus poor outcome versus
good outcome versus excellent outcome
• Ordinal logistic regression
Ordinal logistic regression can be used when the dependent variable is
categorical and ordered. This model is also referred to as the proportional odds
model and the cumulative logit model. It is similar to logistic regression but
simultaneously estimates multiple end points instead of just one. The number
of end points estimated is equivalent to the number of ordered categories
minus one. For example, if the mRS was the dependent variable of interest it
would compare the following j categories: ° versus 1,2,3,4,5,6; 0,1 versus
2,3,4,5,6; 0,1,2 versus 3,4,5,6; 0,1,2,3 versus 4,5,6; 0,1,2,3,4 versus 5,6;
0,1,2,3,4,5 versus 6.
Ordinal logistic regression provides one overall estimate for each covariate in
the model and not one for each cut point. This assumes that the overall odds
ratio is constant no matter which cut is taken. So, for example, the odds ratio
for the treatment effect would be interpreted as the odds of being in category j
or above for all choices of j comparing treatment 1 to treatment ° (Agresti,
1999).
The ordinal logistic regression model has the following form:
j = 1,2........ .k
Here the regression coefficientP is not dependent on the level of the response
variable j .This implies that the relationship between x and Y is independent
of j .This independence is called the 'proportional odds assumption'.
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This method is used in three different ways with the OASTdata:
(i) Raw data
(ii) Three levels - dead versus poor outcome versus good outcome
(iii) Four levels - dead versus poor outcome versus good versus
excellent outcome
• t-test
The t-test assesseswhether the means of two independent samples are equal.
This is a parametric test and makes the assumption that the samples are
normally distributed. The t-test can be used under two different conditions,
either assuming equal variance (pooled) or not (unpooled). Here the version of
the test which does not assume equal variances was used (unpooled t-test).
• Median test
The median test assesses whether two independent groups have been drawn
from a population with the same median. Although the median test is thought
of as a non-parametric test it is basically a chi-square test which uses the
combined median to determine where the data are collapsed into two groups
(Siegel and Castellan, 1988).
• Wilcoxon test
The Wilcoxon test (also referred to as the Mann-Whitney U test) is the non-
parametric equivalent of the t-test and tests whether two independent groups
have been drawn from the same population. The method allowing adjustment
for ties (using the average value) was used, as many patients will share the
same outcome score (Siegel and Castellan, 1988, Wilcoxon, 1945).
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• Robust rank test
The robust rank test is an alternative to the Wilcoxon test, testing whether the
median of one group is equal to another. However, unlike the Wilcoxon test, it
does not assume that the distributions of the two groups are equal, i.e. it
makes no assumptions about the variance of the two groups (Fligner and
Policello, 1981, Siegel and Castellan, 1988). The test statistic for the robust
rank test is given below.
U = mU(YX)- nU(xr)
2~Vx +Vy +U(xr)U(YX)
Where m is the number of patients in group X and n is the number in group
Y. U(xr) and U(YX) are based on the mean placements of the data, the
following example shows how they are calculated.
In this example m =3 and n =4.
Treatment X : 2 4 6
Control Y: 0 1 3 5
Which has rank order
mRS 0 1 2 3 4 5 6
Group Y Y X Y X Y X
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U(YX) is calculated from the mean number of Y values which rank lower than
each X value, as shown below:
2 2
4 3
6 4
U(xy) =tU(YX;)
;=1 m
A similar calculation yields U(XY).
V, and Vy are indices of variability for U(YX;) and U(XYj)' and are calculated:
m 2 n 2
Vx = ~]U(YX;)-U(YX)] and Vy = ~Ju(XYJ-u(XY)]
~I ~I
• Kolmogorov-Smirnov test
This is a test of whether two independent samples have been drawn from a
population with the same distribution. It has the advantage of making no
assumption about the distribution of data (Siegel and Castellan, 1988). The
Kolmogorov-Smirnov test compares the cumulative frequency distributions of
each group and looks for the largest difference between these. The test statistic
for a two sided Kolmogorov-Smirnov test is as follows:
where the observed cumulative distribution for one sample (of size m) is
S; (X) = K / m, where K is the number of data polnts greater than or equal to
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X, the observed cumulative distribution for the other sample is
SJX) = K / n (Siegel and Castellan, 1988).
• Bootstrapping the difference in mean rank
Bootstrapping is a computationally intensive method which involves resampling
data from a given data set. The main advantage of bootstrapping over more
traditional methods is that it does not make any assumptions about the
distribution of the data. Here the difference in mean rank is bootstrapped; the
procedure for doing this is outlined below and is taken from the re-analysis of
the ECASSII data (Efron and Tibshirani, 1993, Stingele et al., 2001):
1. Take a data set, which contains N observations with sample size p in the
control group and q in the treated group
2. Draw a sample with replacement of size N (using replacement means
that some of the original observations may appear in the new sample
more than once and some not at all)
3. The first p values are assigned to the control group and the next q
values to the treatment group
4. Estimate the parameter of interest (here the difference in mean rank)
and store the result
5. Repeat 2 and 3 many times (here three sets of 3,000 iterations were
used)
6. Compare the distribution of the stored results to the actual polnt
estimate from the original data set
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3.2.3 Excluded statistical tests
Three non-parametric tests were excluded as they are inappropriate for
assessing differences between groups of ordinal data or a close alternative is
being used:
• Wald-Wolfowitz runs test
Assesses if the number of 'runs' in an ordering is random or not, where a run is
repetition in a sequence. If the two groups are from different distributions the
number of runs would be mutually independent (Conover, 1971).
• Siegel-Tukey test
Tests for differences in scale between two groups (Siegel and Castellan, 1988).
• Cramer-von Mises two-sample test
This was excluded as it is very similar to the Kolmogorov-Smirnov test
(Conover, 1971).
3.2.4 Comparison of statistical tests
Where possible, each data set was analysed using each statistical test. The
absolute z scores were then ordered within each trial and given a rank, with the
lowest rank given to the test which produced the most significant result, i.e. the
largest absolute z score, within that trial. A two-way analysis of variance test
(Friedman's) was then used to assess which statistical test had produced the
lowest ranks. The statistical tests were then ordered in terms of their efficiency
in identifying treatment effects using Duncan's multiple range test (Duncan,
1955).
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The number of statistically significant (at 5%) results were also assessed for
each test compared.
To assess the validity and reliability of the results, a number of supplementary
analyses were carried out. Firstly, the comparison of statistical tests was
repeated within sub group of trials sharing similar characteristics. Secondly, the
statistical assumptions of the tests were assessed. Lastly, the sensitivity of the
tests was explored to make sure treatment effects were only detected when
they truly existed (the type one error rate). The availability of the tests in
popular statistical packages (SAS, Stata, SPSS) was also assessed. These
analyses are discussed in more detail below.
lOS
3.2.5 Sub group analysis
Sub group analyses were performed by assessing the efficiency of the different
tests for differing trial characteristics:
• Type of intervention tested (thrombolysis, anticoagulation,
antihypertensive, antiplatelet, feeding, neuroprotection, occupational
therapy, procoagulant, and stroke unit)
• Trial setting (acute drug treatment, rehabilitation, stroke unit)
• Trial size «500, >500 participants), 500 falls between the mean and
median trial size included and is used to define smaller and larger trials
• Time between randomisation and stroke onset «6, >6 hours), sub acute
trials «6 hours) tend to include more severe patients and using more
aggressive interventions
• Patient age «70, >70 years), this cut was chosen as the median age of
patients in the included trials was 71
• Baseline severity (median control group death rate adjusted for length of
follow up, <0.05, >0.05), this was used because baseline severity was
not available for many trials or had been measured using a variety of
scales
• Outcome measure (Bl, mRS, 3Q)
• Length of follow up «3 months, >3 months)
• Intervention result, as published (beneficial, harmful)
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3.2.6 Statistical assumptions
The principal statistical assumptions underlying the tests which performed well
were assessedto ensure that their use was appropriate for stroke trial data.
• Ordinal logistic regression - proportionality of odds across response
categories
Ordinal logistic regression makes the assumption that the odds ratio for the
difference between the treatments groups is constant across categories of the
outcome. Because of this assumption, this model is sometimes referred to as
the proportional odds model. This was tested using a likelihood ratio test,
comparing the multinomial logistic model to the ordinal logistic regression
model.
• t-test - normal distribution of outcome scores
The t-test assumes the data is normally distributed. Normality was assessed
both visually by plotting histograms and using the Shapiro-Wilk test (Shapiro
and Wilk, 1965). The equality of variances assumption was not required as the
unpooled version of the t-test was used. But to confirm the usage of this
version, the F-test was used to see if it might be possible to also use the pooled
version of the test.
• Robust rank test - independence of treatment groups
The robust rank test is a non-parametric test and only assumes independence
of groups.
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3.2.7 Type 1 error rate
A type 1 error occurs when a statistical difference between two groups is
observed where no difference truly exists. The type 1 error rate is usually set at
5%, i.e. 5% chance that the observed variation in the data is not true. It is
conceivable that an overly sensitive statistical test might have an inflated type
1 error and therefore find statistically significant differences, where none truly
exist, greater than 5% of the time. The type I error rate was assessed for the
three most efficient statistical tests, using data from three representative trials
including one each of the three most used measures of functional outcome (BI:
RANTTAS,mRS: NINDS, 3Q: 1ST). From these data, 1,000 data sets were
generated, using random sampling with replacement, in which any treatment
difference could have occurred only by chance. Tests maintaining adherence to
the nominal type I error rate would expect to see a significant result in around
50 of the 1,000 data sets.
3.2.8 Availability of tests
Currently many use the chi square test for analysing dichotomised functional
outcome data. A contributing factor to this may be the ease of use and
interpretation. The chi square test is available in every statistical package and
can also be calculated online. The availability of each test being compared was
assessedfor three commonly used statistical packages: SAS,Stata and SPSS.
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3.3 RESULTS
3.3.1 Trial characteristics
As previously discussed all 55 data sets were included in this analysis. The
characteristics of these trials are presented in Chapter 2.
3.3.2 Comparison of statistical tests
The statistical tests assessed differed significantly in the results they gave for
each trial (two way ANOVAp<O.OOOl).The ordering of the tests showed that
those which maintain and analyse the original ordinal data generally perform
better than those which collapse the data into two or more groups. The most
efficient tests included ordinal logistic regression, t-test, robust rank test,
bootstrapping the difference in mean rank, and the Wilcoxon test (Table 3.2).
All of the tests which do not take into account the ordering of the data ranked
the lower.
Where tests had been repeated under different conditions (dichotomous, three
levels, four levels, raw data) and the ordering of the groups was assessed, a
greater the number of levels resulted in greater statistical power. This is
reflected in the results for ordinal logistic regression and the Cochran-Armitage
test for trend. The same pattern was not seen for the unordered chi square
tests.
The median test, which dichotomises the data at the median, which some have
suggested increases power, performed poorly. The lowest performing test was
the Kolmogorov-Smirnov test.
When assessed by how many trials were statistically significant, those tests
which did not collapse the data into groups again out-performed the other
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approaches; for example, ordinal logistic regression (using raw data) gave a
statistically significant result in 25.9% of trials whereas the 2x2 chi-square test
comparing death or poor outcome to an excellent outcome only gave a
significant result in 9.3% of the trials (Figure 3.3).
Interestingly, the median test performed well here compared to the two way
analysis of variance results. This may be because the median test collapses the
data at the median and therefore compares groups of roughly even size.
FIGURE 3.3
The number of statistically significant results found for each test, where p<O.OS
signifies statistical significance.
Chi square test - death or poor vs excellent
Chi square test - dead vs alive
Kolmogorov-Smirnov test
Chi square 2x4 test
Ordinal regression (3 groups)
Cochran-Armitage trend test (3 groups)
Ordinal regression (4 groups)
Chi square 2x3 test
Chi square test - Death or poor outcome vs good
Cochran-Armitage trend test (4 groups)
Bootstrap difference in mean rank
t-test
Ordinal regression (raw data)
Median test
Wilcoxon tes
Robust rank tests
9.3 o Tests usingdatasplit Into groups
11.S • Tests usinggrouped data
12.7 but taking Into accountthe ordering of the groups
14
• Ordinal tests (raw data)
17.6
19.6
20
21.6
21.S
24
25.5
25.5
25.9
27.3
t 27.3
29.1
o 5 10 15 20 25 30 35
% trials significant at 5% level
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3.3.3 Sub group analysis
Table 3.3 shows the two way ANOVAresults and test rankings by intervention.
Statistically significant differences in the ranking of the tests were seen for
thrombolysis, anticoagulation, antiplatelet, neuroprotection and occupational
therapy. Ordinal regression performed well in trials of antiplatelets, feeding,
neuroprotection, occupational therapy and stroke unit trials. Ordinal methods
seem to perform poorly in trials of thrombolysis, in contrast, the four level and
three level chi square tests performed well for these trials. Ordinal logistic
regression using raw data ranked 11th out of the 16 tests for trials of
thrombolysis.
The sub group analysis showed similar ordering of tests irrespective of the trial
setting (acute, rehabilitation, stroke unit), trial size, time between
randomisation and onset, patient age, baseline severity, outcome measure,
length of follow up, and trial result (Table 3.4).
3.3.4 Statistical assumptions
When assessing ordinal logistic regression, the assumption of proportionality of
odds (likelihood ratio test comparing the multinomial logistic model to the
ordinal logistic regression model) was not met (p<0.05) in eight of the 55 data
sets when using the raw data (ASK, ASSIST 07, ATLANTISA, citicoline 10,
FOOD3, MAST-I, Orpington domiciliary care, Orpington team, Table 3.5). Three
of these eight trials were testing thrombolytics, and this may be part of the
reason why ordinal logistic regression may not perform well in thrombolysis
trials (Table 3.5). Similar results were seen for the ordinal logistic regression
when based on three and four levels of data. Figures 3.4 a-c show the
distribution of the MAST-I data for aspirin and streptokinase versus control
data. These plots show that aspirin and streptokinase increase the proportion
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of patients with a good outcome (26% of patients score an mRS of one in the
treated group compared to 22% in the control group) but there is also an
increase in the proportion of patients who die (44% died in the treated group
compared to 29% in the control group), hence the proportional odds
assumption is not met.
The assumption of normality required for the t-test did not hold for all but one
of the data sets (Table 3.6). The equality of variance F test was statistically
significant in 12/55 data sets, implying that using the unpooled version of the t-
test was a necessaryapproach. Additionally, when the two way ANOVAanalysis
was repeated with both the pooled and unpooled t-test included, no difference
was found between the two (Table 3.7).
In contrast, the assumption of independenceof groups for the robust rank test
was met in all cases.
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FIGURES 3.4 A-C
Distribution of the mRS in the factorial MAST-I trial of aspirin and streptokinase
versus control, demonstrating non proportional odds (Multicentre Acute Stroke
Trial-Italy (MAST-I) Group, 1995).
Treatment
3.4.a
Raw data
Control
0% '11% >0% lO% 40% 50% 10'% 10% 111% 111% '00%
Treatment
3.4.b
Four levels
Control
0'% '0'% 20'% lO'% 40% 50% 10'% 10% 111% 111% 'DO%
3.4.c
Three levels
0'% , 0'% 20% :!CI% 40% 50% 10'% 10% 10% 10% I DO%
113
3.3.5 Type 1 error rate
Table 3.8 shows the type 1 error rate results. Analysis of 1,000 re-sampled
random data sets from the three trials (The National Institute of Neurological
Disorders and Stroke rt-PA Stroke Study Group, 1995, The RANTTAS
Investigators, 1996, International Stroke Trial Collaborative Group, 1997) did
not find any evidence of an increased type I error rate for ordinal logistic
regression with the number of 'positive' data sets being: BI 39/1000; mRS
57/1000 and 3Q 56/1000. Similar results were found for both the t-test and
robust rank test.
3.3.6 Availability of tests
The availability of the compared tests within the three packages - SAS, Stata
and SPSSvaried. Chi square, Wilcoxon, median, Kolmogorov-Smirnov, t-test
and ordinal logistic regression were available in all three packages. However,
the Cochran-Armitage test for trend, robust rank and bootstrapping are not
available in SPSS(Table 3.9).
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3.4 DISCUSSION
These results show that statistical approacheswhich analyse the original ordinal
data for functional outcome perform better than those which work on pre-
processed data, which has been collapsed into two or more groups. In
particular, ordinal logistic regression, the t-test, the robust rank test,
bootstrapping the difference in mean rank, and the Wilcoxon test performed
well and appear to be useful irrespective of the type of stroke trial, patient or
setting. However, ordinal methods may not be appropriate for trials of
thrombolytic agents.
Although individual tests based on dichotomised data using chi-square analysis
(e.g. 'dead/dependent' versus 'independent') were effective for some data sets,
they performed poorly in many and therefore cannot be recommended as a
general solution for analysing stroke trials. From a historical perspective, it is
quite possible that trials which collapsed mRS or BI into two groups may have
used a sub-optimal analysis, and this may have contributed to false neutral
findings in some cases in the past. For example, The International Stroke Trial
comparison of aspirin against control was neutral on its primary outcome but
shows a statistically significant treatment effect when re-analysed using ordinal
logistic regression on the raw data (International Stroke Trial Collaborative
Group, 1997).
Ordinal logistic regression assumes the intervention will exert effects of similar
magnitude and direction at each transition of the outcome scale, Le.
'proportionality of odds'. This is unlikely to be the case for treatments where
symmetrical benefits occur (Le. the intervention is effective across a spectrum
of severity) but hazard is asymmetrical tending to effect mainly those with
severe stroke. Thrombolysis is an example and its overall effect is to reduce
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dependency and, to a lesser extent, increase death (largely through promoting
fatal intracerebral haemorrhage). Specifically, thrombolysis probably reduces
dependency across all levels of the mRS, but increases haemorrhage in patients
with severe stroke who are likely to have a poor outcome. Hence, thrombolysis
may be considered, in the context of stroke severity, to have symmetrical
effects on efficacy but asymmetrical effects on hazard, and therefore ordinal
methods are probably not appropriate.
Several comments can be made about this part of the OASTproject. Firstly, the
search for all possible statistical tests relevant to the problem of analysing
ordered categorical data was not exhaustive. Instead, the focus was
concentrated on those approaches which are available in standard statistical
textbooks and computer packages (all tests assessedwere available in SASand
Stata). Additionally, some tests used in recent trials could not be included, e.g.
patient specific outcomes and Cochran Mantel-Haenszel test, since these
require access to individual data for both baseline and outcome variables, and
these data were not available uniformly. These will be assessed in a subsequent
chapter using a sub-set of the OASTdata.
Secondly, some of the statistical assumptions underlying the more efficient
tests were not met in all trials. For example, the t-test assumes data are
normally distributed while ordinal logistic regression assumes that any
treatment effect is similar across outcome levels. Nevertheless, the robustness
of these tests to deviations from their underlying assumptions means that they
remain relevant for analysing functional outcome data from stroke trials.
Indeed some have recommended the use of the t-test for measures with seven
or more ordered categories (Waiters et al., 2001).
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If alternative approaches to analysing functional outcome data are to be used
in the future, it is pertinent to ask how sample size should be calculated at the
trial design stage. Historically, most calculations assumed that functional
outcome would be dichotomised and analysed using a Chi-square test approach
(Weaver et al., 2004). Although future trials could continue to calculate sample
size in the same way (and then gain extra power by analysing their data using
an ordinal approach), specific sample size calculations are available when data
are to be analysed using ordinal logistic regression, or the Wilcoxon or t-tests.
Ideally, it might be considered that the extra power gained by using an ordinal
statistical approach should not be used to reduce sample size; stroke trials
have been too small in the past, as shown in a recent meta analysis (Weaver et
al., 2004), and this may also have contributed to the failure of some studies.
Assessment of sample size in the OASTdata set will be addressed in Chapter 4.
A further issue with using a statistical test which analyses ordered categorical
data is how to report the results to patients, carers, clinicians, and health policy
makers. The results of dichotomous tests may be summarised easily as the
proportion of patients who benefit (or suffer) with a treatment, i.e. alteplase
reduced absolute death or dependency (mRS>l) by 13% in the NINDS part two
trial (The National Institute of Neurological Disorders and Stroke rt-PA Stroke
Study Group, 1995). In contrast, ordinal tests will need to be presented as the
average absolute improvement in outcome, e.g. alteplase improved the mRS by
1 (of 7) point and BI by 22.5 (of 100) points (unpublished). Alternatively, the
combined odds ratio and its confidence intervals would have to be reported if
ordinal logistic regression was used. In this respect, health consumers will need
to decide what differences in mRS and BI are worthwhile, both clinically and in
terms of health economics. In reality, it is reasonable to present the effect on
functional outcome using both absolute percentage change (as a secondary
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outcome) and mean or median change in functional outcome score (as the
primary outcome).
Interestingly, a recent study which sent questionnaires about the design and
analysis of stroke trials to 300 neurologists found that of the 152 who replied,
54% would chose a method of analysis for the mRS which looked for changes
across the whole scale whereas only 39% would choose a dichotomous
endpoint; although, 20% still felt they did not fully understand the results from
shift analyses (Savitz et al., 2008).
3.S SUMMARY
These results suggest that ongoing and future trials should consider using
statistical approaches which utilise the original ordered categorical data in the
primary analysis of functional outcome measures. Such ordinal tests include
ordinal logistic regression, the robust rank test, bootstrapping the difference in
mean rank, and the Wilcoxon test; the t-test may also be used although its
assumptions were not met in many trials.
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TABLE 3.2
Comparison of rank scores for 16 statistical tests; lower ranks imply the test is
more efficient. Analysis by non parametric two-way ANOVA and Duncan's
multiple range test; tests joined by the same band are not significantly different
from each other at p<0.05.
Test No. of Mean Banding
data sets rank
Ordinal logistic regression (raw data) 54 6.11
t-test 55 6.51
Robust rank test 55 6.53
Bootstrap difference in mean rank 55 6.85
Wilcoxon test 55 7.31
Cochran-Armitage trend test (4 groups) 50 7.36
Ordinal logistic regression (4 groups) 50 7.50
Ordinal logistic regression (3 groups) 51 7.92
Cochran-Armitage trend test (3 groups) 51 8.27
Chi Sq - dead or poor outcome vs. good 55 8.87
Chi Sq - dead or poor outcome vs. excellent 54 9.24
Median test 55 9.47
Chi Sq - 2x3 test 51 9.96
Chi Sq - dead vs. alive 51 9.98
Chi Sq - 2x4 test 50 10.02
Kolmogorov-Smirnov test 55 11.29
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TABLE3.5
Testing the proportionality of odds assumption for ordinal logistic regression.
Data given are the p values from the likelihood ratio test. Statistically
significant values are shown in bold and signify that the assumption is not met.
Data set Raw data 3 levels 4 levels
Acute:
AbESTT 0.4229
ASK 0.0286 0.0003 0.0011
ASSIST 07 0.0024 0.2606 0.3685
ASSIST 10 0.8285 0.2873 0.5455
ATLANTIS A 0.0099 0.015 0.0355
ATLANTIS B 0.2208 0.1585 0.1678
BEST pilot aten 0.0791 0.485 0.0538
BEST pilot prop 0.4244 0.5407 0.6823
BEST aten 0.2634 0.0797 0.1835
BEST prop 0.2752 0.2332 0.493
CAST 0.3424 0.1368 0.3424
Citicoline 01 0.5702 0.7586 0.7539
Citicoline 07 0.6205 0.6509 0.7963
Citicoline 10 0.0042 0.2107 0.1265
Citicoline 18 0.121 0.6952 0.1228
DCLHb 0.3371 0.413 0.2291
EAST 0.5075 0.962 0.7138
Ebselen 0.9356 0.9379
ECASS II 0.3011 0.1906 0.0942
Edaravone 0.4007 0.8521 0.9695
Factor Vila 0.9105
FISS high 0.6601 0.8576 0.6601
FISS low 0.2543 0.1599 0.2543
FISS-TRIS 0.7100
FOOD 3 0.0396 0.8416 0.6793
INWEST high 0.2482 0.0741 0.058
INWEST low 0.5118 0.6202 0.849
1ST 0.8975 0.639 0.8975
MAST-E 0.1043 0.0768 0.1398
MAST-I A 0.6082 0.4198 0.6551
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MAST-I S 0.0746 0.3616 0.2077
MAST-I AS 0.0031 0.0002 0.0007
NINDS 0.1148 0.1685 0.0212
PROACTII 0.2495 0.1342 0.305
RANTTAS 0.2832 0.5802 0.5189
RANTTAS II 0.0554 0.8603 0.0947
STIPAS 0.5632 0.7217 0.9417
Streptokinase 0.1347 0.6326 0.7726
pilot
TESS 0.9911 0.4618 0.7372
TESS II 0.7744 0.7763 0.7415
Rehabilitation:
Corr 0.1894 0.7648 0.8463
Gilbertson 0.0708 0.2866 0.4689
Logan 0.2583 0.5619 0.504
Parker ADL 0.5315 0.4086 0.6649
Parker leisure 0.8493 0.9985 0.9689
Walker I 0.511
Walker II 0.0631
Young 0.5777
Stroke unit:
Dover 0.3844 0.2142 0.4318
Helsinki 0.2541 0.047 0.1387
Kuopio 0.1452 0.5874 0.6746
Nottingham 0.2086 0.6037 0.7157
Orpington team 0.0182 0.0174 0.0228
Orpington dom 0.0181 0.1937 0.2773
Newcastle 0.4631
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TABLE3.6
Testing the assumptions of the t-test. The Shapiro-Wilk test assess the
normality assumption, statistically significant values indicate the assumption is
not met. The F test assesses the equality of variance between the treatment
groups. Statistically significant values signify non equal variance across the
groups. Statistically significant values are shown in bold.
Data set Shapiro-Wilk test
W P value
F test
F P value
Acute:
AbESn
ASK
ASSIST 07
ASSIST 10
ATLANTIS A
ATLANTIS B
BEST pilot aten
BEST pilot prop
BEST aten
BEST prop
CAST*
Citicoline 01
Citicoline 07
Citicoline 10
Citicoline 18
DCLHb
EAST
Ebselen
ECASSII
Edaravone
Factor VIla
FISS high
FISS low
FISS-TRIS
FOOD 3
INWEST high
0.90
0.80
0.83
0.83
0.73
0.90
0.79
0.76
0.80
0.81
0.23
0.79
0.79
0.93
0.80
0.93
0.91
0.78
0.91
0.88
0.90
0.86
0.84
0.86
0.74
0.83
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.01
<0.0001
<0.0001
0.0001
<0.0001
0.0003
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
2.73
2.22
0.88
0.50
0.87
0.81
0.00
0.91
0.52
1.02
5.34
0.73
0.01
0.24
0.07
11.35
8.24
5.16
1.63
2.81
0.13
3.71
0.74
3.35
2.04
13.41
0.10
0.14
0.35
0.48
0.35
0.37
0.95
0.35
0.47
0.31
0.02
0.39
0.92
0.63
0.80
0.001
0.004
0.02
0.20
0.09
0.72
0.06
0.39
0.07
0.15
0.0003
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INWEST low 0.82 <0.0001 2.99 0.09
IST* 0.26 <0.01 4.90 0.03
MAST-E 0.83 <0.0001 0.00 0.99
MAST-I A 0.87 <0.0001 3.34 0.07
MAST-I S 0.85 <0.0001 0.76 0.38
MAST-I AS 0.82 <0.0001 0.65 0.42
NINDS 0.90 <0.0001 10.22 0.002
PROACTII 0.90 <0.0001 0.98 0.32
RANTIAS 0.74 <0.0001 4.14 0.04
RANTIAS II 0.79 <0.0001 1.87 0.17
STIPAS 0.68 <0.0001 2.85 0.09
Streptokinase 0.82 0.002 0.00 0.95
pilot
TESS 0.81 <0.0001 0.62 0.43
TESS II 0.81 <0.001 1.05 0.30
Rehabilitation:
Corr 0.91 <0.0001 2.44 0.12
Gilbertson 0.79 <0.0001 0.13 0.72
Logan 0.82 <0.0001 1.14 0.29
Parker ADL 0.93 <0.0001 0.28 0.60
Parker leisure 0.93 <0.0001 0.96 0.33
Walker I 0.96 0.31 1.38 0.25
Walker II 0.74 <0.0001 5.77 0.02
Young 0.90 <0.0001 7.32 O.OOS
Stroke unit:
Dover 0.82 <0.0001 4.79 0.03
Helsinki 0.82 <0.0001 1.18 0.28
Kuopio 0.S2 <0.0001 0.08 0.78
Nottingham 0.S9 <0.0001 6.47 0.01
Orpington team 0.S9 <0.0001 8.56 0.004
Orpington dam 0.90 <0.0001 3.16 0.08
Newcastle 0.90 <0.0001 0.13 0.72
*used the Kolmogorov-Smirnov test as too many observations for the Shapiro-
Wilk test.
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TABLE 3.7
Comparison of the pooled and unpooled t-test. Analysis by non parametric two-
way ANOVA and Duncan's multiple range test; tests joined by the same band
are not significantly different from each other at p<O.OS.
Test Mean Banding
rank
Ordinal logistic regression (raw data) 6.65
t-test (pooled) 7.13
t-test (unpooled) 7.20
Robust rank test 7.31
Bootstrap difference in mean rank 7.39
Wilcoxon test 7.81
Cochran-Armitage trend test (4 groups) 7.86
Ordinal logistic regression (4 groups) 8.04
Cochran-Armitage trend test (3 groups) 8.66
Ordinal logistic regression (3 groups) 8.67
Chi Sq - dead or poor outcome vs. good 9.53
Chi Sq - dead or poor outcome vs. excellent 10.14
Median test 10.28
Chi Sq - 2x3 test 10.28
Chi Sq - 2x4 test 10.37
Chi Sq - dead vs. alive 10.51
Kolmogorov-Smirnov test 11.90
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4.1 INTRODUCTION
The previous chapter showed that statistical tests that use the original ordered
categories describing death or dependency are statistically more efficient than
those which dichotomise the data (The Optimising Analysis of Stroke Trials
(OAST) Collaboration, 2007); suitable approaches include ordinal logistic
regression, the t-test, the robust rank test, bootstrapping the difference in
mean rank, and the Wilcoxon test.
If the analysis of stroke trials should be changed from using dichotomous to
polytomous functional outcome data, then it is critical to consider how sample
size should be calculated. Sample size estimation is an important part of trial
design and is now a compulsory element when applying for funding and
publishing completed trials (The CONSORTStatement, 1996, Gardner and
Altman, 1989). Key components in any sample size calculation include the
intended power (1 - f3) and significance (a), and expected treatment effect
(Weaver et al., 2004).
This part of the project compares sample size estimations obtained using
different methods basedon dichotomous, ordinal and continuous outcomes.
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4.2 METHODS
4.2.1 Trial data
As with the previous chapter, all 55 data sets in the OASTproject were included
in this analysis as only data on functional outcome and treatment assignment
were required. See Chapter 2 for a description of the OASTdata set.
4.2.2 Sample size estimation
Four methods of sample size estimation were chosen for comparison; one is
based on the proportion of events and is currently used in many acute stroke
trials (Weaver et al., 2004). The other three estimate sample size for ordinal or
continuous outcomes (The Optimising Analysis of Stroke Trials (OAST)
Collaboration, 2007). As with the previous chapter, the sample size methods
compared are those which are available in standard statistical packages. All the
methods of sample size estimation assume that the treatment groups are of
equal size. In all cases Za and zp are the appropriate values from the standard
normal distribution based on the significance level (a) and power (1 - P )
chosen by the investigator (see Table 4.1). None of the methods take into
account drop out or non compliance and it is customary to inflate any given
sample size by around 10% to take into account these factors. The methods of
sample size estimation used are described in the next section.
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Comparison of proportions
The formula for estimating the sample size when the outcome is binary is:
where n is the number of patients required in each group, PI and P2 are the
proportions of interest in the two treatment groups (Weaver et al., 2004). This
method was carried out using Stata.
Parametric comparison
If a trial has an outcome which is continuous then the investigator may choose
a comparison of means as the method of analysis for the primary outcome, e.g.
using the t-test. The appropriate sample size calculation is based on:
where f.LI and f.L2 are the expected means in the two treatment groups and
er is the overall expected standard deviation (Bland, 2000). This method was
carried out using Stata.
Non parametric comparison
This method of sample size estimation for comparing ordinal data was proposed
by Payne (Payne, 1993) as part of the Genstat (GenStat, 2005) statistical
program and is relevant when the Wilcoxon test or the robust rank test (Fligner
and Policello, 1981) will be used to analyse the primary outcome once the trial
is completed. The method calculates an approximate sample size needed based
on the probability of response (i.e. the probability that an observation in one
sample will be greater than the equivalent observation in the other sample)
that should be detectable by initially assuming a normal approximation. This is
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then refined by calculating powers for a range of replications centred around
that approximation (Payne, 1993).
This was the only method available in the statistical packages assessed that
carried out a non parametric sample size calculation. The method is specific to
the GenStat program and no algorithm has been published. There are other
published non parametric methods in the statistical literature, such as that
according to Noether (Noether, 1987), but these are not available in standard
statistical software.
Comparison of ordinal data
Sample size estimation for comparing two groups of ordinal data using the
technique of ordinal regression was proposed by Whitehead (Whitehead, 1993).
An estimate of the expected odds ratio and proportion of patients expected to
fall into each category on the scale for the control group is required.
The sample size per group is given by:
where OR is the odds of being in category i or less for one treatment group
compared to the other, k is the number of categories on the scale of interest,
and 1[ is the mean proportion of patients expected in category i . This method
was carried out using GenStat.
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4.2.3 Comparison of methods
Each method of sample size estimation was carried out on each data set. The
parameters needed within the calculation of each sample size were derived
from each data set; these were then used to calculate sample size as if these
treatment effects were desired. The comparison of proportions method was
carried out twice using two different definitions of a functional outcome:
(i) 'Good': death or poor outcome (BI <60, mRS 3-6, 3Q 1/2) versus good
outcome (BI 60-100, mRS 0-2, 3Q 3/4)
(ii) 'Excellent': death or poor outcome (BI <95, mRS 2-6, 3Q 1-3) versus
excellent outcome (BI 95/100, mRS 0/1, 3Q 4)
See Chapter 3 for definitions of outcomes for the other scales used. The use of
two definitions reflects that most trials used, historically, the poor/good
outcome, whilst there has been a tendency recently, to rely on the
poor/excellent outcome, largely based on the results of the NINDS tPA trial
(The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study
Group, 1995).
In all cases significance was set at 5% with a power of 90%. The use of a fixed
power of 90% will have ensured that the risk of a false negative was held
constant. These sample sizes were then ordered within each trial and given a
rank, with the lowest rank given to the method which produced the smallest
sample size. A two-way analysis of variance test was then used to see on
average which method had produced the lowest ranks and therefore the lowest
sample sizes. The methods were than ordered in terms of the average sample
sizes given using Duncan's multiple range test (Duncan, 1955).
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Each method of sample size calculation was then compared to the proportion
method for a 'good' outcome (as this is the most common method used in
stroke trials). The median multiplier by type of intervention was then
calculated, i.e. a value < 1 shows that the method produces a smaller sample
size than the proportion method and > 1 shows that a larger sample size will
result.
Analyses were carried out in SAS (version 8.2), Stata (version 7) and GenStat
(version 8.1, for the methods of Payne and Whitehead) and significance was
taken at p<0.05.
4.3 RESULTS
4.3.1 Trial characteristics
The characteristics of the 55 data sets used are presented in Chapter 2.
4.3.2 Comparison of sample size methods
The sample size methods differed significantly in estimating sample sizes for
each trial (p<O.OOOl). The ordering of the methods showed that the ordinal
method of Whitehead and comparison of means method produced significantly
lower sample sizes than the other approaches, with the comparison of medians
method of Paynegiving the largest sample sizes (Table 4.2).
Table 4.3 shows the change in sample size in relation to the current standard
method based on comparison of proportions for a good outcome (mRS <2 or BI
>60). The ordinal method of Whitehead and comparison of means appear to
reduce sample size by 28% and 30% respectively, relative to comparison of
proportions (Table 4.3). In contrast, the method of Payne produces 12% larger
sample sizes. Whilst this finding appears to be true for most interventions, it
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may not be correct for trials of thrombolytics where ordinal (Whitehead, Payne)
and continuous (comparison of means) approaches produce larger sample
sizes. Interestingly, comparison of proportions based on an 'excellent' outcome
also led to an increase in sample size as compared with comparisons based on
a 'good' outcome.
The following figures give examples of the sample size required with varying
levels of statistical power for each method, for three trials. Overall these plots
show that the 'best' method of sample size calculation may vary slightly by trial
but on average the Whitehead and comparison of means method produce the
smallest sample size.
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FIGURE 4.1
Sample size comparisons at varying levels of power (13) for the 1STmega trial of
aspirin versus control (International Stroke Trial Collaborative Group, 1997).
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Figure 4.1 shows that across all levels of statistical power the comparison of
means and Whitehead method out perform the other methods, consistently
producing lower sample sizes. The method of Payne produces the highest
sample sizes, with little difference between the two comparisons of proportions.
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FIGURE 4.2
Sample size comparisons at varying levels of power W) for a trial of edaravone
(The Edaravone Acute Brain Infarction Study Group (Chair: Eiichi Otomo MD),
2003).
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In the edaravone trial (Figure 4.2) the Whitehead method gives the smallest
sample sizes across all levels of power. Here the dichotomous outcomes gave
the largest sample sizes.
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FIGURE 4.3
Sample size comparisons at varying levels of power (13) for the PROACT II trial
of intra-arterial prourokinase (Furlan et al., 1999).
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The PROACT II trial tested a thrombolytic agent (prourokinase) versus control.
In contrast to the previous two examples, here the two dichotomous
comparisons of proportion sample sizes are much smaller than both the
comparison of means and Whitehead method. As discussed previously (Chapter
3), this is likely to reflect that the assumption of proportionality of odds is not
being met in trials of thrombolytic therapies. The likelihood ratio test, which
here tests the proportional odds assumption, for the PROACT II trial was not
statistically significant (p=O.24), but this test is known to have low power and
therefore may not indicate all cases where this assumption fails.
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4.4 DISCUSSION
The results support the contention that trials designed to use an ordinal
analysis of functional outcome will, on average, be smaller than those using a
dichotomous outcome. In particular, Whitehead's method, which assumes trials
will be analysed using ordinal logistic regression, produces sample sizes which
are typically 28% smaller than the dichotomous approach based on comparison
of good outcome (mRS <2 or BI >60) (Table 4.3, Figures 4.1 and 4.2). A
similar reduction is seen using the comparison of means. Taking this finding
with the results of Chapter 3, it is suggested, with the exception of
thrombolysis trials, that stroke tria lists should consider designing and analysing
stroke trials using approaches which maintain the ordered nature of functional
outcome data based on mRS and BI. Analysis of means may be appropriate for
polytomous outcomes with seven or more levels (Song et al., 2006, Waiters et
al., 2001), as occurs with the BI.
As discussed previously, ordinal logistic regression assumes the intervention
will exert effects of similar magnitude and direction at each transition of the
outcome scale; this is unlikely to be the case for treatments such as
thrombolytic agents, which both reduce dependency and, to a smaller extent,
increase death (Figure 4.4). This is evident in Table 4.3 and Figure 4.3 where
the ordinal (Whitehead, Payne) and continuous methods did not deliver smaller
thrombolysis trials, e.g. PROACTII (Furlan et al., 1999). In contrast, most
other interventions are likely to move patients up (efficacy) or down (hazard)
by a part (or whole) of a mRS level (The Optimising Analysis of Stroke Trials
(OAST) Collaboration, 2007), therefore fulfilling the key assumption underlying
proportionality of odds. Table 4.3 shows that the ordinal method of Whitehead
leads to smaller sample sizes for a wide range of interventions including
antiplatelets, neuroprotectants, occupational therapy, and stroke units.
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FIGURE 4.4
Distribution of the modified Rankin Scale for the six combined data sets of
thrombolytic therapy (ECASS II, MAST E, MAST I (streptokinase vs. control and
streptokinase and aspirin vs. control), NINDS, PROACT II and ATLANTIS B).
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Applying methods of analysis which enable investigators to reduce the sample
size needed for a trial may increase the feasibility of completing stroke clinical
trials. A meta analysis of recruitment into stroke trials showed that over the
last 15 years the number of recruiting centres within each completed trial has
increased significantly over time with a non significant decrease in recruitment
efficacy (subjects enrolled per study centre per month of recruitment) (Elkins et
al., 2006). Another review of sample size in stroke trials found that the sample
sizes of trials is increasing over time (Weaver et al., 2004). These two studies
show that recruitment into stroke trials is becoming more complex and
expensive, with more trial centres being needed to meet the sample size
requirement. Therefore any solution which reduces the number of patients
needed will lower the cost and complexity of trials and increase the potential to
recruit the sample size needed (Elkins et al., 2006, Weaver et al., 2004).
The advantage of our study is that the different methods for estimating sample
size have been tested on data from a large number of real stroke trials. As a
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result, the findings are likely to exhibit external validity. It is evident that
stroke trials are inherently heterogeneous in their design and results in that
interventions, patients and results differ. Modelling approaches which
synthesise data or use data from a single study cannot adequately take account
of this heterogeneity.
A disadvantage of this study is that it aimed to include data from all stroke
trials assessing a beneficial or harmful intervention. Unfortunately, data were
not made available for all identified trials; where possible, individual data from
publications which provided patient numbers by outcome score were created.
Data were missing for a variety of trial types (acute/rehabilitation/stroke unit)
and sizes, and functional outcome measure (mRS/BI), so it is unlikely that a
systematic bias was introduced into the findings; however, the precision of the
results may have been attenuated by the missing trials.
Another possible criticism of these results is the use of the actual trial
parameters in the estimation of the sample sizes. Most of the trials (30/47,
64%) included in this project individually showed no treatment effect and were
therefore included as part of a meta analysis showing a statistically significant
effect. Therefore the parameters used in the calculations were, in the most
part, determined for very small treatment differences. When repeating the
analysis on only those data sets where a beneficial treatment difference was
seen (16 data sets from 14/47 trials) and hence more 'realistic' parameters
were used in the calculations, ordinal methods still ranked highest (see Table
4.4). Using very small treatment effects may add to the validity of these results
as many have argued that sample sizes for stroke trials have been based on
unrealistically large clinically meaningful differences between treatments
(Furlan, 2002, Samsa and Matchar, 2001, Weaver et al., 2004), and small
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effects may still be worthwhile if the treatment can be used across a wide range
of patients.
4.5 SUMMARY
In summary, it is suggested that tria lists designing future stroke studies of
treatments which are likely to act uniformly across populations should consider
analysing functional outcome using an ordinal method that retains the natural
ordering of the outcome data. In doing so, they will be able to maintain study
power for a smaller sample size which will reduce the complexity (less centres),
length and cost of trials (Elkins et al., 2006). However, trials of thrombolysis
(or other interventions where a likely asymmetrical hazard will be present
alongside a symmetrical efficacy) should use current approaches which combine
outcomes. In this respect, the decision to use excellent (mRS 0, 1/2-6), good
(mRS 0-2/3-6) or moderate (mRS 0-3/4-6) splits in functional outcome will
depend on the expected severity of patients.
In contrast, many argue that stroke trials have been underpowered (Weaver et
al., 2004, Furlan, 2002). Therefore, investigators may choose to determine
sample size using a binary cut but increase the statistical power to find a
treatment difference by using an ordinal method of analysis. Using this
approach would also give investigators increased power to assess treatment
effects within certain groups of patients sub group analysis. By carrying out sub
group analyses, investigators are able to assess for whom the treatment works
best, which may be useful if assessing very expensive novel treatments
(Warlow, 2002). Nevertheless, it is apparent that there is no perfect method for
calculating sample size for stroke trials and other factors related to trial design
and patient type should be considered. Software is available to calculate sample
size using the approaches tested here (Whitehead, 1993, GenStat, 2005).
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TABLE 4.1
Lookup table for values of (za + Z p) for various level of a and f3 (Bland,
2000).
f3 Significance level, a
0.05 0.01
0.70 6.2 9.6
0.80 7.9 11.7
0.90 10.5 14.9
0.95 13.0 17.8
0.99 18.4 24.0
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TABLE 4.2
Comparison of sample sizes produced by five methods. Lower ranks imply the
method produces lower sample sizes. Analysis by two-way ANOVA and
Duncan's multiple range test; tests joined by the same band are not
significantly different from each other at p<O.05.
Method Mean rank n Banding
Comparing ordinal data (Whitehead, 1993)
Comparing means
Comparing proportions (good outcome)
Comparing proportions (excellent outcome)
Comparing medians (Payne, 1993)
2.15
2.28
3.18
3.37
3.92
53
55
55
54
54
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TABLE 4.4
Percentage reduction (-)/ increase (+) in sample size in comparison to the
Whitehead ordinal data method for a sub-group of the OAST trials where a
beneficial treatment effect was shown in the original trial publication.
Highlighted cells indicate a greater sample size required in comparison to the
ordinal method of Whitehead.
Sample size method
Means Proportion
(good)
Proportion
(excellent)
Medians
CAST -11
Citicoline 1 +4
Edaravone +29
Factor VII -14
FISS High -5
FISS Low -43
NINDS +7
PROACTII -10
Walker I -14
Walker II +44
Bradford +4
Helsinki +48
Kuopio -97
Nottingham -3
Orpington Team -42
Orpington Domiciliary -53
+39
+73
+71
+21
-5
+3
+14
-77
+56
+98
+61
-45
-99
+25
+53
+73
+34
-21
+57
+25
+26
-83
-34
-55
+70
+60
+56
+17
-95
+83
+95
+99
+40
+35
+37
+32
+39
+41
+36
+33
+40
+44
+37
+39
-85
+35
+36
+37
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ADJUSTMENT FOR PROGNOSTIC FACTORS
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5.1 INTRODUCTION
Results from the 'Optimising Analysis of Stroke Trials' (OAST) Collaboration
have shown that the univariate analysis of stroke trials can be improved by
using the inherent ordering of functional outcome rather than collapsing data
into two or more groups (The Optimising Analysis of Stroke Trials (OAST)
Collaboration, 2007). Specifically, use of ordinal logistic regression, the robust
rank test, the t-test, bootstrapping the difference in mean rank and the
Wilcoxon test, were more powerful methods than those based on collapsed
data. This efficiency can be translated into increased statistical power for a
given sample size, or a reduced sample size for a given power (The Optimising
Analysis of Stroke Trials (OAST) Collaboration, 2008). The next stage of the
OASTproject will look at the effect of adjusting for prognostic factors.
When considering an adjusted analysis, the choice of covariates is of prime
importance. Three main methods have been proposed for selecting covariates
(Raab et al., 2000):
1. Variables which are known to be imbalanced across the treatment
groups, although this requires a post hoc decision
2. Prognostic factors which are related to the primary outcome
3. A combination of adjusting for those variables which are both related to
outcome and imbalanced across treatment groups
Senn suggested that the latter approach may be the most sensible as the
reliability of unadjusted tests is affected by both the correlation between the
outcome and covariate, and the level of imbalance (Senn, 1989). However,
accounting for imbalances requires a post hoc decision and therefore is not
practical in clinical trials where models have to be specified in the statistical
analysis plan prior to database closure, lock and analysis.
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The process of randomisation, whilst reducing bias, does not guarantee the
matching of baseline variables between treatment groups. Imbalances at
baseline between prognostic factors have complicated the interpretation of
several acute stroke trials (International Stroke Trial Collaborative Group, 1997,
De Deyn et al., 1997, Mayer et al., 2007). Further, imbalances reduce
statistical power and it is likely that analysis methods which take account of
pre-randomisation factors will be more efficient than those which do not make
such adjustment. Finally, adjustment reduces the variability in the data so that
more precise comparisons of treatment can be made (Pococket al., 2002).
In 2000 a review of randomised clinical trials published in high quality journals
(British Medical Journal, Journal of the American Medical Association, The
Lancet and the New England Journal of Medicine) was carried out, looking
specifically at the use of baseline data (Assmann et al., 2000). The review
found that in terms of adjustment for covariates, most trials did carry out an
adjusted analysis of the primary outcome (72%), but that the majority of
studies placed emphasis on the unadjusted analysis (76%). Most trials took into
account between five and nine covariates, with the choice being based on
prognostic significance or imbalance in the bulk of cases.
Several studies have examined adjustment for prognostic variables when using
functional outcome scales. Re-analysis of data from the NINDS trial of alteplase
(The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study
Group, 1995) using a logistic regression model adjusted for an estimate of prior
risk found a 13% reduction in sample size (Johnston et al., 2004). A study
using data from brain injury trials measuring outcome on the GlasgowOutcome
Scale found that covariate adjustment lead to a 25% reduction in sample size
when using logistic regression (Hernandez et al., 2006). Other studies have
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found similar reductions in sample size with time to event analyses (Hernandez
et al., 2006, Hauck et al., 1998). However, no studies to date have looked at
the effect of adjustment on ordinal logistic regression.
Furthermore, none of these studies discussed the inherent differences between
adjusted and unadjusted models. Adjusted models are conditional on the
covariates included in the model and therefore interpretation of the results is at
the patient level whereas unadjusted models (which do not account for
covariates) have a population level interpretation.
The aim of the analysis presented in this chapter was to assesswhether stroke
trials using ordinal logistic regression should routinely adjust for important
prognostic factors in their primary analyses. The reduction in the sample size
needed for a specific power will be used to assess the effect of covariate
adjustment.
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5.2 METHODS
5.2.1 Trial data
Trials were included from the OASTindividual patient database where covariate
(age, sex and severity) data had been provided. Three extra trials have been
added to the OASTdatabase since the initiation of the project. Tables 5.1 and
5.2 show the baseline characteristics and primary outcome data for these trials.
Trials of thrombolytic agents were excluded, since the previous two chapters
showed that their analysis does not benefit from ordinal methods (The
Optimising Analysis of Stroke Trials (OAST)Collaboration, 2008).
5.2.2 Outcome and covariate data
Data on demographics (age, sex), stroke severity (National Institutes of Health
Stroke Scale [NIHSS], Orgogozo Stroke Scale, Unified Neurological Stroke
Scale, or other similar measures), treatment group and functional outcome
variables were collected for each trial.
5.2.3 Statistical methods
All analyses were carried out in Stata (version 8). Statistical significance relates
to p<0.05.
Relationship of covariates with functional outcome
Ordinal logistic regression was used to assess the relationship between each
covariate and outcome within each trial.
Baseline imbalances in covariates
Although statistical testing for baseline imbalances should be discouraged, this
was carried out in this study so that the effect of imbalance on adjustment
could be assessed. Baseline imbalances between each covariate and treatment
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were assessed using t-tests for age and severity, and the chi-square test for
sex.
Models
Two models were compared:
(i) unadjusted model, which contained treatment assignment only
(as a binary variable)
(ii) adjusted model, which contained treatment and sex (as binary
variables), and age and baseline severity (continuous variables)
The adjusted model was restricted to these data as age, sex and severity were
the only prognostic variables available for all trials. Additionally, these three
consist of the key demographic and clinical variables.
Simulations
Although some included trials were individually significant on their assessment
of functional outcome, others were neutral but had been included because they
tested effective or hazardous treatments (as determined in published meta
analyses). Therefore significant treatment benefits with three levels of effect
(coefficients of -0.05, -0.30 or -0.56 equivalent to unadjusted odds ratios of
0.95, 0.74, or 0.57 (Hernandez et al., 2006), respectively) were simulated. By
reference, trials of hemicraniectomy (Juttler et al., 2007), thrombolysis (The
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study
Group, 1995), stroke units (Stevens and Ambler, 1982), and aspirin
(International Stroke Trial Collaborative Group, 1997) achieved odds ratios of
0.24, 0.63, 0.60, and 0.94 respectively. For consistency across studies, BI and
3Q scales were reversed so that higher scores related to a worse state of
outcome, as with the mRS; hence, an OR less than one reflects a beneficial
treatment effect across all trials and scales. Simulations were based on the
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method proposed by Hernandez et al for logistic regression (Hernandez et al.,
2006), but extended for outcomes of an ordinal nature by using ordinal logistic
regression.
The probability of having an unfavourable outcome was estimated using ordinal
logistic regression (containing age, sex and baseline severity). Patients were
randomly assigned to each treatment group (with active and control groups of
the same size as the original trial); an artificial treatment effect was then added
to the active group. A new outcome variable was generated by comparing the
probability of an unfavourable outcome (based on the probability from the
prognostic model and the added treatment effect) to a random variable with
values between zero and one, this comparison adds noise into the new outcome
variable produced. Unadjusted and adjusted ordinal logistic regression models
were then applied to the new outcome and the Z-score for the estimate of
treatment effect for each model was saved. This procedure was then carried
out 10,000 times for each of the 23 trials and repeated for each level of
treatment effect.
Reduction in sample size
The reduction in sample size was used to assess the increase in power gained
from adjustment. The Z scores from the unadjusted and adjusted models were
compared and the reduction in sample size calculated using (Hernandez et al.,
2004):
Reduction = 100 -100 x [Mean Z score unadjusted]2
Mean Z score adjusted
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5.3 RESULTS
5.3.1 Trial data
The present data set compared individual patient data from 23 trials (20 from
the original OASTdata set and three new trials (Blanco et al., 2007, Juttler et
al., 2007, Lampl et al., 2007» including 25,674 patients. The characteristics of
the trials included are given in Table 5.3. Thirteen trials measured outcome
using the BI, nine used the mRS, and one used the 3Q scale. Fourteen trials
measured baseline severity using the NIHSSwith others using another measure
such as the Orgogozo Stroke Scale. Trial sizes ranged from 32 to 19,435
patients (median 259) (Table 5.3).
5.3.2 Relationship of covariates with functional outcome
Table 5,4 shows the relationship between age, sex and severity with functional
outcome. A highly statistically significant (p<O.OOOl) relationship between
severity and functional outcome was found for the majority of trials (22/23),
with greater baseline severity leading to worse functional outcome. Twenty two
trials showed a significant relationship between age and outcome, and six
showed a significant relationship with sex. Figures 5.1-5.3 show these
relationships graphically in those trials which measured outcome using the
mRS.
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FIGURE 5.1
Relationship between age (n=9), and outcome (modified Rankin Scale), the
data shown are means and standard deviations.
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FIGURE 5.3
Relationship between sex (n=9) and outcome (modified Rankin Scale), the data
shown are means and standard deviations.
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5.3.3 Baseline imbalances in covariates
Statistically significant differences in baseline covariates were only seen in
three of the included trial data sets, one for age (in the ASSIST 07 trial the
treatment groups differed by 3.6 years, a difference which has borderline
biological significance) and two for stroke severity (a difference in the trial
specific measure of severity of 0.14 points is probably not of biological
significance in the Dover trial, but a difference of 2.82 on the NIHSS in the
DESTINYtrial is clinically relevant) (Table 5.5).
5.3.4 Reduction in sample size
Table 5.6 shows the median reduction in sample size for the three levels of
treatment effect. Trial sample size was reduced by 35-38% when covariates
were introduced and was independent of the magnitude of treatment effect. A
conservative figure for this reduction could be set at the lower end of the
interquartile range, i.e. 20-30%. The adjusted coefficients and odds ratios are
closer to and more tightly packed around the actual simulated treatment effect
than for the unadjusted models (Table 5.6 and Figure 5.4). Table 5.7 shows
that as the treatment effect increased, the proportion of simulations where
odds ratios and treatment coefficients were larger in the adjusted models
compared to the unadjusted also increased.
5.3.5 Sub group analysis
The results from the sub group analyses are shown in Table 5.8. The biggest
reduction in sample size was seen for trials using the SI (40%) as compared to
21-29% for mRS and 20% for 3Q. Trials using the NIHSS as a measure of
stroke severity also had a greater reduction in sample size (37-39%) than
those using other severity scales (29-30%). However, different studies used
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different measures of severity and outcome and it was not possible to compare
directly the relative benefits of using any particular scale.
FIGURE 5.4
Odds ratios for the unadjusted models and the adjusted models for a simulated
treatment effect of 0.57; the points are the mean effect from the 10,000
simulations. Each point on the x axis is an individual trial.
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5.4 DISCUSSION
The increasing number and size of stroke trials, and failure to identify effective
acute treatments, are threatening the viability of future studies. Any method
which reduces sample size (and hence, the cost and duration of trials) or
increases statistical power and thereby improving the likelihood of finding
effective interventions, will be welcome. These results show that the efficiency
of analyses of functional outcome in stroke trials is improved when outcome is
adjusted for three prognostic factors: age, sex and stroke severity. Such
inclusion of covariates allows a substantial reduction in sample size to be
achieved, in this case by approximately one-quarter (lower end of the
interquartile range), for a given power; conversely, statistical power can be
increased for a given sample size. Maintaining sample size has the added
benefit of improving the robustness of sub group analyses. Importantly,
covariate adjustment appeared to be effective irrespective of the scales used to
measure baseline severity and functional outcome.
Other studies have shown that adjustment for baseline covariates improves
statistical power. The IMPACTstudy assessedways of improving the design and
analysis of brain injury trials and found that adjustment for seven predictors of
outcome reduced sample size by around 16-23% when analysed using logistic
regression on a dichotomised GlasgowOutcome Scale (Hernandez et al., 2006).
In contrast to the results presented here, Hernandez looked at two types of
covariate adjustment, an adjustment for seven prognostic factors and then a
model adjusted for the three strongest predictors of outcome from the seven
prognostic variables. They found that adjusting for more variables gave a
greater reduction in the sample size required, ""25% compared to ",,20%
(Hernandez et al., 2006). I have only looked at adjusting for one set of
covariates, but as baseline severity is such a strong predictor of outcome, the
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addition of others would probably not greatly alter the results found. Another
previous paper by Hernandez also looked at the effect of adjustment on logistic
regression; this project was more comprehensive and compared different levels
of treatment effect, covariate effect, outcome incidences and covariate
prevalences (Hernandez et al., 2004). They found, akin with this current
analysis, that the reduction in sample size gained was independent of level of
treatment effect. Interestingly, they found that adjustment for covariates which
were imbalanced across treatment groups did not increase power and therefore
they advised against this. They found that the greatest reductions in sample
size were associated with adjustment for moderate to strong predictors of
outcome. They conclude that randomised controlled trials should consider
adjusted analyses and that the covariates included should be either
prognostically important and therefore pre-specified in the trial protocol, or are
shown to have a statistically significant relationship to outcome. Similar results
have been reported for time to event analyses using the Cox proportional
hazards model (Hernandez et al., 2006). However, this OAST analysis is the
first to look at the effect of adjustment on ordinal logistic regression, and
assessment of potential benefits on sample size.
Adjustment addresses imbalances in baseline prognostic factors which occur by
chance with simple randomisation. Historically, the interpretation of several
stroke trials has been confounded by imbalances at baseline. For example, the
large 20,000 patient 'International Stroke Trial' was neutral in its primary
univariate analysis but statistically significant following adjustment with a
model predictive of outcome (International Stroke Trial Collaborative Group,
1997). Similarly, the SAINT-I trial had a statistically significant result when
adjusted for prognostic factors but showed no effect when analysed without
covariate adjustment (Lees et al., 2006). Such imbalances in baseline factors
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may be reduced using adaptive randomisation (minimisation), a technique
which also moderately improves statistical power (Weir and Lees, 2003).
Adjustment for covariates increases the precision of the estimated treatment
effect and changes the interpretation of the results, as these are now
conditional on the chosen covariates. It is therefore crucial that adjustment is
considered at the protocol development stage of setting up a clinical trial and
that the covariates are chosen and stated a priori; the decision to include
covariates, and which ones, at the time of analysis would be incorrect and
result in misleading data-driven analyses.
There are several limitations to the present analysis. Firstly, only 20 of the
original 55 OAST data sets could be used since many studies did not share
baseline data. Although this is unlikely to have changed the present findings
qualitatively, it will have reduced the power of the analyses. In this respect, it
is vitally important that trialists, both academic and commercial, share data
following publication of the main trial paper for use in other projects (such as
OAST and VISTA (Ali et al., 2007» so that its value is maximised. Secondly,
only three covariates (age, sex severity) were used so as to maximise the
number of included data sets. However, this limitation is not important since,
although there are many baseline characteristics which have prognostic
significance (e.g. atrial fibrillation, temperature, blood pressure, and serum
glucose), severity has been consistently identified as the most powerful
predictive factor of outcome (Sprigg et al., 2007) and explains most of the
variation in covariate-adjusted analyses (as shown here). Age and sex are
added since they are key biological variables. Thirdly, beneficial effects on
study power/sample size may not translate to other clinical areas; stroke is
unusual in having such a strong predictor of outcome in the form of baseline
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severity and, as such, the reduction in sample size gained by adjusting for
covariates will be greatly influenced by the strength of the relationship between
severity and outcome. Lastly, methods of analysis which assess shifts in
outcome over the entire distribution, although popular with physicians, may not
be thoroughly understood and therefore greater input may be needed from
statisticians (Savitz et al., 2008). Additionally, further work needs to address
what magnitude of shift in outcome is meaningful to patients, healthcare
professionals and health funders.
5.5 SUMMARY
In summary, trialists should consider using key prognostic variables in the
analysis of functional outcome in stroke trials when using ordinal analyses. This
will allow trials to be smaller for a given statistical power, or to achieve greater
statistical power for a given sample size. Nevertheless, existing knowledge that
covariate adjusted logistic regression is more powerful than unadjusted
analyses has not led to all trials moving to this approach, perhaps because of
uncertainty about the interpretation and presentation of trial results based on
adjusted analyses. Hence, in practical terms trialists may, at least in the short
term, want to power their study for an unadjusted analysis and then analyse
the completed trial with adjustment for covariates, thereby increasing the
statistical power but maintaining a large enough sample size to carry out an
unadjusted analysis as a secondary endpoint. Nevertheless, the results need to
be reported in the context of the included covariates.
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TABLE 5.3
Included trials.
Trial Intervention Outcome Baseline Sample
scale severity scale size
AbESTT Abciximab mRS NIHSS 400
ASSIST 07 Selfotel BI NIHSS 138
ASSIST 10 Selfotel BI NIHSS 432
Citicoline 1 Citicoline BI NIHSS 259
Citicoline 7 Citicoline BI NIHSS 394
Citicoline 10 Citicoline mRS NIHSS 100
Citicoline 18 Citicoline BI NIHSS 899
DCLHb DCLHb mRS NIHSS 85
DESTINY Decompressive surgery mRS NIHSS 32
Dover Stroke unit mRS Own 235
Ebselen Ebselen BI Own 298
FOOD 3 NG tube mRS Own 321
INWEST HIGH Nimodipine BI ORGO 194
INWEST LOW Nimodipine BI ORGO 201
1ST Aspirin 3Q Own 19435
MAST-I Aspirin mRS Own 309
Minocycline Minocycline mRS NIHSS 151
RANTTAS I Tirilazad BI NIHSS 660
RANTTAS II Tirilazad BI NIHSS 126
Statin withdrawal Statin withdrawal mRS NIHSS 89
STIPAS Tirilazad BI NIHSS 111
TESS I Tirilazad BI UNSS 450
TESS II Tirilazad BI UNSS 355
BI: Barthel Index; mRS: modified Rankin Scale; NIHSS: National Institute of
Health Stroke Scale; ORGO: Orgogozo Scale; UNSS: Unified Neurologic Stroke
Scale.
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TABLE5.4
Relationship between age, sex and severity and outcome using ordinal logistic
regression. Statistically significant results (p<0.05) are given in bold.
Trial Relationship to outcome
Age Sex Severity
AbESTT <0.001 0.126 <0.001
ASSIST 07 0.001 0.327 <0.001
ASSIST 10 <0.001 0.280 <0.001
Citicoline 1 <0.001 0.072 <0.001
Citicoline 7 <0.001 0.234 <0.001
Citicoline 10 0.03 0.030 <0.001
Citicoline 18 <0.001 0.056 <0.001
DCLHb 0.036 0.724 <0.001
DESTINY 0.001 0.687 0.301
Dover 0.004 0.257 <0.001
Ebselen <0.001 0.003 <0.001
FOOD 3 <0.001 0.135 <0.001
INWEST HIGH <0.001 0.044 <0.001
INWEST LOW <0.001 0.078 <0.001
1ST <0.001 <0.001 <0.001
MAST-I <0.001 0.012 <0.001
Minocycline 0.49 0.50 <0.001
RANTTAS I <0.001 0.002 <0.001
RANTTAS II <0.001 0.458 <0.001
Statin withdrawal 0.007 0.12 <0.001
STIPAS 0.005 0.651 <0.001
TESS I <0.001 0.912 <0.001
TESS II <0.001 0.442 <0.001
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TABLE 5.5
Baseline imbalances for age, sex and severity using t-test for age and severity
and chi square test for sex. Statistically significant results (p<0.05) are given in
bold.
Trial Baseline imbalance
Diff in mean age (yrs) Diff in % male Diff in mean
severity
1.32 7.50 0.50
3.60 7.61 0.69
1.93 3.10 0.29
2.54 2.80 0.19
0.56 3.13 0.58
4.20 2.08 0.31
0.58 4.37 0.55
2.56 11.00 0.60
2.83 0.39 2.82
0.81 0.86 0.14
0.15 5.02 4.20
0.23 0.41 <0.0001
1.08 4.32 3.79
0.91 4.45 1.54
0.03 1.07 0.01
0.88 2.97 0.19
1.03 2.72 0.04
0.48 4.88 0.67
2.18 1.79 1.35
1.47 5.66 0.86
3.17 10.18 1.18
1.47 1.00 0.09
0.63 2.59 1.07
AbESTT
ASSIST 07
ASSIST 10
Citicoline 1
Citicoline 7
Citicoline 10
Citicoline 18
DCLHb
DESTINY
Dover
Ebselen
FOOD 3
INWEST HIGH
INWEST LOW
1ST
MAST-I
Minocycline
RANTTAS I
RANTTAS II
Statin withdrawal
STIPAS
TESS I
TESS II
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CHAPTER 6
AN ASSESSMENT OF OTHER METHODS OF ANALYSES
USED IN STROKE TRIALS
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6.1 INTRODUCTION
The OAST project so far has assessed using various univariate methods of
analysis and the effect of taking into account covariates on the results produced
from functional outcome data. As discussed previously in the introduction
chapter, other types of analysis have also been used; namely the global
outcome analysis, patient-specific outcome, and the Cochran Mantel-Haenszel
test. This chapter will consider these approaches.
The global outcome analysis, where data from more than one outcome scale is
combined, has been used in a number of stroke trials. The NINDS trial tested
the thrombolytic agent alteplase against placebo; during the development of
this trial, it was decided that choosing one primary outcome scale was too
limiting. Instead the trialists chose four scales (mRS, BI, NIHSS and GOS) to
cover a number of aspects of stroke recovery rather than focussing on one
disability scale. In 1992 the NINDS trial group held a workshop to discuss
methods of statistical analysis for trials with multiple pre-specified outcomes
(Tilley et al., 1996). The consensus of the participants was that a global test,
utilising generalised estimating equations (GEE) modelling, should be used.
Here, two or more dichotomised outcomes can be tested simultaneously using a
Wald test statistic; the NINDS trial combined the following dichotomised
outcomes:
• BI ~95
• mRS:Sl
• NIHSS:Sl
• GOS=1
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The NINDS trial showed a beneficial treatment effect, both on the global
outcome and for each individual scale. The "Intravenous Magnesium Efficacy in
Stroke" (IMAGES) trial changed their analysis plan during the trial to include a
global measure (BI~9S and mRS~l) as the primary outcome, after a study
using simulated data showed that global outcomes were more powerful than
using BI dichotomised at ~60, which was the trial's original primary outcome
(Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators,
2004, Young et al., 2003). Applying a post hoc global analysis to the ECASS
trial (BI~9S, mRSS1, NIHSS S1) gave a statistically significant result,
compared to the neutral finding of the original analysis (median BI and median
mRS) (Hacke et al., 1998).
The second type of analysis which has been suggested takes into account the
patient's initial level of stroke severity. Here, the definition of a good outcome
varies depending on the baseline severity instead of being constant for all
patients (Adams et al., 2004, Berge and Barer, 2002). In the literature this
type of analysis has been termed:
• "patient-specific" (Young et al., 2003)
• "responder" (Adams et al., 2004)
• "prognosis-adjusted" (Young et al., 2005)
• "sliding dichotomy" (Murray et al., 2005)
This approach has been taken by a few completed trials. The "Stroke Treatment
with Ancrod Trial" (STAT) used a variation of this and defined a favourable
outcome as either ~9S on the BI or at least equal to their pre stroke value at
the day 90 assessment (Sherman et al., 2000). The "Abciximab in Emergent
Stroke Treatment Trial" (AbESlT) was the first trial to use a full responder
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analysis approach as a secondary outcome. This trial used three
dichotomisations of the mRS to define a favourable outcome based on the
patients baseline NIHSS score (mRS=O for NIHSS ~7, mRS~l for NIHSS 8-14
and mRS~2 for NIHSS>14). The trialists found, in line with their primary
outcome, that the patient specific outcome showed increased response in the
abciximab group (Adams et al., 2004, Abciximab Emergent Stroke Treatment
Trial (AbESTT) Investigators, 2005). Unfortunately, the follow-on phase three
trial failed to confirm this finding (Adams et al., 2008). A comparison of
outcomes in thrombolytic trials found that a patient specific outcome and a
normal dichotomisation, which does not take into account baseline severity,
gave similar proportions of patients with an excellent outcome, but that the
types of patients within this category were quite different. The patient specific
outcome categorised fewer mild stroke patients as having an excellent outcome
and more patients with a severe stroke. This study found the patient specific
outcome to be a better and more clinically relevant outcome (Thomassen et al.,
2005). There is also a statistical argument for using this type of analysis, since
it increases statistical power, as compared to approaches which do not take
baseline severity into account (Young et al., 2005).
The final type of analysis also takes into account covariates, such as severity,
but stratifies the analysis by using a Cochran Mantel-Haenszel test, rather than
by setting varying definitions of a favourable outcome. This method was used in
the SAINT trials, where the primary end point of the mRSwas adjusted for the
stratification variables: NIHSS, side of infarct and use of alteplase (Lees et al.,
2006, Shuaib et al., 2007).
The aim of this part of the OAST project was to test whether these three
approaches improve the efficiency of stroke clinical trials.
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6.2 METHODS
6.2.1 Trial data
For this part of the project, trials from the OASTdatabase which had measured
both mRS and BI were used for the global outcome analysis, and those which
had collected data on baseline severity using the NIHSS were used for
assessing the patient specific outcome and Cochran Mantel-Haenszel test.
6.2.2 Global outcome
Global outcome analysis (GO) was calculated using the GEEmethod, as used in
the NINDS study (The National Institute of Neurological Disorders and Stroke
rt-PA Stroke Study Group, 1995, Tilley et al., 1996). In this analysis, a
multivariate model was used to combine two dichotomous outcomes BI~95 and
mRSS1. The model used has the following form:
As two binary variables are being combinedK = 2, this can be extended to any
number of binary variables. Y;jk is the Kth response: K = 1,2 in the ithgroup:
i =0 (control),I (treatment) for the jth subject: j = 1,2, nj• The observation
vectors for each subject are independent, with mean u, and variance
Yijk = (/J)Jjjk (1- )Jijk)' where (/J allows for over dispersion.
The multivariate model uses a logistic model which models the probability of a
good outcome on each scale. The model for the mean E(Yijk)= )Jjk is therefore
logit )Jik = a + f3xj (Tilley et al., 1996).
The GEE method of Lefkopoulou and Ryan is then used to obtain a Wald
statistic which simultaneously tests the null hypothesis that the two outcome
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measures are equal in the two treatment groups (Lefkopoulou and Ryan,
1993).
6.2.3 Patient specific outcome
The definitions of a favourable outcome suggested by Adams et al were used
with equivalent cuts being used for the BI (Adams et al., 2004). A chi square
test, without continuity correction, was then applied to the patient specific
outcome. SeeTable 6.1 for definitions.
6.2.4 Cochran Mantel-Haenszel test
The same strata for NIHSS«8, 8-14, >14) were used for the Cochran Mantel-
Haenszel test as used in the patient specific outcome. A favourable outcome
was defined as BI~95 and mRS::;!. The Cochran Mantel-Haenszel test statistic
is:
F t f 2 2 K t bl Wh E( ) nl+kn+lk h· h . thor a se 0 x x a es. ere J.lllk = nil = , w IC IS e
n++k
expected frequency of the first cell in the Kth table, and the variance of cell
(1,1) is:
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6.2.5 Comparison of statistical tests
The z scores from the three novel approaches were compared to the z scores
from ordinal logistic regression (for trials not testing thrombolytic agents) and
the t-test (all trials); ordinal logistic regression and t-test were carried out on
the primary outcome scale for the trial. The difference between the z scores
was then assessedusing a Wilcoxon test, to see if the z scores produced by one
test were significantly different to those given by the other. Analyses were
carried out in SAS (version 8.2) and Stata (version 7) and significance was
taken at p<O.OS.
6.3 RESULTS
6.3.1 Included trials
Table 6.2 shows the data sets included for each type of analysis. Twelve trials
from a mixture of acute and rehabilitation trials had provided data on both the
mRS and BI and therefore the global outcome could be calculated. Seventeen
and sixteen data sets from acute trials were included in the patient specific
outcome and Cochran Mantel-Haenszel test respectively.
6.3.2 Global outcome
Table 6.3 and Figure 6.1 show the comparison of the global outcome with the t-
test. There was no significant difference between the z scores produced by the
global outcome and those produced by the t-test (p=O.69). The comparison
with ordinal logistic regression for those trials not testing a thrombolytic agent
showed similar results (p=O.89, Table 6.4), with Figure 6.2 showing that the
global outcome and ordinal logistic regression generally give comparable
results.
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6.3.3 Cochran Mantel-Haenszel test
Tables 6.3 and 6.4 show no statistical difference between the Cochran Mantel-
Haenszel test and both the t-test and ordinal logistic regression (p=O.60 and
p=O.77 respectively), although this may be due, in part, to lack of power owing
to the limited number of data sets included. Figures 6.3 and 6.4 show that
although the z scores are similar for the Cochran Mantel-Haenszel test and the
t-test, and the CochranMantel-Haenszel test and ordinal logistic regression, the
Cochran Mantel-Haenszel test produced consistently smaller z scores (smaller
treatment effects) than both other tests (seen when green line falls below
zero).
6.3.4 Patient specific outcome
Similar results to the Cochran Mantel-Haenszel test are seen for the patient
specific outcome (Tables 6.3 and 6.4, Figures 6.5 and 6.6), with analogous but
lower z scores compared to the t-test and ordinal logistic regression (p=O.69
and p=O.70 respectively).
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FIGURE 6.1
Z scores from the global outcome and the t-test, with difference between the
two. Where the difference falls below the line, the global outcome produces a
smaller z score than the t-test. Each point on the x axis is an individual trial.
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FIGURE 6.2
Z scores from the global outcome and ordinal logistic regression, with
difference between the two. Where the difference falls below the line, the global
outcome produces a smaller z score than ordinal logistic regression. Each point
on the x axis is an individual trial.
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FIGURE 6.3
Z scores from the Cochran Mantel-Haenszel test and the t-test, with difference
between the two. Where the difference falls below the line, the Cochran Mantel-
Haenszel test produces a smaller z score than the t-test. Each point on the x
axis is an individual trial.
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FIGURE 6.4
Z scores from the Cochran Mantel-Haenszel test and ordinal logistic regression,
with difference between the two. Where the difference falls below the line, the
Cochran Mantel-Haenszel test produces a smaller z score than ordinal logistic
regression. Each point on the x axis is an individual trial.
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FIGURE 6.5
Z scores from the patient specific outcome and the t-test, with difference
between the two. Where the difference falls below the line, the patient specific
outcome produces a smaller z score than the t-test. Each point on the x axis is
an individual trial.
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FIGURE 6.6
Z scores from the patient specific outcome and ordinal logistic regression, with
difference between the two. Where the difference falls below the line, the
patient specific outcome produces a smaller z score than ordinal logistic
regression. Each point on the x axis is an individual trial.
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6.4 DISCUSSION
This final part of the OASTproject has focussed on methods of analysis which
have been used in stroke trials but which have not been considered so far:
global outcome, Cochran Mantel-Haenszel test and patient specific outcome.
These were compared with the t-test and ordinal logistic regression. The results
suggest that overall there is no difference in the z scores given with the three
methods of analysis assessed, compared to the t-test and ordinal logistic
regression. Although no statistical difference was shown for the Cochran
Mantel-Haenszel test or the patient specific outcome the results suggest that,
on average, these tests produced smaller z scores than either the t-test or
ordinal logistic regression. The lack of a statistically significant result may be
due to a lack of power, as only a maximum of 17 data sets were included in
these analyses. But, reassuringly, the results do suggest that using either of
these methods of analysis (global outcome, Cochran Mantel-Haenszel test or
patient specific outcome) or the comparators (t-test or ordinal logistic
regression) produce very similar results, and therefore one would expect for a
beneficial treatment a statistically significant result would be seen with any of
these tests.
A few comments can be made about these results. Firstly, the initial OAST
paper advised against the use of binary outcomes which dichotomise data into
two groups (The Optimising Analysis of Stroke Trials (OAST) Collaboration,
2007). All three of the methods of analysis assessed here used here are also
based on dichotomisations and therefore require researchers to make
subjective decisions on where the data should be split. Further research should
focus on expanding these methods to take into account ordinal data. Secondly,
it may be argued that comparing the t-test and ordinal logistic regression which
analyse data from one scale, with methods which combine data from two more
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scales is not valid. However, it is important to assess whether the methods of
analysis which combine scales are better than those that do not.
No difference was seen between the methods of analysis assessed and the t-
test or ordinal logistic regression. If a difference was seen, then these methods
of analysis could be recommended for use in stroke trials. As no difference was
seen, and they also have the intrinsic problems of dichotomisation, it might be
advantageous to still consider ordinal logistic regression or another univariate
approach when deciding how the primary outcome of a trial will be analysed. As
shown in the previous chapter, ordinal logistic regression can easily be adjusted
for prognostic factors if needed. As the methods of analysis assessed here and
ordinal logistic regression performed similarly, an adjusted ordinal logistic
regression is likely, therefore, to out perform the global outcome statistic,
patient specific and the Cochran Mantel-Haenszel test.
It may be argued that patient-specific outcomes may be useful in trials of
agents which both increase the odds of a good outcome, but also have an
associated increase in risk, i.e. bleeding in trials of thrombolytic agents. Here,
ordinal logistic regression analysis is not suitable and the t-test can not be
adjusted for covariates.
The global outcome, patient specific and the Cochran Mantel-Haenszel test may
answer interesting clinical questions which are uniquely different to the
question posed by the ordinal logistic regression analysis. For example, the
responder outcome which sets differing definitions of a "good outcome",
depending on the patient's initial level of severity, is assessing a severity
related treatment effect. This would therefore presumably classify more
patients with a good outcome as compared to an analysis based on a set
190
definition for all patients. It could also be argued that the global outcome is
assessing overall outcome across a number of domains, rather than placing
emphasis on one scale.
6.5 SUMMARY
In conclusion this work has shown no additional statistical benefit in using
either the global outcome, patient specific outcome, or the Cochran Mantel-
Haenszeltest over the t-test or ordinal logistic regression.
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TABLE 6.1
Definitions of a good outcome for various levels of baseline severity (Adams et
al., 2004).
Baseline severity (NIHSS) Good outcome
Barthel Index
Good outcome
Rankin Scale
<8
8-14
>14
95, 100
75-90
60-70
o
<1
<2
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TABLE 6.2
Data sets used for each type of analysis.
Outcome calculated
Global outcome Cochran Mantel- Patient specific
Haenszel test
Acute
AbESTT X X X
ASSIST 07 X X
ASSIST 10 X X
ATLANTIS A X X
ATLANTIS B X X X
Citlcollne 01 X X X
Citicoline 07 X X X
Citicoline 10 X X X
Citicoline 18 X X X
DESTINY X
ECASS II X X
MAST-E X
Minocycline X X X
NINDS X X X
RANTTAS X X
RANTTAS II X X
Statin withdrawal X X
STIPAS X X
Rehabilitation
Gilbertson X
Parker ADL X
Parker leisure X
Total Trials 12 16 17
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CHAPTER 7
EXTENDING THE OAST PROJECT TO STROKE
PREVENTION TRIALS
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7.1 INTRODUCTION
The OASTproject has shown that the design and analysis of acute stroke trials
can be improved through the use of ordinal methods of analysis. The
application of ordinal methods to stroke trials could increase the statistical
power to find treatment differences or reduce sample size, which in turn will
improve the quality of stroke trials and reduce their complexity and cost.
Trials looking at the prevention of first (primary prevention) or recurrent
(secondary prevention) strokes have been more successful in finding new
treatments than acute stroke trials, with effective strategies being based on
antithrombotic agents, carotid endarterectomy, blood pressure and cholesterol
lowering. However, this success has made subsequent trials more difficult as
the absolute risk of recurrence, and therefore event rates, have fallen
dramatically over time. Figure 7.1 demonstrates this trend by plotting the
stroke rate in the control group for each trial included in the OASTprevention
project. The regression line shows that the stroke rate has decreased in recent
years (p=O.Ol). Figure 7.2 shows the increase in the sample size of stroke
prevention trials in recent years. This trend is likely to continue as new and
effective interventions are added. Since absolute event rates are a key
component in sample size calculations for binary (stroke/no stroke) outcomes,
low rates equate to larger trials. Another pressure on performing prevention
trials is that their number has increased as new prophylactic strategies are
tested (Figure 7.3). The combination of more and larger trials means it is
becoming increasingly difficult to find sufficient patients to enrol into new
studies.
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FIGURE 7.1
Control group stroke rate (%) by date of trial publication for all trials included
in the OAST prevention project. The red line gives the regression slope, for
every year increase the stroke rate decreases by -0.2 (p=O.Ol).
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FIGURE 7.2
Sample size by date of trial publication for all trials included in the OAST
prevention project. The blue line gives the regression slope, for every year
increase sample size increases by 144 patients (p=0.03).
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FIGURE 7.3
Number of trials published by year for all trials included in the OAST prevention
project. The green line gives the regression slope, for every year increase the
number of trials published increases by 0.1 (p=O.Ol).
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It may be possible to use the results of the acute OASTproject to influence the
design and analysis of stroke prevention trials, in the hope of bringing sample
sizes down while maximising the potential to demonstrate benefit.
In the past, composite outcomes of vascular death, non-fatal stroke, and non-
fatal myocardial infarction (MI) have been used as the primary outcome in
prevention trials, in part to increase the number of events. This approach can
be extended to include further events in the composite such as hospitalisation,
silent brain infarcts, or by counting all events rather than just the first one.
However, the use of composite outcomes has been criticised (Ferreira-Gonzalez
et al., 2007). An alternative approach is to analyse stroke prevention trials in a
way which does not lose clinically relevant data. Most studies compare binary
(stroke/no stroke) event rates between the treatment and control group.
However, stroke events may be fatal or non-fatal, so trichotomous ordinal
outcomes (fatal event/non-fatal event/no event) can be analysed. This
approach can be extended to four (fatal stroke/severe non-fatal stroke/mild
stroke/no stroke) or five (fatal stroke/severe non-fatal stroke/mild
stroke/TIA/no event) levels. Similar ordered categorical outcomes can be
developed for MI and composite vascular outcomes, as well as other vascular
events, such as heart failure and bleeding. Such polytomisation of events
assumes that the ordering of events is meaningful, i.e. that fatal stroke events
are considered more severe than non fatal ones. If so, ordinal outcomes may
be more informative to patients, carers, healthcare professionals and
government than binary outcomes.
This part of the project aims to compare the relative efficiencies of using and
analysing binary and polytomous ordinal outcomes from vascular prevention
trials. This part of the OAST project will be referred to as 'OAST prevention'.
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Vascular trials involving non stroke patients and those measuring non stroke
outcomes are included since, stroke patients suffer subsequent non stroke
vascular events, and those with other vascular conditions can go on to have a
stroke. Here the term 'vascular event' refers to stroke, or MI. Taking this
approach means the findings are generalisable across the field of vascular
medicine.
7.2 METHODS
7.2.1 OASTpreventiondata set
In contrast to the acute OASTproject, the OASTprevention data set is entirely
extracted from the trial publications and individual trial data was not sought. All
data was extracted and collated by Dr Chamila Geeganage, for full details see
(Bath et al., 2008). In brief, data were collated from randomised controlled
trials assessing primary or secondary vascular prevention, i.e. preventing first
or recurrent events respectively, which were either beneficial or harmful
according to the trial publication, or were included in a meta analysis showing
benefit or harm; trials in a meta analysis showing no statistically significant
treatment effect were excluded. This approach follows the acute OASTproject
(The Optimising Analysis of Stroke Trials (OAST) Collaboration, 2007).
Published studies fulfilling these criteria were identified from electronic searches
of the Cochrane Library and included studies of antithrombotic, blood pressure
or lipid lowering therapy, carotid endarterectomy, and hormone replacement
therapy. Trials were excluded if they did not include adequate ordered
categorical information for at least one vascular outcome.
The numbers of subjects at the end of follow-up having a vascular event were
obtained, where available, for each treatment group (active, control) from the
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primary trial publication. In factorial trials, or those having more than two
treatment groups, data were analysed for each active comparison versus
control. Data were assessedby intention-to-treat where possible.
7.2.2 Statistical tests
Ten different statistical tests for assessing treatment effect were compared:
(i) Chi-square 2x2 test - stroke versus no stroke
Cii) Chi-square 2x2 test - death versus alive
(iii) Chi-square test across all categories (unordered data) - e.g. fatal
stroke/ non fatal stroke/ no stroke
(iv) Cochran-Armitage trend test (ordered data) - e.g. fatal stroke/
non fatal stroke/ no stroke
(v) Ordinal logistic regression
(vi) Median test
(vii) Wilcoxon test (adjusted for ties)
(viii) Robust rank test
(lx) t-test
(x) Bootstrap of difference in mean rank (with 3x3,OOOcycles)
The tests compared were used in the same way as in Chapter 3 (see Chapter 3
for detail). Analyses were carried out in SAS (version 8.2) and Stata (version
7); significance was taken at p<O.05 for analyses of trials and p<O.Ol for
ANOVA.
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7.2.3 Comparison of statistical tests
Each data set was analysed using each statistical test. The results were then
ordered within each trial and given a rank, with the lowest rank given to the
test which produced the smallest p-value within that trial. A two-way analysis
of variance test (Friedman's with adjustment for ties) was then performed to
assess which statistical test produced the lowest ranks (i.e. the most
statistically significant values). Duncan's multiple range test was used to assess
the ordering of tests and determine where significant differences between tests
were present. The number of statistically significant (at 5%) results found for
each test was also assessed.
The analysis was repeated for six types of vascular outcome:
(i) Three level stroke: fatal stroke/ non fatal stroke/ no stroke
(ii) Four level stroke: fatal stroke/ severe non fatal stroke/ mild non
fatal stroke/ no stroke
(iii) Four level strokemA: fatal stroke/ non fatal stroke/ TIA/ no
stroke
(iv) Five level strokemA: fatal stroke/ severe non fatal stroke/ mild
non fatal stroke/ TIA/ no stroke (see Figure 7.4 for an example)
(v) Three level MI: fatal MI/ non fatal MI/ no MI
(vi) Three level vascular (composite of stroke or MI) event: fatal
vascular event/ non fatal vascular event/ no vascular event
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FIGURE 7.4
Example of the five level strokejTIA outcome compared to a standard stroke
versus no stroke outcome, using data from the HEP trial (Coope and
Warrender, 1986).
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7.2.4 Sub group analysis
Sub group analyses were performed for the three level stroke outcome by
assessing the efficiency of the different tests for differing trial characteristics:
• type of prevention (primary, secondary)
• type of treatment (anticoagulants, antiplatelets, antihypertensives, lipid
lowering, carotid endarterectomy, hormone replacement therapy)
• patient age «65, >65 years)
• trial size «2,250, >2,250 participants)
• length of follow up «36 months, >36 months)
• baseline severity (control group death rate adjusted for length of follow
up, <median (0.2), >median (0.2»
• time from index event «87 days, >87 days)
7.2.5 Statistical assumptions
The principal statistical assumptions underlying the tests which performed well
for the three level stroke outcome were assessed to ensure that their use was
appropriate for prevention trial data. Assumptions included: proportionality of
odds across response categories for ordinal logistic regression, and
independence of groups for the Wilcoxon test. The bootstrapping method is
assumption free.
7.2.6 Type 1 error rate
Analogous to the OASTacute project, the type 1 error rate for the three most
efficient statistical tests for the three level stroke outcome were tested using
data from five representative trials. From these 1,000 data sets were
generated, using random sampling with replacement, in which any treatment
difference could have occurred only by chance. Tests maintaining adherence to
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the nominal type I error rate would expect to see a significant result in around
50 of the 1000 data sets (5%).
7.3 RESULTS
7.3.1 Trials
Of 243 identified trials, 101 (416,020 subjects) were included, these comprising
35 primary and 66 secondary prevention studies. There were 142 trials
excluded, mainly because their published data did not distinguish between fatal
and non-fatal vascular events so that three level data could not be calculated.
For full details see (Bath et al., 2008).
7.3.2 Stroke
The results of the statistical tests differed significantly for the three level stroke
outcome (85 trials, 335,305 subjects) (ANOVA p<O.OOOl) (Table 7.1); ordinal
analyses ranked above binary approaches with the Wilcoxon test, bootstrapping
(difference in mean rank) and ordinal logistic regression performing
significantly better than the other methods. Similar results were seen for the
other stroke outcome assessments: four level stroke outcome, four level
stroke/TIA outcome, and the five level stroke/TIA outcome (each ANOVA
p<O.OOOl) (Table 7.2).
Although the absolute ordering of the tests varied across the outcomes, ordinal
tests always performed better than binary ones. Six trials gave sufficient data
to compare qualitatively three, four and five level data; four level strokemA
outcome and five level data strokemA outcome appeared to be the most
efficient approaches (Table 7.3). When assessed by how many trials were
statistically significant with each of the ten tests (beneficial or harmful but not
ineffective), those tests which did not collapse the data into groups again out-
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performed other approaches. For example, the Wilcoxon test gave a statistically
significant result in 44% of trials in comparison with the chi square 2x3 test at
32% (Figure 7.5).
7.3.3 Myocardial infarction
Fifty-eight trials (232,515 subjects) gave data for the three level MI outcome.
The analyses differed significantly for the three level MI outcome (p<O.OOOl)
with ordinal approaches performing better than binary (Table 7.2).
7.3.4 Composite vascular event
Forty-three trials (204,108 subjects) gave data for the three level composite
vascular outcome. Ordinal tests performed best (p<O.OOOl) with the Wilcoxon
test, bootstrapping (the difference in mean rank) and ordinal logistic regression
ranking highest (Table 7.2).
7.3.5 Subgroup analyses
The ordering of statistical tests, with ordinal more efficient than binary, was
maintained for all sub groups of trials irrespective of type of prevention and
treatment, average age of patients, trial size and length of follow-up, risk of
death or stroke, and time from index event for the three level stroke outcome
(Table 7.4). When considering the 19 trials (27 data sets) with a high event
rate (>10% overall) ordinal tests remained most efficient. Published hazard
ratios (which take into account the time to event, as derived from the Cox
proportional hazards model) for stroke were available for 36 trials; a
comparison of the 11 statistical tests, including Cox results, revealed
bootstrapping, Wilcoxon test and ordinal logistic regression to be as good if not
slightly superior to the Cox model (Duncan's multiple range test) (Table 7.5).
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7.3.6 Statistical assumptions
The proportionality of odds assumption for ordinal logistic regression was not
violated (p>O.OS) in 79 of 85 trials with three level stroke data (see Figure
7.6).
7.3.7 Type 1 error
The type 1 error analysis showed that the top performing statistical tests
(ordinal logistic regression, Wilcoxon test) were not overly sensitive and
statistically significant treatment effects were only found where they are likely
to be present (see Table 7.6). Figure 7.7 shows that the odds ratios were
similar for different strata of severity for three level stroke, four level
stroke/TIA, and five level stroke/TIA outcome.
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FIGURE 7.5
The number of significant trials (p<O.OS) for each statistical test for the three
level stroke outcome.
o 5
% of trials with significant at 5% level
10 15 20 25 30 35 40 45 50
Median test
Wilcoxon
FIGURE 7.6
The p values from the likelihood ratio test for the proportional odds assumption
for the three level stroke outcome. P<O.OS indicates non proportional odds.
Dotted line is at p=O.OS.
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FIGURE 7.7
Odds ratios across four trials (by ordinal logistic regression) and by individual
outcome levels to illustrate the assumption of proportionality of odds.
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7.4 HORMONE REPLACEMENT THERAPY EXAMPLE
This section describes in more detail an example where the ordinal approach to
analysis has been used.
7.4.1 Introduction
Observational studies have suggested that hormone replacement therapy (HRT)
may be beneficial in the prevention of arterial thrombotic events (Grodstein et
al., 1996, Sarrel, 1996). However, randomised controlled trials have shown that
the risk of stroke and venous thromboembolism (VTE) is increased with HRT
(Bath and Gray, 2005); the effect on coronary heart disease remains unclear.
The aim of this project was to review systematically all trials of HRT assessing
effects on cerebrovascular, coronary heart disease, and VTE events; analyses
assessed both the frequency and severity of events.
7.4.2 Identification of trials
Completed and published non-confounded randomised controlled trials of HRT
versus no HRT (open or placebo-controlled) were included. Trials had to report
event rates for one or more of cerebrovascular (CVO), coronary heart disease
(CHO) or venous thromboembolism (VTE). Non-English language publications
were excluded. Publications were identified from searches of The Cochrane
Library, Embase, Medline (to May 2007), previous reviews (Wren, 1998, Zec
and Trivedi, 2002, Collins, 2002, Salpeter et al., 2004, Bath and Gray, 2005,
Gabriel et al., 2005), and reference lists from identified articles.
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7.4.3 Data extraction
Vascular events (identified as adverse events in some trials) were extracted
from the study papers, ideally by intention-to-treat, and included
cerebrovascular disease (CVO) (stroke, TIA), coronary heart disease (CHO) (MI,
sudden cardiac death, unstable angina (UA)) and VTE disease (deep vein
thrombosis, pulmonary embolism, cerebral venous thrombosis). Each outcome
(e.g. stroke, TlA, MI etc.) was counted separately and as total outcomes under
the pooled headings CVO, CHOand VTE as above. Where sufficient information
was given, events were further categorised by severity. If data were taken from
lists of adverse events rather than tabulations of outcomes, the trial was only
included if it could be determined that adverse events had been reported for
each treatment group. Where it was possible to ascertain that more than one
event occurred in a single subject, the most severe event was counted, i.e.
fatal rather than non-fatal stroke. OVTand PEwere counted as separate events
but the VTEtotal represents the most severe event in a single patient.
7.4.4 Statistical analysis
The effect of HRTon dichotomous outcomes was assessed using the odds ratio
calculated using a random effects model since the trials were expected to be
heterogeneous in their design, patient populations and interventions. Outcomes
were recoded in an ordered categorical manner where appropriate data were
published:
• Three level stroke (fatal stroke / non-fatal stroke / no stroke)
• Four level strokemA (fatal stroke / non-fatal stroke / TlA / no stroke)
• Three level MI (fatal MI / non-fatal MI / no MI)
• Four level MI/UA (fatal MI / non-fatal MI / unstable angina / no MI)
• Three level PE(fatal PE/ non-fatal PE/ no PE)
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Insufficient data were available to do this for DVT and VTE. These ordinal
outcomes were assessed using ordinal logistic regression adjusted for trial.
Data were analysed using Stata (version 8).
7.4.5 Results
Table 7.7 shows the results for all outcomes. The control event rate is given to
provide information on the background risk of each event; the changes in risk
associated with treatment are therefore quantifiable. HRT increased the odds of
having any CVD event by 24% (Figure 7.8), and stroke by 32%. Non fatal
stroke was increased by 28%; both TIA and fatal stroke showed a trend
towards increased odds of having an event with HRT although the statistical
power for TIA was limited owing to the small number of events. No relationship
was seen between HRTand CHD events, including MI. Those taking HRT had a
two-fold increase risk of VTE, this comprising increases in DVT (97%) and PE
(74%). Taking all outcomes together in a single analysis, HRT significantly
increased a person's odds of having any thrombotic event by 23%. No
statistical heterogeneity was found for any outcome apart for overall thrombotic
events.
For ordered categorical data, a statistically significant result was seen for stroke
severity when assessed as fatal stroke, non-fatal stroke, and no stroke (Table
7.8). The odds ratio of 1.31 (95% confidence interval 1.12 - 1.54) signifies that
HRT treatment is associated with a shift to increased stroke severity. Ordinal
regression requires the assumption of 'proportionality of odds' to be adhered to
and this was present in all of the trials with more than two levels of data. Non-
significant trends towards increased severity were seen for strokemA assessed
at four levels, and three level PE; both of these assessments suffered from
limited published data on event severity thereby restricting the statistical power
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of these analyses. No significant difference was seen for three level or four level
MI, and no data were available for DVT, and VTE.
7.4.6 Conclusion
This meta analysis extends the findings of previous trials and meta analyses of
HRT with the additional of ordinal regression analysis to assess the effect of
HRT on severity. In summary, HRT is associated with increased CVD, stroke
and stroke severity, VTE, and its components DVT and PE. In contrast, CHD
rates are not increased.
HRTwas found to increase the rate of total CVD by 24%. Ordering the severity
of stroke by vital status (fatal stroke/non-fatal stroke/no stroke) allowed an
ordinal meta analysis to be performed; HRT increased stroke severity by 31%.
Since the assumption of proportionality of odds was adhered to in all of the
trials reporting more than two levels (and trials which do not adhere to this
would tend to attenuate any treatment effect), this finding of increased severity
is likely to be genuine. This finding of increased severity is supported by a trend
towards more fatal strokes in patients receiving HRT using standard
dichotomous analysis (although this analysis is underpowered because of the
limited number of events).
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FIGURE 7.8
Forest plot of the effect of HRT on cerebrovascular disease.
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7.5 DISCUSSION
Improvements in secondary prevention are leading to falling event rates in
clinical trials. This means that future vascular prevention trials will need to be
larger and, with an increasing number of new interventions, the availability of
subjects is becoming limited. Thus, new approaches to trial design and analysis
are needed to help reduce sample size.
This study has shown that it is feasible to create three level ordered categorical
outcomes for stroke, MI, and a composite vascular event (fatal stroke and
MI/non-fatal stroke and MI). Analysis reveals that, in general, statistical
approaches which use ordinal data are more efficient than conventional binary
tests based on 'event/no event'. A further increase in efficiency comes from
using four level or five level data for stroke (with or without TIA). Ordering
vascular events by severity has both biological and clinical meaning. Fatal
events are clearly the most extreme health state while a severe stroke
(normally defined as a stroke resulting in dependency on others) is a disaster
for the patient, their carer and society, both for clinical and economic reasons.
A mild stroke leaves the patient independent, even if residual impairment
remains, and those who are younger can often return to work.
The most efficient statistical tests were those which examine ordinal data,
including ordinal logistic regression, the Wilcoxon test, and bootstrapping the
mean rank. In addition to improving statistical efficiency, the use of ordered
categorical outcomes gives information on the ability of an intervention to
reduce or increase the severity of an event, not just the number of events. This
was demonstrated in the HRTmeta analysis, where HRTnot only increases the
risk of stroke but also the severity of the event, with those taking HRT being
more likely to have a fatal stroke compared rather than a non fatal stroke.
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Ordinal logistic regression allows both estimation (with confidence intervals)
and inclusion of baseline prognostic covariates in analyses. However, it
assumes that any treatment effect is similar across outcome levels, i.e. the
odds of moving a treated patient from fatal to severe non-fatal stroke are
similar to those for moving from TIA to no event ('proportionality of odds'). This
assumption requires justification since it is neither widely recognised nor
obvious in most published vascular trial data. Firstly, it is biologically plausible
to suggest that prophylactic interventions will reduce severity as well as the
total number of events. Since the development of atherosclerosis and increases
in thrombosis, coagulation and inflammation are not binary events in nature,
and their magnitude is a determinant of the severity of clinical vascular events,
it is reasonable to expect that interventions will move patients from fatal to
severe, severe to mild, and mild to no events. If this assumption (of
proportional odds) is not met, an alternative ordinal model could be considered
(Stokes et al., 1995).
Secondly, there is existing published evidence that interventions do alter
severity:
• Simvastatin reduces the risk of stroke of different severities by similar
risk reductions (Heart Protection Study Collaborative Group, 2002)
• HRTincreases both stroke and its severity (Sare et al., 2008)
• Antiplatelet agents reduce both fatal and non-fatal vascular events
(Antithrombotic Trialists Collaboration, 2002)
The apparent failure of most vascular prevention trials to show individual
effects on death or severe events is largely because they were not powered to
assess these specific and, therefore, relatively uncommon events. Thirdly, the
odds reduction at each outcome level appeared to be relatively constant when
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individual trials were assessed (Figure 7.7); formal statistical assessment using
the likelihood ratio test indicated that 'proportionality of odds' was present in
most cases (although this test is known to be conservative) (Table 7.6). Lastly,
using ordinal statistical tests was more powerful than binary approaches, the
central finding of the OASTprevention study. Although this is not a novel idea
in the statistical community, ordinal outcomes have not been applied to
vascular prevention trials in the past.
Another efficient ordinal test is the Wilcoxon test which is widely available in
statistical packages and can produce a point estimate (median difference
between groups) with confidence intervals. The major assumption of the test is
that the treatment groups should be independent and this is met here. The final
efficient statistical approach was bootstrapping the mean rank; this approach is
computer intensive and its application and the interpretation of results are not
well appreciated by clinicians, although it is free of assumptions (Efron and
Tibshirani, 1993).
The conventional approach to analysing vascular prevention trials is to perform
time to event analyses, as visualised using Kaplan-Meier curves, and analysed
with Cox regression. When the frequency of events is high, analyses based on
time-to-event are more efficient than those using frequencies (as analysed
using logistic regression) (Vittinghoff and McCulloch, 2006). However, the
frequency of vascular events in most primary and secondary prevention trials
running over three to five years is relatively low; recent vascular prevention
trials have tended to report annualised stroke rates of 2-4% (Bhatt et al.,
2006, The Stroke Prevention by Aggressive Reduction in Cholesterol Levels
(SPARCL) Investigators, 2006). Logistic and Cox models give similar results
when the overall event frequency is less than 10% (Ingram and Kleinman,
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1989, Annesi et al., 1989). Where the frequency of events is higher, ordinal
data may be analysed using ordinal time to event analyses (Berridge and
Whitehead, 1991). In the current data set, the Cox model was slightly less
efficient than bootstrapping, the Wilcoxon test and ordinal logistic regression.
Using ordered categorical data means that results will need to be reported
differently to those obtained from binary analyses. The results of binary tests
are summarised easily as the proportion of patients who benefit (or suffer) with
a treatment, i.e. oral anticoagulation reduced absolute stroke recurrence by
1.46% (odds ratio 0.75, p=0.036) in the ASPECTtrial (Anticoagulants in the
Secondary Prevention of Events in Coronary Thrombosis (ASPECT)Research
Group, 1994). In contrast, ordinal tests will need to be presented as the
average absolute improvement in outcome, e.g. anticoagulation reduced stroke
recurrence and its severity with an odds ratio of 0.60 (or reduced the mean
severity by 0.5 points, p=0.013) on a five level scale. In this respect, health
consumers will need to decide what odds ratio or difference in events is
worthwhile, both clinically and in terms of health economics. In reality, it is
reasonable to present the primary result using the odds ratio (or median
change in event severity) and to give the absolute percentage change
calculated from the binary outcome as a secondary measure. Further, a visual
presentation of the data can be displayed as the percentage of patients within
each category by treatment group (as shown in Figure 7.9).
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FIGURE 7.9
Example four-level ordinal data from the North American Symptomatic Carotid
Endarterectomy Trial (NASCET) of carotid endarterectomy (CEA). Note that CEA
moves each polytomous level to the right. Statistical comparisons of binary
(stroke Ino stroke), p=0.002; trichotomous (fatal stroke /non-fatal stroke Ino
stroke), p=O.OOl; and quadrotomous (p=0.0009) data. Note, 70% of patients
with no events are not shown to emphasise those who had an event (North
American Symptomatic Carotid Endarterectomy Trial Collaborators, 1991).
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Just as sample size calculations exist for trials using dichotomised analyses,
analogous approaches exist for ordinal tests. Since ordinal analyses are
statistically more powerful than dichotomous ones, trial size may be reduced for
a given power of say 90% e.g. sample size falls by 15-24% as the number of
outcome categories increases from three to seven (Whitehead, 1993). This
reduction is worthwhile and would reduce competition between trials for
patients, and lower trial costs and complexity. Taking the HEPtrial (Coope and
Warrender, 1986) as an example (and assuming significance=0.05 and
power=0.9), the sample size is reduced by 48% from 1,556 for a binary
outcome of stroke/no stroke to 810 for a three level stroke outcome as
calculated using the method of Whitehead; this is further reduced to 772 with a
five level stroke outcome.
A number of caveats must be made about this study. Firstly, a majority of
identified trials could not be included since they did not publish adequate
information on vascular events. As data were missing for a variety of trial types
(primary, secondary prevention), sizes, and outcome measures (stroke, MI,
vascular) it is unlikely that a systematic bias was introduced into the findings;
however, the precision of the results will have been attenuated by the missing
data. Future trial publications should give this information, including vital status
for the main vascular outcomes, so that ordered outcome categories can be
calculated. Secondly, not use all possible statistical tests relevant to the
problem of analysing ordered categorical data were used; instead, the focus
was concentrated on those approaches which are readily available in statistical
textbooks (Siegel and Castellan, 1988) and computer packages.
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The HRT meta analysis shows the first example of an ordinal analysis being
applied to vascular prevention data. The ordinal analysis added novel
information on the effect of HRTon the severity of stroke suffered.
7.6 SUMMARY
These results show that vascular prevention trials should consider employing
statistical approaches which use the inherent ordered categorical data present
within vascular outcome events. The resulting trials could be smaller (with
savings in patient numbers, numbers of centres, and study cost and
complexity) and would allow appreciation of the effect of interventions on
severity, as well as absolute number of events, to be highlighted. Appropriate
tests include the Wilcoxon test, ordinal logistic regression, and bootstrapping
the mean rank.
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TABLE 7.1
Assessment of ten statistical approaches for analysing stroke as a three level
stroke outcome (fatal/non-fatal/no stroke) in 85 vascular prevention trials.
Analysis by two way ANOVA (p<O.OOOl) on the ranked data (1-10 with 1
'best'); comparison of tests by Duncan's multiple range test - those tests joined
by the same band are not significantly different from each other at p<O.OS.
Test Mean Banding
rank
Wilcoxon test 3.32
Bootstrap (difference in mean rank) 3.32
Ordinal logistic regression 4.12
Robust rank test 4.51
Cochran-Armitage trend test 4.80
t-test 5.08
Chi Sq - 2x3 test 5.94
Chi Sq - stroke vs. no stroke 6.37
Chi Sq - death vs. alive 7.58
Median test 9.97
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TABLE 7.5
Assessment of ten statistical approaches for analysing stroke as a three level
stroke outcome (fatal/non-fatal/no stroke) with the hazard ratio extracted from
the trial publication in 36 vascular prevention trials. Analysis by two way
ANOVA (p<O.OOOl) on the ranked data (1-10 with 1 'best'); comparison of
tests by Duncan's multiple range test - those tests joined by the same band are
not significantly different from each other at p<0.05.
Test Mean Banding
rank
Bootstrap (difference in mean rank) 3.42
Wilcoxon test 3.85
Ordinal logistic regression 4.46
Hazard ratio 4.75
Robust rank test 5.26
Cochran-Armitage trend test 5.43
t-test 5.68
Chi Sq - 2x3 test 6.72
Chi Sq - stroke vs. no stroke 6.86
Chi Sq - death vs. alive 8.61
Median test 10.96
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8.1 INTRODUCTION
The results from stroke trials have greatly improved the treatment and care,
and therefore outcome, of patients who have suffered from a stroke. Stroke
units can be used to treat all types of stroke, and combine the skills of a multi-
disciplinary team of therapists and clinicians. Aspirin has wide utility, but
limited efficacy in ischaemic stroke, while thrombolytic therapy has high
efficacy, but with limited usage. Hence, treatment options remain limited for
those with stroke, especially for those who have suffered from a haemorrhagic
stroke.
Although there have been successes in stroke research, there have also been
many failures. For over two decades trials have been assessingneuroprotective
agents, treatments which aim to protect brain tissue from cell death, with no
success (Kidwell et al., 2001). Many factors have been suggested as reasons
for this, including the applicability of animal findings to humans, and trial
design and analysis (Rother, 2008). Although the recent SAINT trials were
reported to be the "perfect" trial, with animal data fulfilling all of the STAIR
criteria, a primary outcome which took into account baseline severity, an early
time window, and the allowance of thrombolysis (Lees et al., 2006), NXY-059
was still shown to be ineffective in a second phase three trial (Shuaib et al.,
2007). Research is now being carried out to try and find out why such
promising initial results in both animal and man lead to the ultimate failure of
the phase three trial (Bath et al., 2008). This specific example highlights the
need for further research, such as the OASTproject, to try and improve aspects
of the design and analysis of stroke clinical trials
OASTis the largest data pooling project, to date, in stroke to look at improving
the statistical analysis of stroke trials. Previous research had focussed on re-
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analysing data from one trial or using simulated artificial data to describe
effects. The quirks and complexity of data from stroke trials means that using
'real-life' data from many situations is beneficial. Also, other studies have
focussed on only acute trials, whereas this project includes data on not only
acute interventions, but also stroke unit trials and those assessing occupational
therapy. This section will discuss the main findings of both the acute and
prevention projects, reflect on these, and suggest places for further work.
8.2 OAST PROJECT
The acute OAST project gathered individual patient data on over 50,000
patients from 47 completed trials. Re-analysis of these trials with various
statistical methods revealed that many stroke trials have been using sub
optimal methods for analysing data from functional outcome scales, with the
most powerful methods of analysis being: ordinal logistic regression, the t-test,
the robust rank test, bootstrapping the difference in mean rank, and the
Wilcoxon test. All of these tests take into account the inherent ordering of
functional outcome data, whereas traditional methods of analysis, such as the
chi square test, lump these categories together to create two or more groups
ignoring any ordering. The assessment of sample size showed that by changing
to an ordinal method of analysis, tria lists could reduce the sample size needed
for a given power by 28%. This saving could also be transferred into greater
statistical power to find a difference between treatments for a given sample
size.
The assessment of sample size showed an interesting finding, with ordinal
methods not performing as well in trials of thrombolytic agents, where the lack
of proportional odds means that dichotomous outcomes may be more
appropriate.
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Although finding that ordinal methods are more statistically powerful than those
which dichotomise is not surprising or novel in the statistical community, the
novelty of this work is in the application to stroke data. Very few stroke trials to
date have used an ordinal method of analysis for their primary outcome, and
although statistical analysis is receiving more interest in the field of stroke,
most studies still choose their method of analysis on hearsay or the results of
previous trials. The OASTacute project is a rigorous and thorough examination
of the available methods of analysis and the results can therefore be used
reliably in future trials.
The next part of the project assessed the impact of taking into account
covariates on the sample size required. Adjusting ordinal logistic regression for
three prognostic factors (age, sex and severity) can further reduce the sample
size needed by around 37%. This part of the project used less data than the
preceding analyses, as data was required not only from the primary outcome
but baseline variables as well. The initial analysis showed that ordinal methods
are not suitable for trials of thrombolytic agents, so trials testing these agents
were also excluded. Given the smaller number of trials included, simulation was
used to examine the effect of adjustment for covariates on sample size. Using
simulations allowed the comparison of three different levels of treatment effect
and used the actual covariate structure of those patients in the included trials.
When assessing a global outcome, the Cochran Mantel-Haenszel test, and a
patient specific outcome, no difference between these and either the t-test or
ordinal logistic regression were found. This may, in part, be due to the low
number of trials included in this part of the analysis. It may also be argued that
it is not valid to compare outcomes which combine more than one scale with an
analysis based on only one scale.
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Several comments can be made about the OASTacute project. First, it aimed to
include data from all stroke trials assessinga beneficial or harmful intervention.
Unfortunately, data were not made available for all identified trials; where
possible, individual data from publications that provided patient numbers by
outcome score, were created. Data were missing for a variety of trial types
(acute/rehabilitation/stroke unit) and sizes, and functional outcome measure
(mRS/BI), so it is unlikely that a systematic bias was introduced into the
findings. However, the precision of the results may have been attenuated by
the missing trials. It is important that data from completed trials are shared
with data pooling projects such as OAST or the Virtual International Stroke
Trials Archive (VISTA) (Bath and Gray, 2008, Ali et al., 2007). Unlike OAST,
VISTA collates data from only the control arms of completed trials. Second, the
OAST project only included data from trials of 'beneficial' or 'hazardous'
treatment as shown with an individual trial or as part of a meta analysis. The
rationale for this is that re-analysing data for interventions known not to have
an effect on outcome, looking for more statistically significant findings, could be
perceived as data dredging. Theoretically all of the included trials should have
shown a beneficial/hazardous outcome if they had been powered correctly and
analysed in an appropriate manner.
Overall, this part of the OAST project has shown that improvements can be
made to the statistical analysis of functional outcome data in stroke trials.
Where distributions meet the proportional odds assumption, i.e. they exert a
similar treatment effect across all levels of the scale, it is suggested that
trialists use ordinal logistic regression. Using a modelling approach of analysis
also allows adjustment for prognostic factors. Where the proportionality of odds
assumption is not met, i.e. with interventions such as thrombolytic therapy,
trialists can consider other methods which assess treatments across the whole
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functional outcome scale, such as the t-test, robust rank test, bootstrapping the
difference in mean rank or the Wilcoxon test.
S.2.1 Efficacy of Nitric Oxide in Stroke trial
The results of the OAST project are being used to improve the statistical
analysis of the ongoing 'Efficacy of Nitric Oxide in Stroke' (ENOS) trial. The
ENOStrial is a factorial randomised phase three trial comparing the efficacy of
transdermal glyceryl trinitrate against control, and stopping or continuing pre
stroke antihypertensive therapy (The ENOS Trial Investigators, 2006). The
initial primary outcome of the trial was a dichotomised death or dependent
versus independent on the mRS, cut at two (0-2 vs. 3-6). On the basis of the
OASTproject, the trial steering committee in April 2008 decided to change this
to an analysis of data across the whole mRS scale using ordinal logistic
regression and to adjust this for age, sex and baseline severity. The committee
decided to retain the planned sample size of 5,000 but to increase the
statistical power for finding a treatment difference.
S.2.2 Extensions to the OAST project
There are still many unanswered questions around the analysis of stroke trials
and therefore there are many ways this project could be built upon.
The global outcome, patient specific outcome and Cochran Mantel-Haenszel test
assessed here were all based on dichotomous data. Even though taking into
account baseline severity or merging more than one scale may be beneficial,
there are still the inherent problems of defining where scales should be
dichotomised and the loss of information associated with collapsing data into
groups. Future work could look at developing these outcomes to take into
account the ordinal nature of functional outcome data. The global outcome
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could be extended to ordinal outcomes by either using an ordinal GEEmodel
(Lumley, 1996) or by using a multivariate t-test, such as Hotelling's t-test,
which compares by treatment group correlated data from two or more
continuous or ordinal scales (Hotelling, 1931). The patient specific outcome
currently uses a chi square test to analyse dichotomous data. Future analysis
could look at using a test for trend to take into account the ordering of this data
and using more than two categories for collapsing the data. For example,
comparing those who are independent versus mildly dependent versus severely
dependent versus dead, instead of the binary outcome, independent versus
dead or dependent. Researchwould need to focus on creating well defined and
valid categories for various levels of baseline severity. The Cochran Mantel-
Haenszel test assessed in Chapter 6 stratifies by collapsed baseline severity. It
may be preferable here to use ordinal logistic regression instead, with
adjustment for severity.
If trialists decide to use an ordinal approach it is important to consider how the
number needed to treat would be calculated. Methods have been developed but
these are based on the within patient correlation and therefore require paired
data. Cross-over trials are rare in stroke research and therefore it is difficult to
calculate an estimate of the within patient correlation (Walter, 2001). Saver has
begun to address this problem by using a panel of experts to independently
specify a joint distribution, based on the NINDS tPA trial, for samples of 100
patients assigned to placebo and active treatment, and uses these joint
distributions to estimate the within patient correlation (Saver, 2004).
Development of a method which removed the need for independent experts
would save money and time and allow all tria lists to present this important data
in the trial manuscript to aid interpretation of the results. A Possible approach
to this could involve creating matched data from a completed trial and using
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this to estimate the within patient correlation, i.e. taking a patient from each
treatment group who share similar characteristics (e.g. age, sex and baseline
severity) and compare their outcomes.
The OAST project is promoting the use of ordinal analyses to stroke trialists.
While applying ordinal methods improves the analysis of stroke trials, this will
complicate the ability of future researchers to carry out meta analyses. Trials
which use binary outcomes will normally present the number and percentage of
patients who fall into each category by treatment group. These numbers can be
easily extracted and added to a binary meta analysis. Trialists will need to
display the number and percentage of patients falling into each category on the
scale being used to allow ordinal meta analyses (see example from the FOOD 3
trial).
TABLE 8.1
mRS score, primary outcome, and death taken from the FOOD 3 trial
manuscript.
Modified Rankin Scale Early tube (n=429) Avoid tube (n=430) PEGtube (n=162) Nasogastrictube (n"lS9)
0 4(1%) 9 (2%) 2 (1%) 1(1%)
l! 10 (2%) 16 (4%) 0 3(2%)
2 26 (6%) 19 (4%) 7 (4%) 6(4%)
3 50 (12%) 41 (10%) 9(6%) 20 (l3%)
4 53(12%) 42 (10%) 8{S%) 12 (8%)
5 104(24%) 9S (22%) 57 (35%) 41(26%.)
Dead 182(42%) 207 (48%) 79(49%) 76 (48%)
Unknown 0 1 «1%) 0- D
MRSO-3 90 (21%) 85 (20%) 18 (11%) 30 (19%)
MR54-S 157(37%) 137 (32%) 6S(40%) S3 (33%»
Dead or MRS 4-5 339(79%) 344(&0%) 144 (&9%) 129(81%')
Reprinted from The Lancet, 365. Dennis M et al. Effect of timing and method of enteral
tube feeding for dysphagic stroke patients (FOOD): a multicentre randomised controlled
trial. 764-72, Copyright (2005), with permission from Elsevier.
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Ordinal meta analysis methods are only available for individual patient data
(IPD) and not for combining summary ordinal data (Whitehead et al., 2001). If
data are presented as in Table 8.1, IPD can be formed for the primary outcome
by treatment and then combined using IPD methods. Future work could look at
combining the odds ratios from ordinal logistic regression so that summary
meta analyses can also be performed.
8.3 OAST PREVENTION PROJECT
The OAST prevention project aimed to improve the analysis of vascular
prevention trials. The acute OAST project showed that employing an ordinal
approach to analysis could improve statistical power and this idea was used to
create ordinal categories for analysis from vascular prevention data. The results
showed that creating ordinal categories from binary outcome data and using an
approach which looks for changes across these, improved the statistical power
to find a treatment effect.
Akin to the acute OASTproject not all vascular prevention trials showing benefit
or harm either individually or in a meta analysis were included. This was
because data was extracted from the trial publication and this was only possible
if outcome data by treatment group had been presented for the categories of
interest. For example, if the number of fatal and non fatal stroke had not been
presented separately, the data could not be included. Of the 151 studies
excluded, 128 (8s%) did not provide adequate outcome data (see (Bath et al.,
2008». This is in part due to the types of analyses routinely used in prevention
trials, for example, if the primary outcome is a composite event, there may not
be data on the individual events. Although these missing trials will have
reduced the statistical power, the missing trials were from a Wide range of trial
types (different treatments, primary and secondary trials, smaller and larger
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trials etc) so it is assumed that their exclusion will not have induced a
systematic bias.
The ordinal event analyses shown here do not take into account the time to the
event. It is argued that time to event analyses are more powerful than those
based on event counts, although it was shown that the Wilcoxon test and
ordinal logistic regression produced similar results to the Cox model. This
analysis was only based on 36 trials where hazard ratios and their p value had
been presented in the trial manuscript.
8.3.1 Extensions to the OAST prevention project
Further work is still to be done in this area. Firstly, as with the acute OAST
project, the effect on sample size could be assessed. The reduction in sample
size gained from ordinal analysis is probably more meaningful to trialists
carrying out prevention trials and can be converted easily into savings in terms
of trial costs, the number of centres required, length of follow up needed etc. In
the HEP trial given as an example in the discussion of Chapter 7, a 48%
reduction in sample size was seen when changing from a binary to a three level
stroke outcome. A similar approach could be used here as carried out in
Chapter 4 for the acute project. Secondly, a criticism of the ordinal prevention
outcomes is that they do not take into account the timing of the event. Many
prevention trials analyse their primary outcome with a time to event analysis,
such as the Cox proportional hazards model. There are ordinal survival models
described in the literature (Berridge and Whitehead, 1991), and an extension to
this work could look at combining the ordinal prevention outcomes with the
time of the event. Finally, reflecting the acute OAST project adjustment for
prognostic covariates could also be considered. Each of the extensions
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discussed above require IPD, and therefore IPD would need to be sought from
the Chief Investigators of each trial.
Ordinal methods of analysis are yet to be applied to an actual prevention trial,
but have been used in a meta analysis of HRT(Sare et al., 2008).
8.4 OTHER AREASOF RESEARCH
When considering how the OAST project could be used in other areas of
research, there are two main considerations:
1. Other areas in stroke, apart from functional outcome and prevention,
which use ordinal scales
2. Other clinical areas, apart from stroke, which use ordinal scales
In stroke research, scales are used to measure many aspects of recovery. The
main aspect is functional outcome, which is usually the primary outcome in
large phase three clinical trials. However, secondary outcomes also use scales
to measure domains of interest, such as quality of life, mood and cognition.
Although these are usually secondary outcomes, many agree that these are
perhaps the most important outcomes to the patient and therefore novel
treatments which show an effect in these more patient centred outcomes could
still be clinically beneficial. Akin to functional outcome scales, other scale data
is also routinely dichotomised when analysed. It might not be possible to simply
apply the results from the functional outcome data to those other domains of
recovery. As shown earlier, functional outcome after stroke has a 'U' shaped
distribution with around a third of patients dying post stroke, a third returning
to full independence and the remaining third being distributed across the scale.
Data on domains such as mood and cognition may not follow the same
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distribution. Data on quality of life has been shown to be highly related to
functional outcome (Gray et al., 2007) and therefore the results presented here
may translate and be useful when analysing quality of life data. However,
unlike functional outcome scales some quality of life scales, such as the EuroQol
(Brooks and with the EuroQol Group, 1996), are linear and therefore ordinal
methods, which do not assume linearity, may not be optimal. Analysis of the
quality of life data gained from the Short-form 36 has been assessed previously
and has been described in the introduction of this thesis (Waiters et al., 2001).
To date, no studies have looked at the optimal ways of analysing data from
mood or cognition scales. To do this IPD from trials which have assessedquality
of life, mood or cognition could be collated and the methods of the OASTacute
project repeated to look for the optimal method of analysis.
Other areas of research have also reported problems in the analysis of ordinal
data from clinical trials and have taken steps to rectify these. One example is
traumatic brain injury, where a group similar to OAST, have looked at some
issues with the analysis of the Glasgow Outcome Scale. In line with the OAST
findings they reported that statistical power could be increased by using a shift
analysis. They have also assessed patient specific outcomes and adjustment of
logistic regression analysis.
There may be other areas which could also benefit from the results of the OAST
project. For example, problems with the presentation and analysis of ordinal
data have also been described in veterinary dermatology (Plant et al., 2007),
rheumatology (Lavalley and Felson, 2002), and in nursing literature
(Jakobsson, 2004).
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8.5 SUMMARY
In summary, the OAST project has shown that many stroke trials have used
sub-optimal methods of analysis and this could be a contributing factor to why
so many stroke trials have found neutral results. This project has shown that
functional outcome scales should always be analysed in a way that retains the
ordinal nature of the data. This not only provides greater statistical power and
more information on the effect of the intervention, but can also be used to
lower sample size and if a modelling approach is chosen to take into account
covariates. Ordinal methods can be applied to both acute and prevention trials.
Statistical power can be increased in prevention trials by turning binary event
accounts into ordinal variables.
Changing the design and analysis of trials to improve statistical power gives
new effective interventions the best possible chance of being used in everyday
medicine, both reducing the number of people needed to be involved in clinical
trials and possibly the actual number of trials needed.
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